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Summary 
Vitiligo is an acquired depigmenting disorder characterised by the loss of 
functional melanocytes from the cutaneous epidermis. A role for autoimmunity 
is supported by the presence of circulating antibodies and T lymphocytes which 
react against melanocyte antigens in patients with vitiligo. The identification and 
characterisation of these autoantigens will improve understanding of the immune 
response in vitiligo, and may allow development of better therapies and 
diagnostic tools. 
Candidate immunoregulatory genes may predispose to vitiligo. However, 
this study failed to find an association between vitiligo and a polymorphism of 
the cytotoxic T lymphocyte antigen-4 (CTLA-4), although the polymorphism 
increases the likelihood of autoimmune endocrinopathy patients developing 
vitiligo. 
The epitopes on melanocyte-specific antigens tyrosinase and Pmel17 
which are recognised by antibodies in vitiligo patient sera were identified by 
molecular mapping. Multiple regions of tyrosinase and at least two domains on 
PmeI17 were identified as B cell epitopes. Sequence analysis revealed that the 
tyrosinase epitopes are likely to be cross-reactive with tyrosinase-related 
proteins but that the antibody response to Pmel17 is distinct. 
Antibody reactivity to a melanocyte protein, MelanA, targeted by a 
cellular immune response in vitiligo and melanoma was investigated by 
immunoblotting and radioimmunoassay. No MelanA-specific antibodies were 
isolated suggesting that either it is not a target of the humoral immune response 
in vitiligo, or that antibody reactivity was not detectable by the methods used. 
To identify novel vitiligo autoantigens, a melanoma cDNA expression 
library was constructed in a phage-display cloning system and immunoscreened 
with vitiligo patient IgG. Several possible autoantigens were enriched by this 
technique, including proteins previously characterised as autoantigens in other 
disorders. Additionally, humoral reactivity was identified to a protein with a 
possible role in pigmentation, the melanin-concentrating hormone receptor 1 
(MCHR1). MCHR1-specific antibodies were detected in 16.4% (9/55) of vitiligo 
patients but not in other diseases or healthy control subjects. The study 
demonstrates the usefulness of phage-display for further autoantigen 
identification in vitiligo. 
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1 General introduction 
1.1 Structure and function of the skin 
1.1.1 General skin functions 
The skin is a complex organ, comprising approximately one-twelfth of total body 
mass (Millington & Wilkinson 1983), and forming the boundary between the 
body and its external environment. It performs many essential functions which 
include the maintenance of internal homeostasis via thermoregulatory secretary 
activity, protection against chemical and physical assault (Millington & Wilkinson 
1983), and the prevention of invasion by pathogenic micro- and macro- 
organisms (Reeves & Todd 1996). 
1.1.2 Ultra-structure of the skin 
Human skin is formed of two layers, the epidermis, a cellular, avascular 
epithelium which derives from the embryonic ectoderm, and the dermis, a dense 
vascularised connective tissue arising from the embryonic mesoderm. The 
ultra-structure of the skin is summarised in Figure 1.1. The cutaneous epidermis 
comprises a multi-layered epithelium, consisting mostly of keratinocytes. Five 
epithelial layers are described as follows: the basal cell layer (stratum basale), 
prickle cell layer (stratum spinosum), granular cell layer (stratum granulosum), 
transitional cell layer (stratum lucidum) and the dead squamous cell layer 
(stratum corneum) (Wood & Bladon 1985). The nomenclature is based on the 
different morphological appearances of the keratinocytes according to their 
stage in the process of keratinisation. The innermost basal layer consists of a 
single layer of cylindrically shaped cells attached to a basement membrane that 
forms the junction between epidermis and dermis. The basal keratinocytes 
continually proliferate by mitotic division and move outwards through the layers 
undergoing subsequent differentiation, to be shed eventually at the exterior. 
The prickle cells are keratinocytes, so called because their protruding 
desmosomes, filled with keratin filaments, are visible as prickles on the cell 
surface under a light microscope. Above the prickle cell layer are keratinocytes 
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Figure 1.1: A schematic representation of the ultra-structure of the skin. 
(Adapted from Alberts et al. 1989). 
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in the penultimate stages of keratinisation. They appear granular because of the 
aggregation of keratohyaline. The transitional cells are terminally differentiated 
keratinocytes undergoing loss of their cellular contents. The outermost layer is 
made up of flattened dead keratinocytes termed squames. 
In addition to keratinocytes, the basal epithelial layer contains small 
numbers of other cell types: Merkel cells, Langerhans cells and melanocytes. 
Merkel cells are closely associated with nerve terminals of Schwann cells in the 
epidermis, often lying adjacent to hairs, and are considered to function as 
sensory receptors or transducers (Montagna & Parakkal 1974; Lacour et al. 
1991). Langerhans cells, which also reside in the upper layers of the epidermis, 
are dendritic cells capable of antigen presentation. They function in the immune 
system by binding antigen molecules encountered in the skin and subsequently 
migrating from the epidermis to regional lymph nodes, where they are able to 
present antigen to T cells (Reeves & Todd 1996). The epidermis is also 
transected by other cell types that originate in the underlying dermis, for 
example, secretory cells associated with sebaceous and sweat glands, and 
appendages such as hair. Melanocytes are responsible for the production of 
skin pigmentation and are discussed below. 
1.1.3 The melanocyte 
Cutaneous melanocytes arise from an independent embryonic lineage to the 
epidermis. Melanocytes of the skin, uveal tract, inner ear and leptomeninges 
derive from melanoblasts that originate from the embryonic neural crest (Rawles 
1947). In contrast, the ocular melanocytes of the retinal pigment epithelium 
arise from neural ectoderm as it invaginates to form the optical cup (Feeny- 
Burns 1980). Early in human embryonic gestation, considered to be seven 
weeks, the melanoblasts migrate into the developing epidermis and eventually 
settle in the basal epithelial layer (Holbrook et al. 1989). The control of 
migration and differentiation of embryonic melanoblasts is not fully understood, 
but the involvement of several genes, especially c-kit proto-oncogene, pax gene 
and stem cell factor gene, and transcription factors, especially microphthalmia- 
associated transcription factor and SOX10, has been elucidated from mice 
mutants (Boissy 1995; Ortonne & Ballotti 2000). The melanocytes reside in the 
basal epithelial layer for the life of an individual at a density of 1000-1500 cells 
3 
per mm2 (Quevedo et aL 1987). The primary function of the melanocyte is the 
synthesis of the pigment melanin which is deposited into the keratinocytes of the 
upper epidermis to absorb incident ultraviolet (UV) light, thereby protecting the 
genome of the dividing basal keratinocytes and melanocytes (Boissy 1995). In 
addition, melanin effectively absorbs oxygen free radicals (Korytowski et al. 
1987) and therefore might serve to protect the metabolically active keratinocytes 
from oxidative stress (Boissy 1995). Melanocytes have a roughly pyramidal 
morphology with numerous fine dendritic processes which can transfer melanin 
granules to surrounding keratinocytes. The appearance of melanocytes in 
culture is demonstrated in Figure 1.2. One melanocyte contacts an average of 
thirty-six keratinocytes in the normal human epidermis, this ratio being termed 
the `epidermal melanin unit' (Fitzpatrick et al. 1967). The epidermal melanin unit 
is the same in all ethnic groups. Differences in the rate of melanin synthesis 
(Iwata et al. 1990), the type of melanin produced (Quevedo et al. 1974) and the 
way it is distributed within keratinocytes (Szabo et al. 1988), account for the 
different appearances of skin colour between ethnic groups. 
In addition to their principal function of melanin synthesis or 
melanogenesis (Section 1.1.4), melanocytes also act as accessory cells in the 
skin immune response (Das et al. 2001). They are capable of secreting 
cytokines which assist in the maturation and migration of antigen presenting 
cells, such as Langerhans cells, and are involved in the recruitment of immune 
infiltrates into the skin (Zachariae et aL 1991; Swope et aL 1994). Additionally, 
there is evidence to suggest that melanocytes can themselves act as antigen 
presenting cells (Le Poole et al. 1993b; Das et al. 2001). 
1.1.4 Melanogenesis 
The initiation of melanogenesis has two parts: the synthesis of the melanosome, 
the specialised organelle which carries the melanin and the synthesis of the 
enzymes responsible for melanin synthesis. Each process occurs 
independently in the melanocyte in the smooth and rough endoplasmic 
reticulum, respectively, before convergence in the melanosome. The 
melanosome is required to enclose safely the pigmentary pathway, many of the 
intermediates being highly reactive and potentially toxic to the melanocyte 
(Pawelek et al. 1980; Urabe et a!. 1994). 
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Figure 1.2: Melanocytes grown in culture X200 magnification. 
(Provided by Miss C. Balafa and Professor S. MacNeil, Division of Clinical Sciences North, 
University of Sheffield). 
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The pathways by which melanin is synthesised are summarised in Figure 1.3. 
Melanogenesis essentially comprises of the conversion of tyrosine into 3,4- 
dihydroxyphenylalanine(DOPA)chrome in a two-step reaction controlled by the 
enzyme tyrosinase. The DOPAchrome is subsequently processed in further 
reactions, catalysed by tyrosinase, tyrosinase-related protein-1 (TRP-1), 
tyrosinase-related protein-2 (TRP-2) and Pmel17, into eumelanin. Eumelanins 
are brown/black melanin polymers and provide protection in response to UV 
irradiation. A second form of melanin, pheomelanin, a reddish-yellow melanin, 
can be synthesised in the presence of sulphydryl-containing compounds such as 
glutathione or cysteine, and appears not to be photoprotective. The 
melanosome bearing melanin is transported to surrounding keratinocytes via the 
dendritic processes of the melanocyte. The keratinocytes take up the 
melanosome by endocytosis of the dendritic ends (Wolff 1973). 
In addition to exposure to UV light, several cytokines and growth factors, 
including tumour necrosis factor alpha (TNF-a), endothelin, stem cell factor 
(SCF) and basic fibroblast growth factor (bFGF), are known to mediate 
melanogenesis (Nordlund 1998). Of particular importance in the control of 
melanogenesis are the melanotrophic peptides alpha-melanocyte stimulating 
hormone (a-MSH) and adrenal corticotrophin hormone (ACTH) which derive 
from a common precursor propiomelanocortin (POMC), synthesised in both the 
pituitary gland and locally in the skin, and which competitively bind to 
melanocortin 1 receptor (MC1R) on the melanocyte (Ortonne & Ballotti 2000). 
Cell-signalling pathways, including the cyclic adenosine monophosphate 
(cAMP)-dependent protein kinase pathway and the mitogen-activated protein 
(MAP) kinase pathway, are activated in response to a-MSH binding to MC1 R 
and ultimately bring about an up-regulation of melanogenesis (Ortonne & Ballotti 
2000). However, the complete pathways, and regulation, of melanogenesis 
have yet to be fully elucidated and the role of many melanocyte-specific proteins 
in these processes remains to be identified. Table 1.1 summarises some key 
melansomal proteins and their known function in melanogenesis. 
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tyrosine 
tyrosinase 
DOPAquinone 
3,4-dihydroxyphenylalanine` 
(DOPA) 
cysteine or glutathione 
DOPAchrome cysteinylDOPA 
Tyrosinase-related protein-2 
cysteinylDOPAquinone* 
5,6-dihydroxyindole 5,6-dihydroxyindole-2- 
(DHI)* carboxylic acid quinone 
(DHICA)* 
tyrosinase Tyrosinase-related protein-1? 
Indolequinone* indole-2-carboxylic acid 
quinone* 
Pmel17 PmeI17 
eumelanin phaeomelanin 
mixed melanin 
denotes intermediates of melanogenesis that are ultimately incorporated into the melanin 
polymers, in addition to eumelanin and phaeomelanin. 
Figure 1.3: A diagramic overview of the melanogenesis pathway. 
(Adapted from Riley 1997, with additional information from Boissy 1995 and 
Ortonne & Ballotti 2000). 
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Tyrosinase is the rate-limiting enzyme in the melanogenesis pathway 
through its action of the hydroxylation of tyrosine to DOPAquinone (Oetting 
2000). The presence of tyrosinase activity was first described in mammalian 
skin by Durham, (Durham 1904), who also noted an absence of tyrosinase 
activity in the skin of albino animals. The tyrosinase protein is a membrane 
glycoprotein containing 529 amino acids, including a signal protein at the amino 
end, two copper binding sites and a transmembrane region at the carboxy-end 
(Oetting 2000). The requirement for two copper atoms in the catalytic site of 
tyrosinase is demonstrated by the expression of hypopigmentation in the 
phenotype of Menkes disease, a disorder in which copper transport is deficient 
(Ortonne & Ballotti 2000). The control of tyrosinase (TYR) gene expression, in 
response to stimuli such as UV light and a-MSH production, has yet to be fully 
elucidated, but an important regulatory element contained within the TYR 
promoter has been identified and termed the `M' (melanocyte)-Box (Oetting 
2000). The `M'-Box is known to bind the family of transcription factors which 
include the microphthalmia-associated transcription factor (MITF) (Oetting 
2000). Oculocutaneous albinism type 1 (OCA-1), characterised by a complete 
lack of melanin synthesis in the hair, eyes and skin, is an autosomal recessive 
disorder caused by mutations of the TYR gene (King et aL 1995), of which more 
than ninety patients have been described (Oetting 2000). 
The tyrosinase gene family (Kwon 1993) includes two other structurally 
homologous glycoproteins: tyrosinase-related protein 1 (TRP-1) and tyrosinase- 
related protein-2 (TRP-2). The primary amino acid sequences of TRP-1 and 
TRP-2 are overall approximately 45% identical to that of tyrosinase and contain 
a similar signal sequence and trans-membrane domain (Kwon 1993). However, 
both proteins differ significantly from tyrosinase at their carboxy-end (Orlow et al. 
1993) and have distinct catalytic activities. TRP-2 acts as a DOPAchrome 
tautomerase, catalysing the conversion of DOPAchrome to 5,6-dihydroxyindole- 
2-carboxylic acid quinone (5,6-DHICA) (Aroca et al. 1990). The function of TRP- 
1 has not been determined in human melanogenesis, despite its role being 
characterised as DHICA oxidase in murine melanosomes (Hearing 2000). It is 
thought to stablise tyrosinase activity (Kobayashi et al. 1994b) and mutations of 
TRP-1, which affect its ability to do this, may lead to oculocutaneous albinism 
type 3 (OCA-3) (Hearing 2000). 
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Pmel17 is a melanosomal matrix glycoprotein (Kobayashi et al. 1994a; 
Zhou et al. 1994) with a limited structural homology to the tyrosinase gene family 
proteins (Kwon 1993). Indeed, Pmel17 cDNA was originally isolated from a 
human melanocyte cDNA library using anti-tyrosinase antibodies (Kwon et al. 
1991). However, the homologous regions are confined to five short regions of 
amino acids only and it is classified within its own gene family (Kwon 1993). 
Mutations at the mouse silver (si) locus, which encodes Pmel17, result in a loss 
of melanocytes in the coat hair and subsequent silvering (Johnson & Jackson 
1992). Similar mutations in the human PmeI17 gene, D12S53E, have been 
speculated to cause greying of human hair (Ortonne & Ballotti 2000). The 
PmeI17 protein is thought to function as a stablin, more specifically an indole 
blocking factor, that regulates the deposition of 5,6-dihydroxyindole (DHI) and 
DHICA into eumelanin (Boissy 1995). 
1.2 Vitiligo 
1.2.1 Definition 
Vitiligo is an acquired depigmentary disorder characterised by the loss of 
functional melanocytes from the cutaneous epidermis. Additionally, the disorder 
may affect pigment cells in the mucous membranes, inner ear and eye. Pigment 
is lost in circumscribed maculae which have a tendency to enlarge peripherally 
with disease progression. 
1.2.2 Prevalence 
Large population surveys have estimated a prevalence ranging from 0.38 
(Howitz et al. 1977) to 1.13% (Mehta et al. 1973). The consensus prevalence is 
around 1% (Lerner 1971). In approximately 50% of cases the disease presents 
before the age of 20 years (Majumder et al. 1993). The incidence of the disease 
in both sexes is equal. There is no preponderance of particular racial skin 
types, although the disease is more visually apparent in darker skin. 
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1.2.3 Inheritance and genetics 
A family history is reported in over 20% of vitiligo patients (Ortonne et al. 1983; 
Majumder et al. 1993) and concordance in monozygotic twins has been reported 
(Mohr 1951; Siemens 1953; Mayenburg et al. 1976) but the exact frequency of 
concordance has not been determined and the reporting of isolated cases is 
subject to ascertainment bias. Genetic studies of familial cases of vitiligo 
conclude that the disorder is most likely due to the action of genes at multiple 
loci (Majumder et al. 1993; Kim et al. 1998; Acros et al. 1999) and is not 
transmitted by a simple mendelian mechanism. However, some authors 
propose that an autosomal dominant gene with variable expression and 
incomplete penetrance may be responsible (Mosher et al. 1979; Lorincz 1985). 
In the Smyth line chicken (Smyth 1989), an animal model of vitiligo, the disorder 
results from a genetically inherited defect that is expressed in the melanocytes 
and which appears to be transmitted to offspring as an autosomal recessive 
trait. Similarly, the depigmentation in a mouse model, strain C57BU6J Ler-vidvit 
developed to study vitiligo, results from a genetic mutation that is inherited as an 
autosomal recessive trait (Lerner et al. 1986). The mutation in the vidvit mouse 
occurs at the microphthalmia (mi) locus which encodes microphthalmia- 
associated transcription factor (MITF), and, therefore, interest arose in the 
human homologue as a susceptibility gene for vitiligo. However, linkage studies 
proved negative (Tripathi et al. 1999). A mutation in the human mi gene is 
responsible for Waardenburg syndrome type 2, a disease characterised by 
congenital depigmentation and abnormalities in neural development (Ortonne & 
Ballotti 2000). 
Since vitiligo may have an immune involvement (Sections 1.3.6,1.4), 
candidate genes include those that have a regulating role in the immune system. 
The study of the major histocompatibility complex (MHC) genes has revealed 
associations of vitiligo with certain human leukocyte antigen (HLA) specificities 
but there is no consistent association with any of the major MHC class I or class 
II alleles (Table 1.2), and the reported relative risks have been modest. 
Additionally, the genes encoding complement components C2 and C4 (MHC 
class III molecules) have been proposed to influence the development of vitiligo 
since an increased frequency of heterozygous C4 and C2 deficiency has been 
found in patients with the disorder (Venneker et al. 1992). 
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A further candidate is the recently identified AIRE (autoimmune regulator) 
gene which is involved in autoimmune polyglandular syndrome type 1 (APS1), a 
disorder with which vitiligo can be associated (The Finnish-German APECED 
Consortium 1997; Nagamine et al. 1997). This novel gene encodes aT cell- 
specific protein that contains motifs indicative of a transcription factor and 
mutation analysis has identified several mutations in this gene in APS1 patients 
(Heino et al. 2001; Myhre et al. 2001). However, this gene is unlikely to be 
related to the development of vitiligo which is not associated with APS1. 
A recent study, involving 552 vitiligo patients and their families, examined 
polymorphic markers in a panel of twenty-four candidate genes that might confer 
susceptibility to vitiligo (McCormack et al. 2001b). The genes analysed in this 
study included those encoding tyrosinase, TRP-1, TRP-2, tyrosine hydroxylase, 
phenylalanine hydroxylase, guanosine triphosphate-cyclohydrolase, the 
transcription factor nuclear factor 1, and two genes involved in melanocyte 
embryogenesis, kit and pax3. No association was found between any of these 
genes involved in melanocyte function and an increased risk of vitiligo. Genes 
encoding proteins involved in the immune response, including: MHC class II 
molecules; low molecular weight protein (LMP)-2 and LMP-7, and transporter 
involved in antigen-processing (TAP)-1 and TAP-2; the proteosome 
multicatalytic endopeptidase complex-like 1 (MECL1); CD4; CD59; membrane 
cofactor protein (MCF); cytokine and cytokine receptors interleukin (IL)-1 ß, 
tumour necrosis factor-alpha (TNFa) and IL-1 receptor-alpha (IL-1 R-a); 
intercellular adhesion molecule-1 (ICAM-1); co-stimulatory lymphocyte activation 
ligands CD28 and cytotoxic T lymphocyte antigen-4 (CTLA-4), were also 
examined in these family studies. Polymorphic markers for the immune 
response LMP/TAP and CD28/CTLA-4 gene regions appeared to be positively 
associated with vitiligo susceptibility (McCormack et al. 2001b). Further details 
on CTLA-4 and its association with vitiligo will be discussed in Chapter 3. 
1.2.4 Pathology 
Affected skin shows a loss of melanin and decreased numbers of melanocytes 
in the epidermis. Figure 1.4 demonstrates the difference in density of epidermal 
melanocytes between normal and vitiligo skin. Immunohistochemical studies 
and electron microscopic analysis of vitiligo lesions demonstrate the 
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Figure 1.4: (a) Melanocytes in a section of normal epidermis. 
(b) Melanocytes in an epidermal section from a patient with 
vitiligo showing a much reduced cell density. 
Both sections are treated with a DOPA immunohistochemical stain, which detects tyrosinase 
activity and reveals the melanocytes in brown. 
(Provided by Dr D. J. Gawkrodger, Royal Hallamshire Hospital, Sheffield). 
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degeneration of melanocytes and also the presence of abnormal keratinocytes 
(Moellmann et al. 1982; Le Poole et al. 1993c). In peri-lesional regions, 
abnormal melanocytes are seen which are fragmented, grossly enlarged or 
show the appearance of vacuoles (Le Poole et al. 1993c; Abdel-Naser et al. 
1994). Additionally, in the peri-lesional areas of inflammatory vitiligo (Bleehan 
1979), and in some cases of generalised vitiligo (Le Poole et al. 1993c), a 
lymphocytic infiltration can be identified in the basal layer of the epidermis in 
proximity to the melanocytes. 
1.2.5 Clinical features 
The progression of vitiligo is variable and there are five disease categories 
dictated by the extent of involvement and distribution of the vitiligo maculae: 
generalised or symmetrical, segmental, focal, acrofacial and universal (Kovacs 
1998). Generalised or symmetrical type vitiligo is characterised by a bilateral, 
symmetrical depigmentation which can affect the face (especially periorificial 
areas), neck, torso, the extensor surfaces or bony prominances of the hands, 
wrists, and legs, axillae and also orifices or mucosal surfaces (Kovacs 1998). 
Segmental type vitiligo has a dermatomal, asymmetrical distribution of 
depigmentation (Kovacs 1998). This type of vitiligo often begins in childhood, is 
rarely associated with autoimmune disorders and has stable results after 
autologous grafting (Section 1.2.7). In contrast, symmetrical vitiligo has a later 
age of onset, is frequently associated with autoimmunity and has unstable 
results with autologous grafting (Kovacs 1998). These contrasts have lead to 
speculation that symmetrical and segmental vitiligo represent two quite separate 
disease manifestations (Kovacs 1998; Taieb 2000). Focal type vitiligo is 
localised and non-dermatomal in distribution (Kovacs 1998), whereas acrofacial 
vitiligo is characterised by depigmentation of the distal fingers and facial orifices 
only, the latter being in a circumferential pattern (Kovacs 1998). Finally, patients 
with universal vitiligo exhibit a loss of pigment over the entire body surface 
(Kovacs 1998), a type of vitiligo that occurs rarely. The two most common 
clinical presentations are symmetrical and segmental vitiligo which are shown in 
Figures 1.5a and 1.5b, respectively. 
Trichrome, inflammatory, and occupational vitiligo represent unusual 
forms of the disease. Trichome vitiligo involves macules in which there are 
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(a) 
I 
(b) 
Figure 1.5: (a) Segmental vitiligo affecting one side of the neck. 
(Provided by Professor A. P. Weetman. Division of Clinical Sciences 
North, University of Sheffield). 
(b) Symmetrical vitiligo on the dorsal aspects of the 
hands. (Provided by Dr D. J. Gawkrodger, Royal Hallamshire 
Hospital, Sheffield). 
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areas of both complete and partial loss of pigment, forming a pattern of varying 
hues between the affected and non-affected skin (Fitzpatrick 1964; Gawkrodger 
1998). Uniquely, areas of normally pigmented skin adjacent to an area of vitiligo 
may become hyperpigmented (Gawkrodger 1998). Inflammatory vitiligo is 
characterised by actively spreading lesions which are inflamed, presenting a 
raised erythematous peri-lesional border (Grab & Wise 1948; Le Poole et al. 
1996). Chemically induced occupational vitiligo can occur in workers exposed to 
compounds such as catechols, phenols, hydroquinone and monobenzene. The 
depigmentation is usually confined to the parts of the body exposed to the 
chemical, e. g. the hands and forearms, but can arise in areas distant from the 
original point of contact, suggestive of systemic exposure through percutaneous 
adsorption, inhalation or ingestion. Some of the compounds shown to cause 
depigmentation in occupational vitiligo are now specifically used in depigmenting 
therapies in idiopathic vitiligo (Table 1.4). 
In addition to the disease categories described by the distribution of 
vitiligous skin, a three-grade pathological staging system corresponding to 
depletion of the melanocytes has been proposed by Gauthier (Gauthier 1994). 
In this classification scheme, grade I vitiligo exhibits only a partial depletion in 
epidermal melanocytes and results in the possibility of repigmentation, without a 
follicular pattern, after phototherapy treatment. Grade II vitiligo has complete 
depletion of the epidermal melanocytes and corresponds to a follicular pattern of 
repigmentation, in which melanocytes have migrated from the follicular reservoir 
to replace the absent epidermal melanocytes, after phototherapy treatment. 
Grade III vitiligo is characterised by a total depletion of both epidermal and 
follicular melanocytes and patients at this stage do not respond to medical 
therapy. More recently, a vitiligo disease activity (VIDA) score has been 
proposed which measures disease activity in relation to time, as assessed by 
the patient (Njoo et al. 1999). 
Although vitiligo may be considered a relatively minor disorder, the 
psychological effects can be considerable, particularly in those with racially 
darkly pigmented skin in whom the appearance of the lesions is more marked. 
Detrimental feelings of stress, embarrassment or self-consciousness when in 
contact with strangers, perception of discrimination and low self-esteem are 
common, especially in patients with visible lesions (Porter et al. 1986; Porter et 
al. 1990; Kent & AI'Abadie 1996). 
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1.2.6 Associated disorders 
Vitiligo is frequently associated with autoimmune disorders (Table 1.3) including 
autoimmune thyroid disease (Ochi & DeGroot 1969), type 1 diabetes mellitus 
(Macaron et al. 1977), alopecia areata (Sharma et al. 1996), pernicious anaemia 
(Dawber 1969), Addison's disease (Dunlop 1963) and autoimmune 
polyendocrine syndromes (Neufeld et al. 1981; Ahonen et al. 1990). Patients 
with vitiligo are also more likely to suffer from an autoimmune condition than 
those in the general population. Autoimmune thyroiditis, for example, has a 
prevalence of up to 30% in vitiligo patients (Cunliffe et al. 1968), a figure 
significantly higher than that of 1% prevalence reported in the general 
population. 
Halo naevi, areas of depigmentation seen surrounding a melanocytic 
naevus or 'mole', may be associated with vitiligo and sometimes pre-date the 
onset of the disorder (Lerner 1971). Premature greying of the hair (canities) 
may also be found in patients with vitiligo (Lerner 1971). Vitiligo can affect all 
active melanocytes, including those of the retinal pigment epithelium and uveal 
tract of the eye and the scala vestibuli of the inner ear, which may lead to ocular 
abnormalities such as iris, conjunctival and chorioretinal depigmentation and 
uveitis (Albert et al. 1979; Cowan et al. 1986) or auditory problems including 
hearing impairment in the 2-8 kHz range (Thurmon et al. 1976; Tosti et al. 1986; 
Tosti et al. 1987), respectively. The combination of vitiligo with uveitis, canities, 
auditory anomalies and neurological involvement is known as Vogt-Koyanagi- 
Harada (VKH) syndrome (Barnes 1988). It has been proposed that VKH 
syndrome may represent a systemic manifestation of vitiligo, since the 
neurological involvement may also result from melanocyte destruction in the 
leptomeninges of the brain (Kovacs 1998). 
1.2.7 Treatment 
Since the aetiology of vitiligo is yet to be determined, there are no effective 
treatments available to correct the basic defect/s that lead to destruction of the 
melanocytes. Repigmenting therapies are, therefore, often unsustained and the 
patient has to resort to covering the patches with cosmetics. Therapies can be 
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categorised as medical or surgical and are summarised in Table 1.4. On-going 
psychological support is also important, particularly for patients who have 
suffered serious psychological affects or social stigma as a result of the disease. 
1.3 Theories of vitiligo aetiology 
The aetiology of vitiligo is presently unknown. There have been three basic 
hypotheses proposed to explain the aetiology as follows: (i) autoimmunity, (ii) 
neurochemical-mediated effects on the melanocyte and (iii) an intrinsic 
melanocyte defect causing the melanocytes to self-destruct. In the convergence 
theory, the causal factors of each of the previous three hypotheses act together, 
or independently, to bring about the destruction of melanocytes (Le Poole et al. 
1993a). Furthermore, environmental factors, including psychological stress, 
mechanical stress injury and infections, have been proposed to contribute to 
vitiligo aetiology (Taieb 2000), in addition to a possible inherent genetic 
predisposition (Section 1.2.3). 
1.3.1 Psychological stress 
Many vitiligo patients report that their vitiligo lesions first appeared or expanded 
under conditions of extreme stress (Lerner 1959; Papadopoulos et al. 1999). 
Stress induces an increase in the production of catecholamines, the possible 
influence of which in melanocyte destruction is described in Table 1.5. 
1.3.2 Physical stress (Koebner's phenomenon) 
Vitiligo maculae may appear at the site of mechanical stress or friction injury to 
the skin (Taieb 2000). Gauthier (Gauthier 1996) demonstrated that the 
distribution of vitiligo lesions commonly correlates to areas of the body subjected 
to the most mechanical stresses. A recent study showed that the appearance of 
experimentally induced Koebner's phenomenon, after small skin biopsy, to some 
degree correlated with the disease activity in non-segmental type vitiligo patients 
(Njoo et al. 1999). 
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Table 1.4: Therapies for vitiligo. 
Treatment Reference 
I. MEDICAL TREATMENTS 
Cosmetic modalities Kovacs 1998 
Corticosteroids (topical or systemic) Boissy 1995; 
Gawkrodger 1998; 
Kovacs 1998 
Psoralen (topical or systemic) and ultraviolet A (PUVA) Boissy 1995; 
Gawkrodger 1998; 
Kovacs 1998 
Khellin (topical or systemic) with ultraviolet A or natural sunlight Gawkrodger 1998 
Phenylalanine (topical or systemic) with ultraviolet A Kovacs 1998 
Topical pseudocatalase with ultraviolet B Gawkrodger 1998 
Oral antioxidants (e. g. vitamin E acetate; selenio-methionine) Gawkrodger 1998 
5-Fluorouracil (topical) Kovacs 1998 
Depigmentation with monobenzyl ether of hydroquinone Kovacs 1998 
II. SURGICAL TREATMENTS 
Epidermal grafting Boissy 1995; Kovacs 
1998 
Autologous minigrafts Boissy 1995; Kovacs 
1998 
Transplantation of cultured epidermis Boissy 1995; Kovacs 
1998 
Transplantation of non-cultured melanocytes Boissy 1995; Kovacs 
1998 
I Tattooing Boissy 1995 
(Adapted from Kemp et al. 2001 b). 
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1.3.3 Infections 
It is possible that an infection may result in melanocyte destruction by triggering 
an immune response leading to vitiligo in some patients. The melanocyte may 
be destroyed as a result of harbouring an infectious agent or because it exposes 
antigens similar to a micro-organism to immune surveillance (Le Poole et al. 
1993a). Vitiligo-like hypopigmetation has been reported in some infectious 
diseases such as leprosy (Shegan 1971), candidiasis (Howanitz et al. 1981) and 
acquired immunodeficiency syndrome (AIDS) (Ivker et al. 1994). 
Cytomegalovirus (CMV) DNA was found in skin biopsies in 11 out of 29 patients 
with vitiligo, with particular prominence in biopsy specimens of active lesions 
(Grimes et al. 1996), and has therefore been suggested as a trigger for vitiligo. 
However, the seroprevalance of CMV in the general population is also very high 
(Hizel et al. 1999). 
1.3.4 The neuronal theory 
Neurochemical-mediated effects on melanocytes would explain the often 
symmetrical distribution of vitiligo lesions or the dermatomal pattern of 
segmental-type vitiligo (Lerner 1959). Indeed, immunohistochemical studies of 
lesional and perilesional vitiligo skin have demonstrated abnormalities in the 
levels of skin neuropeptides. AI'Abadie et al., (1994), reported that 5 of 10 
patients with symmetrical type vitiligo had increased levels of neuropeptide Y in 
the margins of vitiligo lesions and of these patients, those with active disease 
also had elevated neuropeptide Y within lesional skin. In addition, the number of 
nerve fibres immunoreactive to nerve growth factor (NGF) and calcitonin gene- 
related peptide has been shown to be increased in vitiligo lesions compared to 
the uninvolved and control skin (Liu et al. 1996). The secretion of both NGF and 
calcitonin gene-related peptide is thought to influence normal melanocyte 
function (Yaar et al. 1991; Hara et al. 1995b) and could be implicated in vitiligo 
pathogenesis (Liu et al. 1996). Studies of the ultra-structure of dermal nerves 
using electron microscopy have also demonstrated regenerative and 
degenerative changes (Al'Abadie et al. 1995), as well as direct cell-cell contact 
with melanocytes (Morohashi et al. 1977), in vitiligous skin. Furthermore, 
melanocytes originate from the neural crest and, in many cases of vitiligo, 
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perilesional melanocytes appear progressively more neural in their behaviour, 
both in an increasingly dendritic morphology and in an ability to synthesise 
adrenalin (lyengar & Misra 1988; Iyengar 1989). Investigations into the levels of 
neurotransmitters in vitiligo patients are summarised in Table 1.5 and are 
discussed in relation to the influence of psychological stress (Section 1.3.1). 
Several clinical observations provide further evidence for an association 
of the nervous system with vitiligo. It has been noted that vitiligo spares 
denervated skin, for example, below the level of neurological damage in certain 
patients with severe spinal cord injury (Lerner 1959). Spontaneous 
repigmentation of lesions occurs occasionally in vitiligo patients whose nervous 
system has been compromised by diabetic neuropathy. In contrast, vitiligo-like 
hypopigmented macules are sometimes produced in inflammatory diseases 
affecting the peripheral nervous system such as leprosy, and in neurodysplasias 
such as neurofibromatosis and tuberous sclerosis. Additional indirect evidence 
is provided by the requirement for innervation for skin transplants to repigment 
an area. While vitiligo patients do not complain of sensory abnormalities in 
lesional skin, autonomic dysfunction has been reported, including: increased 
skin surface temperature and an increased sweating response in vitiliginous 
areas, when compared to normal skin, and an abnormal sympathetic skin 
response quantified by electrical measurement of sympathetic nerve activity 
(Chanco-Turner & Lerner 1965; Dutta & Mandal 1982; Merello et al. 1993). 
However, this could be associated with the absence of Merkel cells from the 
basal layer of vitiligo lesions (Bose & Ortonne 1994) that are thought to interact 
with nerve endings (Lacour et al. 1991). 
1.3.5 The melanocyte defect/self-destruction theory 
It has been hypothesised that intrinsic melanocytes defects such as the 
accumulation of toxic intermediate products of melanin synthesis (Pawelek et al. 
1980; Moellmann et al. 1982), the breakdown of free radical defence (Nordlund 
& Lerner 1982) and the build-up of excessive hydrogen peroxide (Schallreuter et 
al. 1991; Schallreuter et al. 1994) might result in the self-destruction of pigment 
cells in vitiligo. The theory is supported by the clinical observation that certain 
chemical compounds can produce a pattern of depigmentation indistinguishable 
from idiopathic vitiligo, e. g., mercaptoamines (Bleehan 1979) and phenolic 
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agents (Le Poole et al. 1999). The suggestion that vitiligo melanocytes show an 
increased sensitivity to oxidative stress (Schallreuter 1999; Jimbow et al. 2001) 
has also led to the use of the antioxidant pseudocatalase in the treatment of 
vitiligo (Section 1.2.7). The proposed involvement of some of the biochemicals 
thought to contribute to vitiligo pathogenesis through melanocyte autocytoxicity 
is summarised in Table 1.5. 
1.3.6 The autoimmune theory 
A role for autoimmunity was initially suggested by the frequent clinical 
association of vitiligo with diseases of an autoimmune origin (Table 1.3) and by 
the presence of organ-specific autoantibodies (Table 1.7) in vitiligo patients 
(Brostoff 1969; Betterle et al. 1976; Zauli et al. 1986; Mandry et al. 1996). 
Subsequently, autoantibodies targeting pigment cell antigens which are capable 
of causing damage to the melanocyte have been identified in vitiligo patient sera 
(Section 1.4) (Naughton et al. 1983b; Naughton et al. 1983a; Norris et al. 1988b; 
Cui et al. 1992; Gilhar et al. 1995). Autoreactive T lymphocytes targeting 
melanocyte-specific proteins have also been identified both circulating in the 
blood and at the margins of advancing lesions of vitiligo patients (Section 1.4) 
(Ogg et al. 1998; van den Wijngaard et al. 2000; Lang et al. 2001). 
Furthermore, systemic disorders in vitiligo caused by damage to melanocytes at 
sites other than the epidermis, e. g., the inner ear and eye, indicate that a 
progressive immunological response might play a role in the disease 
development. 
The association, albeit weak, of vitiligo with certain HLA specificities 
(Table 1.2) and other immune response genes (Section 1.2.3) adds credence to 
an autoimmune hypothesis. All autoimmune endocrinopathies are associated 
with particular alleles of the MHC class II human leukocyte antigen (HLA)-DR 
(Dahlberg et al. 1981; Platz et al. 1981; Maclaren & Riley 1986). Although 
studies of association of MHC specificities with vitiligo have shown variability 
(Table 1.2), several studies have reported a significant association of HLA-DR 
with vitiligo patients in different ethnic populations (Foley et al. 1983; Dunston & 
Haider 1990; Poloy et al. 1991; Venneker et al. 1992; Venkataram et al. 1995; 
Zamani et al. 2001). Additionally, several autoimmune disorders are associated 
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with homozygous or heterozygous deficiencies of the MHC class III molecules, 
complement components C4 and C2 (Kahl & Atkinson 1988), and a 
heterozygous deficiency of C4 and C2 has been reported to be associated with 
vitiligo (Venneker et al. 1992). A recent study has also identified significant 
associations between vitiligo and polymorphisms in immune response genes 
including those encoding the co-stimulatory lymphocyte activation ligands CD28 
and CTLA-4, and the MHC class II molecules LMP and TAP (McCormack et al. 
2001b) (Section 1.2.3). 
The therapeutic response of some vitiligo patients to psoralsen with 
ultraviolet A radiation (PUVA) (Parrish et al. 1976), topical corticosteroids 
(Kumari 1984) and topical cytotoxic drugs such as fluorouracil (Tsuji & Hamada 
1983) is believed to result from immunosuppression of the local immune 
reactions responsible for damaging melanocytes. Approximately 50% of vitiligo 
patients will note significant return of pigment in those lesions which retain 
melanocytes after the application of topical steroids (Boissy 1995). 
There are several spontaneous animal models of vitiligo (Boissy & 
Lamoreux 1988) but how the acquired depigmentation relates to that of the 
human disease remains to be established. The best documented model, the 
Smyth line chicken (Smyth 1989), expresses a genetically inherited vitiligo-like 
depigmentation with considerable autoimmune involvement. Depigmentation of 
Smyth chicks begins soon after hatching due to loss of melanocytes from the 
feathers and ocular tissues. An autoimmune response involving both cellular 
and humoral reactions is initiated by an intrinsic defect of the chicken 
melanocytes (Boissy et al. 1983). An increase of T cells is seen in the feather 
pulp and in the circulation of Smyth chicks prior to the onset and during 
development of vitiligo-like depigmentation (Erf et al. 1995; Erf & Smyth 1996). 
In addition, serum antibodies to melanocytes are present before and after 
presentation of the disease phenotype (Austin & Boissy 1995). These anti- 
melanocyte antibodies are detected in the sera of 100% of Smyth line chicks but 
not in the sera of normally pigmented birds (Austin & Boissy 1995). The 
depigmentation can be decreased by treatment with cyclosporine A, a selective 
inhibitor of inflammatory T cells, and by performing neonatal bursectomy which 
causes B cell deficiency (Lamont & Smyth 1981). The vitiligo-like disorder of 
Smyth chickens is accompanied by autoimmune hypothyroidism and an avian 
equivalent of alopecia areata (Smyth 1989). 
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Autoantibodies targeting pigment cell surface antigens have also been 
identified in several other animal models of vitiligo, including Arabian horses, 
Siamese cats and Tervuren dogs (Naughton et al. 1986a) as well as in the 
Sinclair pig, an animal model for regressive melanoma with vitiligo-like 
hypopigmentation (Cui et al. 1995a). These antibodies recognise a similar 
pattern of melanocyte antigens in immunoprecipitation experiments as 
antibodies in vitiligo patients (Naughton et al. 1986a), indicating that similar 
immunological responses may occur in both animals and humans. 
Despite persuasive evidence detailed above for an autoimmune cause of 
vitiligo aetiology, exactly how the immunological mechanisms, which are 
described in further detail in Section 1.4, might function in the disease 
pathogenesis remains open to speculation. It is currently unknown whether the 
abnormal immune response forms the primary cause of the disease or arises as 
a secondary phenomenon, resulting from damage to the melanocytes via other 
mechanisms, and in turn exacerbates the condition. It is also possible that 
different pathogenic mechanisms account for the different clinical subtypes of 
vitiligo (Section 1.2.5). For example, associated autoimmunity is rare in patients 
with segmental vitiligo and, therefore, immune mechanisms might be supposed 
to play a lesser role than in forms of the disease in which associated 
autoimmunity is more common. 
1.3.7 The convergence theory 
The convergence theory (Figure 1.6) proposes that all of the previously 
described mechanisms can contribute to the development of vitiligo (Le Poole et 
al. 1993a; Taieb 2000). Moreover, the different causal factors can act 
independently or synergistically to bring about the local destruction of 
melanocytes and are differentially involved in separate vitiligo patients (Le Poole 
et al. 1993a). 
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1.4 The immune response in vitiligo 
The possible mechanisms by which both cellular and humoral immune 
reactivities in vitiligo may arise and contribute to its pathogenesis are 
summarised in Figure 1.6. 
1.4.1 Cellular immunity 
1.4.1.1 T lymphocytes 
The study of circulating T cell subpopulations in vitiligo patients has generated 
contrasting results. Whilst some groups identified an expansion of peripheral 
CD4' T lymphocytes and an increase in the CD4+: CD8+ ratio (Soubiran et al. 
1985; D'Amelio et al. 1990; Al-Fouzan et al. 1995), indicative of an autoimmune 
response (Stites 1994), other groups observed a decrease in CD4+ T 
lymphocytes and a decreased CD4+: CD8' ratio (Grimes et al. 1986; Haider et 
al. 1986). While such discrepancies may indicate technical differences in the 
evaluation of these ratios in the circulation, the overall conclusion remains that 
the circulating T cell populations in vitiligo are rarely normal, although how these 
changes relate to T cells at the site of the lesion remains speculative. A 
proportion of activated peripheral T cells, as determined by HLA-DR expression, 
have been shown in vitiligo patients compared to healthy individuals (Abdel- 
Naser et al. 1992). 
Of more functional relevance, a recent study has demonstrated in the 
circulation of a significant number of patients with vitiligo, the presence of 
cytotoxic T cells, expressing a skin-homing receptor cutaneous lymphocyte- 
associated antigen (CLA), that react with the melanocyte antigen MelanA, (Ogg 
et al. 1998). These results were confirmed in a subsequent study, in which the 
presence of MelanA-specific cytotoxic T cells expressing CLA was also found to 
be significantly greater in the peripheral blood of vitiligo patients with active, 
progressive disease (Lang et al. 2001). These studies have also demonstrated 
the presence of CD8+ cytotoxic cells which react with peptides from tyrosinase 
(Ogg et al. 1998; Lang et al. 2001) and Pmel17 (Lang et al. 2001), when 
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presented with HLA class I antigen-A2, in the circulation of vitiligo patients. 
These data supports the role of skin-homing autoreactive melanocyte-specific T 
cells in causing destruction of melanocytes in vitiligo. 
A dermal and epidermal inflammatory infiltrate consisting of CD3+, CD4+ 
and CD8+ T cells and macrophages, closely associated with areas of 
melanocyte depletion, has been observed in vitiligo patients (Al Badri et al. 
1993b). The infiltrate is most prominent at the margins of vitiligo lesions and 
contains a significant number of activated T cells, as measured by expression of 
MHC class II antigen HLA-DR and CLA antigen (Al Badri et al. 1993b). There is 
also evidence of interleukin 2 receptor (IL-2R) and interferon y receptor (IFN-yR) 
expression by the lymphocytic infiltrate (Abdel-Naser et al. 1994). In rare cases 
of inflammatory vitiligo, similar observations with regard to perilesional, 
epidermis-infiltrating T cells have been made (Le Poole et al. 1996). A recent 
study isolated MelanA-specific CD8+ T cells expressing CLA antigen from vitiligo 
skin biopsies, demonstrating the presence of a cytotoxic response to a 
melanocyte-specific antigen within vitiligo lesions (van den Wijngaard et al. 
2000). However, the absolute numbers of infiltrating cells in lesional and 
perilesional skin are small when compared with other inflammatory skin 
disorders (van den Wijngaard et al. 2000) and it remains to be seen whether the 
infiltrate arises as a result of the disease process as opposed to being the cause 
of vitiligo. 
1.4.1.2 Cytokines 
Cytokines mediate many functions of cellular immunity and a number of studies 
have analysed the levels of various cytokines in patients with vitiligo (Table 1.6). 
Studies have demonstrated that the level of soluble interleukin-2 receptor (IL- 
2R) in patients with vitiligo is significantly increased compared with that of 
controls, indicating an activation of T lymphocytes may be involved in the 
disease pathogenesis (Caixia et al. 1999; Yeo et al. 1999). The levels of 
production of interleukin-6 and interleukin-8 by peripheral mononuclear cells are 
also elevated in vitiligo patients, both of which can act to recruit lymphocytes to 
the site of an immune response (Yu et al. 1997). In contrast, the production of 
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granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumour 
necrosis factor-alpha (TNF-a) by peripheral mononuclear cells in active vitiligo 
was found to be reduced compared with healthy controls (Yu et al. 1997). The 
expression of cytokines by lymphocytes from the margins of vitiligo lesions has 
yet to be fully characterised but initial data suggest that cytokines which promote 
inflammation and cytotoxicity, that is, those of the T helper lymphocyte type-1 
(Th1) subset, particularly interferon-gamma (IFN-y) and TNF-a, are 
predominantly expressed (Das eta!. 2001). 
1.4.1.3 Adhesion molecules 
Adhesion molecules, which allow cell-cell attachments, are required for 
lymphocyte migration and infiltration through the epidermis and also for 
interaction with antigen-presenting cells. Several studies have shown increased 
expression of intercellular adhesion molecule-1 (ICAM-1) by melanocytes and 
keratinocytes in perilesional skin compared with non-lesional and control skin 
(Norris 1990; Al Badri et al. 1993a; van den Wijngaard et al. 2000), which may 
contribute to the abnormal cellular immune responses seen in vitiligo. 
Immunohistochemistry of serial sections of vitiligo skin biopsies has shown that 
the epidermal expression of ICAM-1 coincides with the expression of HLA-DR 
(van den Wijngaard et al. 2000). A similar pattern of ICAM-1 and HLA-DR 
expression is shown by thyroid follicular cells in autoimmune thyroid disease 
(Hanafusa et al. 1983; Weetman et al. 1989; Zheng et al. 1990), and is 
dependent on cytokines, particularly interferon-gamma (IFN- y). 
Vascular expression of E-selectin, the adhesion molecule responsible for 
capture of leucocytes from the circulation to initiate migration to the site of a 
local immune response, appears neither to be upregulated nor more widely 
dispersed in post-capillary venules in vitiligo, when compared to control skin 
(van den Wijngaard et al. 2000). However, immunohistochemical analysis 
demonstrated that where there is expression of E-selectin in perilesional skin, it 
is co-localised with T cell infiltration (van den Wijngaard et al. 2000). The 
expression of E-selectin is dependent on cytokines, particularly tumour necrosis 
factor-alpha (TNF-a) (Pilewski et al. 1995). 
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1.4.1.4 Langerhans cells 
The density of Langerhans cells in vitiligo lesions has been reported as normal 
(Claudy & Rouchouse 1984) or increased (Riley 1967), relative to that of the 
non-lesional skin and skin from control subjects. These dendritic cells are active 
in the epidermis, presenting antigen to primed T lymphocytes and, therefore, an 
increase in their numbers may contribute to immunological responses to 
melanocytes in vitiligo. Indeed, patients with repigmenting lesions in response 
to PUVA or Fluocinonide cream show a decrease in epidermal Langerhans cells 
further supporting a role for these cells in the disease (Kao & Yu 1990). 
1.4.1.5 Natural killer cells 
It has been shown that the number of natural killer cells (NK cells) present in 
affected vitiligo skin is no different from that present in the skin of control 
subjects (Abdel-Naser et al. 1992; Hann et al. 1993b). Although previous 
studies have implicated an involvement of these cells in the destruction of 
pigment cells in vitiligo (Haider et al. 1986; Mozzanica et aL 1989), a recent 
study found no significant differences between the level of activity of natural 
killer cells from vitiligo patients and control subjects, against both normal and 
malignant melanocytes (Durham-Pierre et al. 1995). 
1.4.2 Humoral immunity 
1.4.2.1 Organ-specific autoantibodies 
In addition to the frequent association of vitiligo with autoimmune disorders, 
previously described (Section 1.2.6 and Table 1.3), a variety of organ-specific 
autoantibodies are commonly detected in the sera of vitiligo patients (Table 1.7). 
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1.4.2.2 Anti-melanocyte antibodies 
A significant piece of evidence in the debate over a role for autoimmunity in 
vitiligo is the observation that antibodies to melanocyte antigens are present in 
the circulation of most patients with the disease (Naughton et al. 1983a). In one 
study, 12 out of 12 of vitiligo patients but none of control subjects were found to 
have anti-pigment cell antibodies in their sera (Naughton et al. 1983b). 
Furthermore, a correlation has been described between the incidence and level 
of melanocyte antibodies and disease activity in vitiligo: 8/10 patients with active 
vitiligo, 0/14 with inactive disease and 0/19 controls were found to have 
circulating anti-pigment cell antibodies (Harning et al. 1991). A decrease in the 
titre of melanocyte antibodies, correlating with the suppression of vitiligo, with 
PUVA treatment further suggests that the disease activity is somehow related to 
incidence of these antibodies (Hann et al. 1997). Additionally, the presence of 
these antibodies is related to the extent of disease: they were detected in 50% 
of patients with minimal vitiligo (< 2% of skin area involved) compared to 93% of 
patients with greater depigmentation (covering 5-10% of their skin) (Naughton et 
al. 1986b), although this would fit with either a primary or secondary causation. 
Vitiligo antibodies are most commonly directed against pigment cell 
antigens with molecular weights of 35 kDa, 40-45 kDa, 75 kDa, 90 kDa and 150 
kDa which are located on the cell surface, as determined by detection 
techniques specific to the cell exterior (Cui et al. 1992; Cui et al. 1995b). 
Although the proteins have not been specifically identified, some (40-45 kDa, 75 
kDa and 150 kDa) appear to be common tissue antigens, while others (35 kDa 
and 90 kDa) are preferentially expressed on pigment cells (Cui et al. 1992). In 
addition, antibodies to the melanocyte-specific proteins tyrosinase (Song et al. 
1994a; Baharav et al. 1996; Kemp et al. 1997a), TRP-1 (Kemp et al. 1998c), 
TRP-2 (Kemp et al. 1997b; Okamoto et al. 1998) and Pmel17 (Kemp et al. 
1998b) have been detected in the sera of patients with vitiligo. Although these 
proteins may be considered cytoplasmic autoantigens, with the exception of 
TRP-1 which can be expressed on the melanocyte surface (Takechi et aL 1996), 
a de novo mechanism may exist whereby antibodies recognise autantigens 
directly via cell surface or cytoplasmic penetration (Okamoto et al. 1998). For 
example, antibodies have been shown to be taken up by nonhemopoietic cells 
and react with nuclear antigens in vivo (Isenberg et al. 1997). Alternatively, 
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antigens may be released if the melanocyte is damaged by another mechanisms 
such as cytotoxic T cell lysis. In a recent study, the transcription factors SOX9 
and SOX10 have been identified as melanocyte autoantigens related to vitiligo 
in patients with autoimmune polyglandular syndrome type 1 (Hedstrand et al. 
2001). A summary of the antibody autoantigens implicated in the disorder is 
given in Table 1.8. 
The capacity for anti-melanocyte antibodies to injure pigment cells has 
been demonstrated experimentally: vitiligo antibodies are able to destroy 
melanocytes in vitro by complement-mediated cytotoxicity and antibody- 
dependent cellular cytotoxicity (Norris et al. 1988b) and in vivo following passive 
immunisation of nude mice grafted with human skin (Gilhar et al. 1995). The 
selective destruction of melanocytes in vitiligo may result from antibody reactivity 
directed to the antigens preferentially expressed on pigment cells (Cui et al. 
1992). Alternatively, an antibody response against antigens expressed on a 
variety of cell types may selectively destroy melanocytes because they have 
been shown to be intrinsically more sensitive to immune-mediated injury than, 
for example, keratinocytes or fibroblasts (Norris et al. 1 988a). 
The stimulus for the production of anti-melanocyte antibodies has not 
been identified and it is unknown whether vitiligo antibodies initiate the 
development of the disease. It is possible that cross-reacting antigens 
expressed either on other cell types or on infecting micro-organisms may elicit 
their production. For example, common antigens have been identified in 
mycobacteria and malignant melanocytes (Bystryn 1997). Alternatively, vitiligo 
antibodies might result from a secondary immune response to melanocyte 
antigens following damage to pigment cells by other mechanisms, and these 
antibodies might further exacerbate the condition. It is presently unknown if 
humoral immune responses actually damage melanocytes in vivo and it is still 
possible that they play no direct part in vitiligo aetiology. Nontheless, these 
antibodies serve as relevant markers to identify potential autoantigens, even if 
the disease is T cell-mediated. 
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1.4.2.3 Other antibody reactivities 
Aside from organ-specific antibodies (Table 1.7), anti-keratinocyte intracellular 
antibodies that correlate with disease extent and activity have been detected in 
vitiligo patients (Yu et al. 1993) and specific IgA reactivity against human 
melanoma cells in patients with active vitiligo has been reported (Aronson & 
Hashimoto 1987). An increased incidence of anti-nuclear, anti-microsomal, and 
anti-smooth muscle cell antibodies has also been observed in the sera of vitiligo 
patients (Hann et al. 1993a). A significant number of vitiligo patients also have 
antibodies against compounds containing the benzene ring structure (Wojdani et 
al. 1992; Vojdani & Grimes 1996). These were investigated for immune 
reactivity because compounds containing the benzene ring, including catechols, 
phenols, hydroquinone and mono-benzene, can induce cutaneous 
depigmentation (Section 1.2.5). Although the nature of the action of the anti- 
benzene ring antibodies is not proven, it has been suggested that exposure to 
compounds containing this structure may induce aberrant immunological 
responses in some individuals with vitiligo (Wojdani et al. 1992; Vojdani & 
Grimes 1996). As with melanocyte antibodies, although to a greater degree, it is 
presently unclear how these antibodies relate temporally and pathogenically to 
the lesions in vitiligo. 
1.5 Melanoma-associated hypopigmentation 
Metastatic malignant melanoma is a form of skin cancer caused by uncontrolled 
growth of melanocytes. It responds poorly to standard treatments, including 
chemotherapy and radiotherapy, and patients with distant metastases have a 
poor prognosis (Okamoto et al. 1998; Kawakami et al. 2000). However, the 
spontaneous appearance of a vitiligo-like depigmentation, termed melanoma- 
associated hypopigmentation, in approximately 10% of metastatic melanoma 
patients (Merimsky et al. 1994), during the course of their disease, is thought to 
be associated with an improved prognosis (Nordlund et al. 1983; Bystryn et al. 
1987; Richards et al. 1992). In animal models of melanoma in which 
hypopigmentation is observed, such as Arabian and Lipizzaner horses and the 
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Sinclair miniswine, the disease progresses more slowly and can also regress 
(Lerner & Cage 1973; Oxenhandler et al. 1979). 
Melanoma-associated hypopigmentation is thought to arise from immune 
reactivity to the metastatic disease directed against common antigens on both 
the melanoma cells and normal melanocytes. Indeed, antibodies reactive to 
tyrosinase (Fishman et al. 1997), TRP-1, TRP-2, Pmel17 (Huang et aL 1998) 
and melanoma cells (Naughton et al. 1983a) have been identified in some 
melanoma patient sera. Antibody responses to pigment cell antigens of 40-45 
kDa, 75 kDa and 90 kDa, yet to be fully characterised, that are also recognised 
by patients with vitiligo have also been identified in melanoma patients (Cui & 
Bystryn 1995). Additionally, some melanoma patients have cytotoxic T 
lymphocytes specific to tyrosinase (Brichard et al. 1993), TRP-1 (Wang et al. 
1995), and TRP-2 (Wang et al. 1996), Pmel17 (Kawakami et al. 1995) and 
MelanA (Coulie et al. 1994). These responses to melanocyte-specific antigens 
and their potential to induce the rejection of melanoma have led to the 
development of active, specific immunotherapy treatments for melanoma 
including DNA and peptide vaccines, and adoptive transfer of tumor-infiltrating 
lymphocytes, in addition to non-specific cytokine therapy using IL-2 to stimulate 
proliferation of activated T cells. 
The clinical efficacy of immune therapy for the treatment of metastatic 
melanoma is currently being studied. Vaccination with the melanoma- 
associated antigens; tyrosinase (Robbins et al. 1994), Pmell7 (Kawakami et aL 
1994b), MAGE-1 (Noon et aL 1995), and melanoma cell vaccines (Morton et al. 
1992; Hayashi et al. 1993) has been shown to induce antigen-specific antibodies 
and cell-mediated immunity in melanoma patients. Melanoma-associated 
hypopigmentation has been reported in patients responding to immune therapy; 
for example, IL-2 administration alone induced depigmentation in 20% of 
patients (Rosenberg & White 1996), and the appearance of vitiligo-like lesions 
has been reported in patients vaccinated with TRP-2 (Okamoto et al. 1998) and 
MelanA/MART-1 (Yee et al. 2000), both at sites of vaccination and distant 
locations. Recent immunisation strategies have involved vaccination with 
autologous dendritic cells, pulsed with either tumour lysates or melanoma- 
associated peptides, to act as antigen presenting cells to acquire tumor-specific 
cytotoxic T cell reactivity (Nestle et al. 1998). 
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It has been suggested that the immune response in melanoma patients 
which results in melanocyte destruction is cell-mediated, operating via 
mechanisms involving CD8+ T cells and natural killer cells, and does not occur 
by means of a humoral response (van Elsas et al. 1999; Nagai et al. 2000; Yee 
et al. 2000). It is possible that the melanocyte-specific antibodies in patients 
with melanoma arise as a secondary immune response following melanocyte 
damage through cell-mediated effects. Moreover, the serum titres of melanoma- 
associated antibodies are low, and levels are similar between patients with and 
without melanoma-associated hypopigmentation. However, the amount of 
measurable antibody may be decreased due to the formation of immune 
complexes, the trapping of antibodies by shed antigen or a high number of 
binding sites on the melanocytes thereby reducing the amount of free antigen 
(Merimsky et al. 1996). Experimental immunotherapy treatments are currently 
being tried in a mouse model of melanoma, the C57BU6 strain, which develops 
the 1316 melanoma, and several studies have accomplished immune rejection of 
B16 melanoma accompanied by associated hypopigmentation (Hara et al. 
1995a; Weber et al. 1998; Bowne et al. 1999; Overwijk et al. 1999; van Elsas et 
al. 1999; Nagai et al. 2000). It has also previously been shown that passive 
administration of vitiligo patient immunoglobulin G (IgG) to C57BU6 mice results 
in the development of fewer metastases than mice injected with normal human 
IgG (Fishman et al. 1993). One author has speculated that vitiligo is "an 
experiment of nature that accomplishes the goal of melanoma immunotherapy" 
(Bystryn 1989). 
It is not known whether melanoma-associated hypopigmentation and 
vitiligo are the same disease. Despite a similar clinical appearance and a 
common association with abnormal immune reactivities to pigment cell antigens, 
it has yet to be established if they have an identical aetiology. Melanoma 
patients with associated hypopigmentation have been variously reported to have 
circulating antibodies with different (Merimsky et al. 1994), or shared (Cui & 
Bystryn 1995) specificities providing evidence that they have distinct or similar 
aetiologies, respectively. More insight will be gained as the immune response in 
each disease is further characterised. 
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1.6 Implications of understanding autoimmune responses in 
vitiligo 
Characterising the autoimmune response in vitiligo has several potential clinical 
implications and applications. It is possible that elucidating the mechanisms 
involved in the abnormal immune response in vitiligo may lead to the 
development of more effective treatments, as well as a greater understanding of 
the action of current immunosuppressive treatments, such as PUVA, which are 
effective in some cases of vitiligo. The identification of melanocyte autoantigens 
recognised by autoantibodies and/or autoreactive T cells in vitiligo patients might 
be of use in the diagnosis of the disorder and in the development of markers for 
disease activity and progression. If autoimmune responses could be identified 
routinely, more appropriate treatments could be applied to individual patients. It 
may also be possible to establish whether particular clinical subtypes of vitiligo 
do indeed have separate disease aetiologies. Furthermore, characterisation of 
pigment cell antigens that can elicit either a humoral or cellular immune 
response to melanocytes in vitiligo could provide new targets for gene/peptide 
vaccines in melanoma. 
1.7 Aims of this study 
The overall aim of this study was to investigate the immune aspects of vitiligo 
with particular reference to identifying and characterising melanocyte 
autoantigens recognised by autoantibodies in sera from vitiligo patients. The 
following specific aims were addressed: 
(1) To examine any association of a microsatellite polymorphism of the 
immunoregulatory gene cytoxic T lymphocyte-associated antigen 4 (CTLA-4) in 
patients with vitiligo, in order to determine potential subgroups in which 
autoimmune responses may be more frequent. 
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(2) To characterise the B cell epitope reactivity of two previously identified 
vitiligo autoantigens, namely tyrosinase and Pmel17. 
(3) To investigate the prevalence of autoantibodies to the melanosomal 
protein MelanA/MART-1 which forms a significant antigenic target for cytotoxic T 
lymphocytes in vitiligo. 
(4) To construct a phage-display library of melanocyte polypeptides and to 
apply a novel biopanning technique using vitiligo patient IgG to identify novel 
disease autoantigens. 
(5) To investigate the frequency in vitiligo patient sera of autoantibodies 
targeting any novel autoantigens identified using the phage-display library. 
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2 General Materials and Methods 
2.1 Patient sera 
Sera from patients with vitiligo and other autoimmune diseases were collected 
from dermatology and endocrinology clinics at the Northern General Hospital, 
Sheffield, U. K., and the Royal Hallamshire Hospital, Sheffield, U. K. between 
1990-2001. Specific patient details are given in the relevant chapters. Control 
sera were also obtained from healthy laboratory volunteers with no personal or 
family history of vitiligo or of autoimmune disorders. Serum was separated from 
whole blood samples (10-20 ml) by centrifugation in a Sorval® RT6000-D 
centrifuge (3000 revolutions per minute (rpm), 10 min). Sera were kept frozen at 
-20°C until use. 
All work was approved by the Ethics Committee of the Northern General 
Hospital NHS Trust, and all subjects gave informed consent. 
2.2 Chemicals 
The majority of chemicals were purchased from either Sigma (Poole, U. K. ), or 
BDH, (Poole, U. K. ), and were of either molecular biology grade or `AnaIR' grade, 
respectively. The source of some chemicals is indicated in the text where 
appropriate. 
2.3 Media 
The media used in this study are given below. All media were sterilised either 
by autoclaving or by filtration using Millipore GS disposable filters (Millipore 
Corp., Bedford, MA, U. S. A). 
2.3.1 Luria Bertani (LB) medium and agar 
Luria Bertani (LB) medium was prepared in double distilled water and contained: 
1% (w/v) Bacto-tryptone (Sigma), 0.5% (w/v) yeast extract (Sigma) and 1% (w/v) 
NaCl (Sigma). Luria Bertani agar was made by adding 1.5% (w/v) Bacto-agar 
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(Sigma) to LB medium. After sterilisation, the agar was left to cool to 40-45°C 
before the addition of appropriate antibiotics. The agar was then poured into 90 
mm petri-dishes, allowed to set and the plates stored at 4°C until required. 
2.4 Antibiotics 
Antibiotics (Sigma) were prepared as 100x concentrated stocks in double- 
distilled water, sterilised by filtration with a Millex® Filter Unit (Millipore Corp. ) 
and used in medium at either the final concentration shown below or as stated in 
the text. Tetracycline was dissolved in 50% (v/v) ethanol/H20. The stocks were 
stored at -200C. 
Final concentration 
in medium (Ng/ml): 
Ampicillin 100 
Kanamycin 12 
Tetracycline 10 
2.5 Bacterial strains 
The bacterial strains used in this study were derivatives of Escherichia coli K-12 
and are given in Table 2.1 a. Derivatives of strains carrying various plasmids 
were constructed by transformation (Section 2.12) and are defined in the text. 
2.6 Plasmids 
The plasmids used in this study are listed in Table 2.1b. They were kept at - 
20°C in sterile TE buffer (10 mM Tris-HCI; 1 mM ethylenediaminetetraacetic acid 
(EDTA); pH 8.0). Maps of the plasmid expression vectors used in DNA cloning 
experiments are given in the relevant chapters. 
48 
Table 2.1: Bacterial Strains and Plasmids used. 
a: Bacterial Strains 
E. coli K-12 strain Source Reference 
JM109 Promega Yanisch-Perron et al. 1985 
(Southampton, U. K. ) 
DH5a Clontech Laboratories Hanahan 1983 
U. K. Ltd. 
(Basingstoke, U. K. ) 
XL-1 Blue Stratagene Bullock et at. 1987 
(La Jolla, CA, U. S. A) 
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b: Plasmids 
Plasmid Characteristics Source 
pBluescript SK Multico? y 2.96 kb selectable R 
Stratagene 
) expression vector. (amp (La Jolla, CA, 
Multiple cloning site flanked by U. S. A) 
promoters for T3 and T7 
polymerases. 
pcDNA3 Multicopy 5.4 kb selectable Invitrogen 
(ampR) expression vector. (Abingdon, U. K. ) 
Contains promoters for T7 and 
SP6 polymerases flanking a 
diverse multiple cloning site. 
pBSTYR pBluescript SK with a 1.9 kb E. H. Kemp 
Xbal-Sall insert of tyrosinase (Division of Clinical 
cDNA Sciences North, 
University of 
Sheffield, U. K. ) 
pcDNA3TYR pcDNA3 with a 1.9 kb Kpnl- E. H. Kemp 
Xbal insert of tyrosinase 
cDNA. 
pcDNA3PmeI17 pcDNA3 with a 2.0 kb EcoRl- P. F. Robbins 
Xhol insert of Pmell7 cDNA (National Institues 
fragment of Health, 
Bethesda, MD, 
U. S. A. ) 
Reference 
Alting-Mees et at. 
1992 
Akrigg et al. 1985 
Boshart et al. 
1985 
Kemp et al. 1997a 
Kemp et at. 1997b I 
pSC11 MelanA pSC11 with a 400 bp Bglll- V. Cerundolo - 
Ncol insert of MelanA cDNA (Nuffield Department 
of Clinical Medicine, 
University of Oxford, 
U. K. ) 
pGEX-4T-1 A 4.9 kb glutathione S- Amersham Kaelin et al. 1992 
transferase fusion vector. Pharmacia Biotech 
Contains a tac promoter for (Little Chalfont, 
chemically inducible high-level U. K. ) 
prokaryotic expression. 
pJuFo A 4.28 bp (ampR) phage- 
display vector. Contains the 
leucine zippers Jun and Fos, 
and the viral coat protein, pill, 
of the filamentous phage. 
Prokaryotic expression under 
the control of lac promoter 
R. Crameri (Swiss Crameri & Suter 
Institute of Allergy 1993 
and Asthma 
Research, Davos, 
Switzerland) 
'AmpR, ampicillin resistance 
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2.7 Growth and maintenance of bacterial strains 
When first obtained, strains were checked for the presence of relevant antibiotic 
markers by streaking onto selective LB agar. All E. coli strains were routinely 
grown from single colonies on LB agar plates in LB medium, with the 
appropriate antibiotics, at 37°C in a rotary incubator shaking at 250 rpm. 
For storage, bacterial strains were streaked onto LB agar plates, 
containing appropriate antibiotics, and incubated overnight at 37°C and then 
placed at 4°C for up to one month. Additionally, 10 ml bacterial cultures were 
grown overnight at 37°C and then mixed with an equal volume of 50% (v/v) 
sterile glycerol/H20 for long-term storage at -20°C. 
2.7.1 Small-scale plasmid preparation 
The Wizard TM Minipreps DNA Purification System (Promega, Southampton, 
U. K. ) was used to purify plasmid DNA from a 5-10 ml overnight culture of a 
required bacterial strain, according to the manufacturer's protocol. Briefly, single 
colonies of the desired bacterial strain were isolated by streaking out 20 pi of 
frozen bacterial stock onto LB agar containing the appropriate antibiotic. A 
single colony from a selective plate was then used to inoculate 10 ml of LB 
containing the relevant antibiotic. This culture was shaken in a rotary incubator 
at 250 rpm at 37°C overnight. A bacterial cell pellet was obtained by 
centrifugation at 10,000 g for 5 min. The pellet was resuspended in 300 pl of 
WizardTM resuspension solution (50 mM Tris, pH 7.5; 10 mM EDTA; 100 pg/ml 
RNase A), and the cells were lysed by addition of 300 pi of WizardTM cell lysis 
solution (0.2 M NaOH; 1% (w/v) SDS) and then neutralised by addition of 300 pl 
of WizardTM neutralisation buffer (1.32 M potassium acetate). The resulting 
solution was mixed gently and centrifuged at 10,000 g for 10 min at room 
temperature. The clear lysate was then mixed with 1 ml of WizardTM resin and 
loaded on to a WizardTM minicolumn via a2 ml syringe, followed by 2 ml of 
WizardTM column wash solution (80 mM potassium acetate; 8.3 mM Tris-HCI, 
pH 7.5; 40 pM EDTA; 55% (v/v) ethanol). The WizardTM minicolumn was 
centrifuged at 10,000 g for 2 min to remove excess column wash solution prior 
to DNA elution. Fifty microlitres of TE buffer, heated to 65°C, was subsequently 
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added to the column, left for 1 min and then centrifuged at 10,000 g for 30 sec. 
The concentration of the DNA was determined by spectrophotometry at 260 nm. 
2.7.2 Large-scale plasmid preparation 
Larger scale overnight culture of a desired plasmid was prepared by inoculating 
0.5-1 L of LB (containing a relevant antibiotic) and growing as before, shaking, 
at 37°C. The culture was then centrifuged at 2500 rpm (Sorval® RC-3B) for 30 
min and plasmid extracted from the cell pellet using a Qiagen Plasmid DNA 
Maxiprep Kit (Qiagen Ltd., Crawley, U. K. ) as per the kit instructions. The 
bacterial cell pellet was first resuspended in 10 ml of buffer P1 (50 mM Tris-HCI, 
pH8.0; 10mM EDTA; 100 pg/ml RNase A). An equal volume of buffer P2 (0.2 M 
NaOH; 1% (w/v) SDS) was added to the resuspended cells and mixed by gentle 
inversion, followed by incubation at room temperature for 5 min. The tube was 
then mixed gently again after the addition of 10 ml of buffer P3 (1.32 M 
potassium acetate, pH 5.5) and incubated on ice for 20 min. The mixture was 
subsequently centrifuged at 20,000 g for 30 min at 4°C resulting in a clear 
supernatant. A Qiagen column was equilibrated by adding buffer QBT (750 mM 
NaCl; 50 mM 3-[N-morpholino]propanesulphonic acid (MOPS), pH 7.0; 15% 
(v/v) isopropanol and 0.15% (v/v) Triton X100) and was allowed to empty by 
gravity flow. Clear supernatant was then loaded onto the column and left to flow 
through, followed by washing of the column twice with 30 ml of QC buffer (1 M 
NaCl; 50 mM MOPS, pH 7.0; 15% (v/v) isopropanol). Plasmid DNA was 
subsequently eluted with 15 ml of buffer QF (1.25 M NaCl; 50 mM Tris-HCI, pH 
8.5; 15% (v/v) isopropanol) and precipitated by the addition of 10.5 ml of 
isopropanol and centrifugation at 15,000 g for 30 min at 4°C. The resulting DNA 
pellet was washed with 70% (v/v) ethanol, centrifuged at 15,000 g for 10 min at 
4°C and finally resuspended in 300 pl of TE buffer that had been pre-heated to 
65°C. The concentration of the DNA was ascertained by spectrophotometry at 
260 nm. 
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2.8 Restriction enzyme digestion 
All restriction endonucleases and restriction endonuclease reaction buffers were 
supplied by Promega. Restriction enzyme digests of plasmid and polymerase 
chain reaction (PCR) amplified products were carried out in a volume not 
normally exceeding 25 pl, containing 10 U of enzyme(s) and 0.1 volumes of an 
appropriate 10x concentration restriction buffer. Each reaction proceeded for 2 
h at 37°C, with the exception of Stil digestion reactions (Chapter 6) which were 
carried out at 50°C. A typical reaction comprised: 
1 NI 1 pg/NI DNA 
16 NI dH2O 
2 pI 1 Ox reaction buffer (Promega) 
1 NI 10 U/pl restriction endonuclease (Promega) 
2.9 Agarose gel electrophoresis 
Agarose gels, 0.8-1% (w/v), were prepared by boiling molecular biology grade 
agarose (Sigma) in TAE electrophoresis buffer (40 mM Tris-base; 0.1% (v/v) 
glacial acetic acid; 100 mM EDTA, pH 8.0) for 1-2 min in a microwave oven. 
One microlitre of ethidium bromide (10 mg/ml) was added for every 50 ml of the 
gel solution. The molten agarose was cooled and poured into the casting deck 
of a dedicated gel electrophoresis apparatus. After it had set, the combs were 
removed, and the electrophoresis tank was filled with TAE as a running buffer. 
A loading dye (6x: 0.25% (w/v) bromphenol blue; 40% (w/v) sucrose, Sigma) 
was added to the DNA, acquiring approximately 1/6th of the volume to be 
loaded, and this was then pipetted into the gel slots. A `marker' lane was always 
included which contained Hindi ll-restricted bacteriophage A DNA (Promega), 
with which to size the DNA products after they had migrated through the gel. 
The gels were run at 100 volts (V) and subsequently viewed using an ultraviolet 
transilluminator. 
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2.10 Preparation of DNA fragments from agarose gels 
When electrophoresis was performed to purify a particular DNA fragment, either 
from a PCR or a restriction digest, the DNA fragment of interest was recovered 
from the gel using a WizardTM PCR Prep DNA Purification Kit (Promega). 
Briefly, the area of the gel containing the relevant piece of DNA was excised 
using a clean scalpel and placed in a 1.5 ml eppendorf tube. One millilitre of 
purification resin was used to dissolve the gel slice and the resulting mixture was 
applied via a2 ml syringe to a WizardTM minicolumn followed by 2 ml of 80% 
(v/v) isopropanol. The Wizard TM minicolumn was centrifuged at 10,000 g for 2 
min, to remove excess isopropanol, prior to DNA elution with 30 pl of sterile TE 
buffer, which had been pre-heated to 65°C. 
2.11 DNA ligations 
Ligation of vector and DNA fragments was performed using T4 DNA ligase 
(Promega). An estimation of the concentration of each vector and insert was 
performed by agarose gel electrophoresis next to molecular weight markers of a 
known concentration. Approximately 200 ng of vector DNA were mixed together 
with insert, (the amount of which to be added was calculated using a molar ratio, 
vector: insert, of between 1 and 3), and sterile H2O added to a final volume of 18 
pi in a clean 0.5 ml tube. The mixture was heated to 65°C and gradually cooled 
to 16°C in a thermal cycler block, to allow DNA to anneal slowly, before addition 
of 1 pI of T4 DNA ligase enzyme (Promega) and 2 pI of 10x ligase buffer (300 
mM Tris-HCI, pH 7.8; 100 mM MgCl2; 100 mM dithiothreitol (DTT); 10 mM ATP) 
(Promega). The reaction was subsequently incubated at 16°C overnight. 
2.12 Bacterial transformation 
When required, a 100-pl aliquot of competent E. coli JM1 09 (Promega) cells was 
thawed. The appropriate DNA sample, usually 0.5-1 pg, was gently mixed with 
the cells and this was incubated on ice for 10 min. The cells were then heat 
shocked at exactly 42°C for 45 sec and returned to ice. After 2 min, the cells 
were transferred to a culture tube containing 990 pl of chilled SOC medium (Life 
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Technologies Ltd., Paisley, U. K. ) which comprises 2% (w/v) tryptone, 0.5% (w/v) 
yeast extract, 10 mM NaCl, 2.5 mM KCI, 10 mM MgCI2r 10 mM MgSO4 and 20 
mM glucose. The culture tube was placed in the rotary incubator and grown for 
1 h, to allow expression of the antibiotic resistance genes carried by the 
transforming plasmid DNA. A 100-pl aliquot of undiluted transformed cells, and 
of 1: 10 and 1: 100 dilutions, were then spread on agar plates containing the 
appropriate antibiotic, and incubated at 37°C overnight. A proportion of the 
colony forming units, which had selectively grown from successful 
transformations, were then picked with a sterile pipette tip and streaked on to 
fresh antibiotic plates for growth overnight at 37°C. 
2.13 Polymerase chain reaction 
Preceding the PCR reaction, oligonucleotide primers were appropriately 
designed to amplify regions of a DNA fragment (details are given where relevant 
in text). Reactions were carried out in 50-pl volumes comprising, unless 
indicated, 50 ng of template DNA, 0.3 mM of each required (forward and 
reverse) primer, 1U of ExpandTM High Fidelity Taq polymerase (Roche 
Diagnostics Ltd., Lewes, U. K. ), 0.1 mM deoxynucleotides (Promega), in buffer 
containing 1.5 mM MgC12,10 mM Tris-HCI (pH 8.3), 0.01% gelatin, 50 mM KCI, 
0.1% Tween 20 and 0.1% Nonidet P-40 (Roche Diagnostics Ltd. ). Each 
reaction was overlaid with a drop of mineral oil to prevent evaporation during 
heating and was subject to PCR amplification in a DNA Thermal Cycler (Perkin- 
Elmer/Cetus, Norwalk, CT, U. S. A. ) using the conditions stated in the text. 
2.14 Direct purification of PCR products 
PCR amplification products were directly extracted from the PCR constituents 
using a WizardTM PCR Prep DNA Purification Kit (Promega). Briefly, one or 
more PCR reactions assuming a volume of no more than 300 pl, were mixed 
with 100 pl of WizardTM direct purification buffer (50 mM KCI; 10 mM Tris-HCI, 
pH 8.8; 1.5 mM MgCl2; 0.1% (v/v) Triton X-100). One millilitre of WizardTM PCR 
Prep DNA Purification resin was added and the mixture vortexed briefly three 
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times during a period of 1 min. The mixture was then applied to a WizardTM 
minicolumn, which was treated as previously described in Section 2.10. 
2.15 DNA sequencing 
Sequencing of plasmid DNA was performed using a T7 Sequenase® Version 2.0 
DNA Sequencing Kit (Amersham Pharmacia Biotech, Little Chalfont, U. K. ) by 
the dideoxy-chain termination method (Sanger et al., 1977) using the 
appropriate oligonucleotide primer and [a 35S]dATP (NEN, Hounslow, U. K. ), as 
outlined below. Sequencing of PCR amplification products performed according 
to a Thermo Sequenase Cycle Sequencing Kit (USB Corp., Cleveland, OH, 
U. S. A. ) with [y_32 P]ATP (ICN Pharmaceuticals Ltd., Basingstoke, U. K. ) is 
described separately in Chapter 6. 
One-to-three micrograms of plasmid DNA in a volume of 10 pl of TE were 
denatured by incubation at 37°C with 1 pl of 2 mM EDTA (pH 8.0) and 1 pl of 2 
M NaOH for 30 min. One microlitre of 3M sodium acetate (pH 5.2) and 50 pl of 
100% ethanol were added and the DNA was precipitated at -20°C for 1-2 h. A 
pellet was collected by centrifugation at 12,000 g for 15 min and was air-dried, 
before being resuspended in 10 pl of diluted sequencing primer mixture 
containing 7 pl sterile dH2O, 2 pl of T7 Sequenase® reaction buffer and 1-5 pmol 
of the relevant primer (details are given where appropriate in text). The reaction 
was then heated to 65°C for 2 min, to allow annealing of the primer with its 
target sequence, prior to slow cooling to 0°C. 
Two-point-five microlitres of each of four termination mixes (ddGTP, 
ddATP, ddTTP, ddCTP; ddGTP contained 80 pM each dGTP, dATP, dTTP, 
dCTP and 8 pM ddGTP; ddATP as before except ddGTP replaced with 8 pM 
ddATP; ddTTP as before except with 8 pM ddTTP; ddCTP as before except with 
8 pM ddCTP) were aliquoted to separate tubes and heated to 37°C. To the 
annealed DNA, 1 pl DTT, 2 pl diluted labelling mix (7.5 pM dGTP, 7.5 pM dTTP 
and 7.5 pM dCTP 5x concentrate, diluted to 1x with sterile H20), 1 PI [a- 
35S]dATP (1250 Ci/mmol; 12.5 mCi/ml; NEN) and 2 pl diluted T7 Sequenase® 
polymerase (diluted 1: 8 with enzyme dilution buffer) were added. This was 
incubated at room temperature for 2 min before 3.5 pl was removed from the 
reaction into each of the four tubes containing dideoxynucleotides. These were 
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then incubated at 37°C for five min after which 4 pl of stop solution were added. 
The tubes were subsequently heated at 85°C to denature the DNA and then 
applied to sequencing gels for electrophoresis as described below. 
2.16 Sequence gels and autoradiography 
The sequencing reactions were resolved on 6% (w/v) polyacrylamide gels 
containing 7mM urea, 89 mM Tris-base, 2 mM EDTA (pH 8.0), 89 mM boric 
acid, and 0.03% (w/v) ammonium persulphate and 0.07% (v/v) of N, N, N, N'- 
tetramethylethylenediamine (TEMED). A standard non-gradient sequencing gel 
apparatus, (Bio-Rad Laboratories Ltd., Hemel Hempsted, U. K. ), was used in the 
set up. The gel running buffer contained 89 mM Tris-base, 2 mM EDTA (pH 8.0) 
and 89 mM boric acid. The gel and buffer were warmed to 50°C prior to 
electrophoresis by running at 2000 V for one hour. Gel slots were flushed with 
buffer to remove any urea and unpolymerised acrylamide. DNA sequence 
reactions were then loaded. Gels were run at a voltage of approximately 1800 V 
for 2 to 4h at 50°C depending on the length of the sequence to be studied. 
After the reactions had run to the desired extent, the current was turned off, 
apparatus dismantled and the gel fixed in 12% (v/v) methanol, 10% (v/v) glacial 
acetic acid. The gel was then transferred to a sheet of 3MM blotting paper 
(Whatman International Ltd., Maidstone, U. K. ) and dried (Bio-Rad Gel Dryer 
583; Bio-Rad Laboratories Ltd. ) at 80°C for 2 h. 
The dried gel was subjected to autoradiography by exposure to Fuji RX 
x-ray film (Genetic Research Instrumentation Ltd., Dunmow, U. K. ) in a 
HypercassetteTM (Amersham Phamarcia Biotech) at room temperature for 24 h. 
The film was subsequently developed using Photosol CD18 x-ray developer 
(Photosol Ltd., Basildon, U. K. ) for 3 min, rinsed in water and then fixed for 3 min 
in Photosol CF40 fixer (Photosol Ltd. ). 
2.17 SDS-PAGE and autoradiography 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of 
protein samples was performed in 12,12.5, or 15% SDS-polyacrylamide 
resolving gels. The exact constitution of gels and associated buffers is shown in 
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Table 2.2. The percentage acrylamide of the gel varied according to the size of 
the protein products to be electrophoresed. The gels were created using a Bio- 
Rad Protean II apparatus (Bio-Rad Laboratories Ltd. ). 
Briefly, two glass plates (12 cm2 and 12 x 16 cm) and 1 mm spacers were 
assembled using the dedicated equipment according to the manufacturer's 
instructions. The resolving gel solution was poured into the space between the 
plates, (to a level approximately 5 cm from the top of the smaller plate), and 
overlaid with 1 ml butan-1-ol. After the gel mixture had polymerised the butanol 
was poured off, and a comb was inserted before the solution for the stacking gel 
was poured in on top. Subsequently, the comb was removed and the full 
apparatus assembled. Laemilli buffer (250 mM Tris-base; 0.1% (w/v) SDS, 0.2 
M glycine) was poured into the tank until the bottom of the plates was covered 
and the top reservoir was full. 
Prior to loading, each protein sample was mixed with 2x SDS sample 
buffer (2x: 4% (w/v) SDS; 20% (v/v) glycerol; 0.002% (w/v) bromophenol blue; 
2% (v/v) 2-mercaptoethanol; 25% (v/v) buffer B (Table 2.2)) and heated at 85°C 
for 5 min. Between ten and thirty microlitres of each sample was then loaded 
into the wells along with a protein molecular weight marker (Sigma). Protein 
molecular weight standards used were: myosin, 205 kilodaltons (kDa); ß- 
Galactosidase, 116 kDa; phosphorylase B, 97 kDa; bovine albumin, 66 kDa; 
ovalbumin, 45 kDa; glyceraldehyde-3-phosphate dehydrogenase, 36 kDa; 
carbonic anhydrase, 29 kDa; trypsinogen, 24 kDa; soybean trypsin inhibitor, 20 
kDa; a-lactalbumin, 14 kDa. Gels were run at a current of 35 milli-amperes (mA) 
for 3-5 h or until the visible dye front had reached the bottom of the plates. The 
apparatus was subsequently dismantled and the gel transfered to a plastic tray 
and covered with Coomassie® Blue stain (0.05% (w/v) Coomassie® Brilliant 
Blue, Bio-rad Laboratories Ltd.; 10% (v/v) glacial acetic acid; 25% (v/v) 
isopropanol). This was placed on a rocking platform. After a minimum of 30 min 
staining the gel was destained, by repeated fresh additions of a solution 
containing 10% (v/v) glacial acetic acid/ 25% (v/v) isopropanol, until the protein 
markers were clearly visible. The destain was discarded and the gel was 
soaked for a further 30 min in Amplify scintillant (Amersham Pharmacia 
Biotech), before being dried for 2h at 60°C onto 3MM Whatman paper. 
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Table 2.2: Constitution of SDS-PAGE1 gels. 
Resolving gel: 
Constituent 
Buffer A: 
Tris-Base (BDH) 
SDS2 (Sigma) 
Acrylamide: bisacrylamide (37.5: 1) 
(Bio-Rad Laboratoriesn Ltd. ) 
Ammonium persuiphate (BDH) 
TEMED3 (Sigma) 
Final concentration in gel 
OA M 
0.1 % (w/v) 
12% (w/v) or 12.5% (w/v) or 15 % (w/v) 
0.04% (w/v) 
0.0004% (v/v) 
Stacking gel: 
Constituent Final concentration in gel 
Buffer B: 
Tris-Base 0.125 M 
SDS 0.1 % (w/v) 
Acrylamide: bisacrylamide (37.5: 1) 4% (w/v) 
Ammonium persulphate 0.05% (w/v) 
TEMED 0.075% (v/v) 
1SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis. 2SDS, sodium 
dodecyl sulphate. 3TEMED, N, N, N, N'-tetramethylethylenediamine. 
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Gels containing radiolabelled proteins were exposed to Fuji RX x-ray film at - 
70°C for the required time (usually overnight) and then developed as in Section 
2.16. 
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3 Analysis of a microsatellite polymorphism of the 
cytotoxic T lymphocyte antigen-4 gene in patients 
with vitiligo. 
3.1 Introduction 
3.1.1 Cytotoxic T lymphocyte antigen-4 structure and function 
The cytotoxic T lymphocyte antigen-4 (CTLA-4) is aT cell surface protein that 
was first identified by differential screening of a murine cytolytic T cell cDNA 
library (Brunet et al. 1987). The protein is classified within the immunoglobulin 
(Ig) superfamily (Brunet et al. 1987) since initial studies have demonstrated that 
it has an Ig-like structure consisting of a membrane-bound single variable 
domain (Brunet et al. 1987; Dariavach et al. 1988; Harper et al. 1991). This is 
illustrated in Figure 3.1a. In addition, the structure of CTLA-4 is very similar to T 
lymphocyte receptors that are involved in transmembrane signalling, including 
the CD3 complex (van den Eisen et al. 1984; Gold et al. 1986) and CD28 (Aruffo 
& Seed 1987), and is also highly conserved between human and mouse 
(Dariavach et al. 1988; Harper et al. 1991). 
CTLA-4 is found on the surface of T lymphocytes following T cell 
activation (Brunet et al. 1987; Linsley et al. 1992; Alegre et al. 1996) induced by 
the interaction of the T cell receptor with a MHC antigen/peptide complex 
together with an appropriate costimulatory signal (June et al. 1994). CTLA-4 
appears to act as a negative regulator of T cell activation (Bluestone 1997; 
Oosterwegel et al. 1999) through engagement with the B7 family of ligands 
(Green et al. 1994) on antigen presenting cells (APC). Functional studies have 
also shown the receptor to be involved in the negative control of T cell 
proliferation (Robey&Allison 1995) and in mediating T cell apoptosis (Gribben et 
al. 1995). This is in direct contrast to the role of the structurally homologous T 
cell receptor CD28 which also acts through B7 costimulation, but which is 
essential for the proliferation of activated T lymphocytes (Krummel & Allison 
1995). 
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(a) 
disulphide bridges 
CTLA-4 protein 
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Transmembrane domain 
Cytoplasmic tall 
(b) 
5' 
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Leader v-domain Transmembrane Cytoplasmic 
sequence domain tail 
3' 
Figure 3.1: A schematic diagram of: (a) the CTLA-4 protein; (b) the CTLA- 
4 gene. 
(Adapted from June of al. 1994). 
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region 
3.1.2 The CTLA-4 gene and its polymorphisms 
The CTLA-4 receptor is encoded by the CTLA-4 gene which is located at band 
q33 of chromosome 2 (Harper et al. 1991). Analysis of the preliminary 
sequence of the human CTLA-4 gene revealed three exon regions encoding the 
variable, transmembrane, and cytoplasmic domains of the protein, respectively 
(Dariavach et al. 1988). However, subsequent sequence data demonstrated the 
presence of a fourth exon containing the leader sequence (Harper et al. 1991) 
and the initial nomenclature was altered. A schematic representation of the 
gene, indicating the different functional domains of the protein, is shown in 
Figure 3.1 b. 
Three polymorphisms have been defined within the CTLA-4 gene as 
follows: a promoter polymorphism with a cytosine to thymine (C/T) substitution 
at position -318 (Deichmann et al. 1996), an exon 1 polymorphism with an 
adenine to guanine (A/G) substitution at position +49 (Harper et al. 1991) and a 
microsatellite polymorphism with variant lengths of a dinucleotide (AT),, repeat 
beginning at position +642 of the 3'-untranslated region (UTR) of exon 4 
(Polymeropoulos et al. 1991). Figure 3.2 demonstrates the sites described for 
these polymorphisms in a schematic map of the CTLA-4 gene. 
How these various polymorphisms affect the expression or function of 
CTLA-4 is open to speculation. The microsatellite polymorphism has a possible 
functional significance to the molecule as differences in the length of the (AT)n 
repeat in the 3'-UTR of the CTLA-4 gene could affect mRNA stability (Yanagawa 
et al. 1995). For example, it is well established that AT-rich regions in 3'-UTRs 
can affect RNA stability, particularly of cytokine genes (Shaw & Kamen 1986). 
The promoter polymorphism does not affect any known consensus sequence in 
the regulatory region of the promoter (Deichmann et al. 1996) and is therefore 
unlikely to affect CTLA-4 expression. The A to G transition at position +49 in 
codon 17 results in an amino acid exchange (threonine to alanine) in the leader 
sequence of the CTLA-4 gene, but is not expected to affect the function of the 
leader peptide (Nistico et al. 1996). However, recent in vitro studies suggest 
that both the promoter and exon 1 polmorphisms may indeed influence the level 
of CTLA-4 gene expression and the inhibitory function of the protein. Ligers et 
al. 2001 reported that peripheral blood mononuclear cells (PBMC) from 
individuals with a thymine at position -318 of the CTLA-4 promoter, who are 
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also homozygous for adenine (A/A) at position +49 of exon 1, show significantly 
increased expression of CTLA-4 when compared with PBMC from individuals 
without this genotype. In addition, Kouki et al. 2000, demonstrated that 
peripheral blood T cells cultured from individuals homozygous for guanine (G/G) 
at position +49 of exon 1 showed greater proliferation in response to stimulation, 
by incubation with allogenic B cells, than those from A/A individuals. 
Furthermore, these cells showed reduced augmentation of the same 
proliferative response when binding of CTLA-4 was prevented with blocking 
antibodies, therefore suggesting that CTLA-4 protein is less able to negatively 
regulate T cell proliferation in G/G individuals (Kouki et al. 2000). Further 
experiments are needed to determine how these apparent genotypic affects are 
mediated. 
3.1.3 CTLA-4 and its relationship to autoimmunity 
The role of CTLA-4 in autoimmunity has yet to be established but since the 
receptor plays a part in the regulation of the immune response by modulating T 
cell reactivity, it is possible that defective CTLA-4 expression or function may 
predispose to the development of autoimmune disease. This hypothesis is 
increasingly supported by experimental evidence. For example, a lethal 
lymphoproliferative disorder in CTLA-4 knockout transgenic mice was 
characterised by T cell infiltration of multiple organs and destruction of tissue 
(Waterhouse et at 1995). Recent studies, in which the CTLA-4 protein is 
manipulated in animal models of autoimmunity, have demonstrated that it is 
capable of regulating the initiation and progression of autoimmune diseases. 
The development of experimental autoimmune encephalomyelitis, a murine 
model of multiple sclerosis, can be accelerated and exacerbated by the 
blockade of CTLA-4 and its B7 ligand by intra-peritoneal administration of an 
anti-CTLA-4 antibody (Karandikar et al. 1996). The disease can also be 
prevented by both systemic intra-peritoneal administration and intra-cranial 
delivery direct to the central nervous system (CNS) of a cross-linking CTLA-4 
immunoglobulin (Croxford et al. 1998). In addition, the onset of autoimmune 
disease in diabetic mice can be induced far more rapidly and aggressively by in 
vivo administration of anti-CTLA-4 antibody (Luhder et al. 1998). 
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The experiments described above raise the possibility that 
polymorphisms in the CTLA-4 gene may modulate the function of the resulting 
protein, in turn promoting the development of autoimmune disease. Indeed, 
recent results have revealed associations between polymorphic regions of the 
CTLA-4 gene and various autoimmune disorders, the details of which are 
summarised in Table 3.1. In particular the 106 base pair allele of the exon 4 
microsatellite polmorphism, the G allele of the exon 1 diallelic polymorphism and 
the T allele of the diallelic polymorphism in the promoter have been associated 
with autoimmune disease 
3.2 Aim 
Since vitiligo is frequently associated with autoimmune disorders and may have 
an autoimmune origin, the CTLA-4 exon 4 microsatellite polymorphism was 
analysed in a series of patients with vitiligo to determine whether or not an 
association exists between this disorder and the gene polymorphism. 
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3.3 Materials and Methods 
3.3.1 Patients and controls 
Sixty-four consecutive British vitiligo patients (19 males, 45 females) were 
included in this study. They had been examined in dermatology and 
endocrinology clinics in Sheffield between January 1990 and October 1997. A 
summary of the patient details is presented in Table 3.2. When characterised 
with respect to the presence of associated autoimmune disorders: 46 patients 
had no other disease (18 males, 28 females); 18 had one or more autoimmune 
disorders (1 male, 17 females). The 173 (84 males, 89 females) regionally 
matched, healthy controls had no clinical evidence of vitiligo or any other 
autoimmune disorder. 
3.3.2 Polymerase chain reaction amplification of the CTLA-4 gene 
exon 4 microsatellite polymorphism 
Briefly, a microsatellite polymorphism in exon 4 of the CTLA-4 gene was 
analysed by PCR amplification of genomic DNA. The products were resolved on 
sequencing gels and, due to the inclusion in the PCR amplification reaction of a 
radiolabelled nucleotide [a_32 P]dCTP, could be visualised by autoradiography. 
High molecular weight genomic DNA was prepared from heparinized 
venous blood samples (10-20 ml) using a Gentra Systems Puregene DNA 
Isolation Kit (Flowgen, Lichfield, U. K. ). Approximately 5 pg of DNA was 
produced per 0.5 ml of blood applying the manufacturer's protocol. The DNA 
was resuspended in sterile TE buffer and stored at -20°C until use. The primers 
used were 5'GCCAGTGATGCTAAAGGTTG3' and 5'AACATACGTGCTCTAT 
GCA3' (R and D Systems, Abingdon, U. K. ) and were designed to amplify a 
polymorphic (AT)n repeat site beginning at base pair 642 in the 3'-untranslated 
region of exon 4 of the human CTLA-4 gene. Samples of DNA (50 ng) were 
subjected to 34 amplification cycles using the following conditions: 94°C, 1 min; 
55°C, 1 min; 72°C, 1.5 min; and 72°C for 10 min to terminate the reaction. The 
composition of each PCR amplification reaction was as previously described 
(Chapter 2; 2.13), except that each contained deoxynucleotides dATP, dTTP and 
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dGTP at a concentration of 0.1 mM, but with dCTP at 0.01 mM and 0.5 pCi of [a- 
32P]dCTP (10 mCi/ml; 3000 Ci/mmol; Amersham Pharmacia Biotech). 
Amplified products were resolved in 6% (w/v) polyacrylamide gels 
(Section 2.16). Gels were dried and autoradiographed at -70°C using Fuji x-ray 
film (Section 2.16). Genotypes were determined by comparing to OX174 
DNA/Hinfl markers (Promega) and confirmed by comparison with a dideoxy 
sequencing ladder. 
Figure 3.3 shows an autoradiogram executed by Yanagawa et al. (1995), 
that demonstrates all alleles of the CTLA-4 microsatellite polymorphism which 
are detected by this methodology. 
3.3.3 Statistical analysis 
The frequency of the CTLA-4 106 base pair allele was compared between vitiligo 
patients and controls by 2x2 contingency tables and chi-squared tests. Yates' 
correction was applied and P values < 0.05 (two-tailed) were regarded as 
significant. Where sample values were small, for example when comparing data 
between clinical subclasses of vitiligo and controls, Fisher's exact test was used. 
Odds ratios associated with the 106 base pair allele were calculated by the 
method of Woolf (Woolf 1955). 
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Table 3.2: Summarised details of patients included in this study. 
Gender (female: male) 45: 19 
Mean age (yr) 46 
Age range (yr) 7-78 
Mean age of onset (yr) 30 
Age range of onset (yr) <1-70 
Mean disease duration (yr) 16 
Range of disease duration (yr) <1-60 
Vitiligo type: 
Symmetrical 26 females, 11 males 
Segmental 5 females 
Focal 2 females, 2 males 
Symmetrical/peri-orificial 8 females, 4 males 
Occupational 1 male 
Extensive/near total 3 females 
Halo naevi 1 male 
Autoimmune disorders: - 
Autoimmune thyroid disease 13 females 
Autoimmune polyglandular syndrome type 2 2 females 
Alopecia areata 2 females, 1 male 
Addison's disease 1 female 
Type 1 diabetes mellitus 2 females 
Systemic lupus erythematosus 1 female 
Pernicious anemia 1 female 
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Figure 3.3: An autoradiogram of the CTLA-4 gene microsatellite 
polymorphism. 
(Reproduced from an original figure by Yanagawa et al. 1995). 
Lane M on both sides contains size markers. The genotype of each sample is as follows: 
Lane 1,96/134; 2,98/108; 3,100/88; 4,102/130; 5,104/88; 6,106/88; 7,108/126; 8, 
110/88; 9,112/88; 10,114/88; 11,116/88; 12,118/108; 13,120/106; 14,122/106; 15, 
124/106; 16,126/108; 17,128/88; 18,130/106; 19,132/106; 20,134/96. 
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3.4 Results 
3.4.1 Frequency of the CTLA-4 106 base pair allele in vitiligo patients 
and controls 
Twenty-one CTLA-4 microsatellite polymorphic alleles were observed as 
previously described (Polymeropoulos et al. 1991; Yanagawa et al. 1995; Nistico 
et al. 1996; Kotsa et al. 1997; Kemp et al. 1998a), with sizes ranging from 88 to 
134 base pairs. The distribution of these genotypes is shown in Table 3.3. An 
example of a typical autoradiogram of CTLA-4 genotypes obtained in this study 
is shown in Figure 3.4. 
In vitiligo patients as a whole, the frequency of the 106 base pair allele 
was significantly increased (x2 = 5.96; P=0.01) when compared to healthy 
controls. However, when the patients were divided into those with and those 
without an autoimmune disorder, a significant increase (x2 =1 3.73; P=0.0002) in 
the frequency of the 106 base pair genotype was found only in the group of 
vitiligo patients who also had an autoimmune disorder. There was no significant 
increase in the frequency of the 106 base pair allele in the group of patients 
without an associated autoimmune disorder (x2 = 1.03; P=0.31 compared to 
controls). 
3.4.2 Frequency of the 106 base pair allele in vitiligo patient 
subgroups 
3.4.2.1 Clinical subclass 
When the vitiligo patients were divided into their clinical subclass (segmental, 
focal or symmetrical) no significant association of vitiligo type and the 106 base 
pair allele was revealed (Table 3.4). However, it is interesting to note that two of 
the three patients with extensive/near total vitiligo were homozygous for the 106 
base pair allele. Patients who could not be diagnosed to a single vitiligo type 
were excluded from this analysis. 
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Figure 3.4: A typical autoradiogram of CTLA-4 microsatellite 
polymorphism genotypes obtained in this study. 
The genotype of each sample is as follows: Lane 1,88/106; 2,88/104; 3,88/106; 4, 
104/106; 5,88/126; 6,126/128; 7,88/108; 8,88/104; 9,110/122; 10,124/128; 11,104/128; 
12,88/88; 13,110/128; 14,88/104; 15,88/110; 16,106/136; 17,88/128; 18,88/104; 19, 
106/118; 20,88/106; 21,114/120; 22,112/128. 
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Table 3.3: CTLA-4 microsatellite polymorphic allele genotype frequencies 
in the investigated groups. ' 
Allele size 
(base pair) 
Controls 
(n = 346)2 
Vitiligo3 
(n = 128) 
Vitiligo4 
(n = 92) 
Vitiligo5 
(n = 36) 
88 177 (51.2) 45 (35.2) 39 (42.4) 6 (16.7) 
96 1 (0.3) 1 (0.8) 0 (0.0) 1 (2.8) 
98 0(0.0) 1 (0.8) 1 (1.1) 0(0.0) 
100 1 (0.3) 1 (0.8) 1 (1.1) 0(0.0) 
102 4(1.2) 0(0.0) 0(0.0) 0(0.0) 
104 30(8.7) 4(3.1) 2(2.2) 2(5.6) 
106 47 (13.6) 30 (23.4)* 16 (17.4)** 14 (38.0)*** 
108 10(2.9) 4(3.1) 3(3.3) 1 (2.8) 
110 5(1.4) 4(3.1) 3(3.3) 1 (2.8) 
112 10(2.9) 2(1.6) 1 (1.1) 1 (2.8) 
114 6(1.7) 2(1.6) 1 (1.1) 1 (2.8) 
116 6(1.7) 1 (0.8) 1 (1.1) 0(0.0) 
118 5(1.4) 5(3.9) 3(3.3) 2(5.6) 
120 9(2.6) 1 (0.8) 1 (1.1) 0(0.0) 
122 7(2.0) 5(3.9) 5(5.4) 0(0.0) 
124 5(1.4) 2(1.6) 1 (1.1) 1 (2.8) 
126 8(2.3) 5(3.9) 5(5.4) 0(0.0) 
128 6(1.7) 9(7.0) 5(5.4) 4(11.1) 
130 6(1.7) 2(1.6) 2(2.2) 1 (2.8) 
132 1 (0.3) 2(1.6) 1 (1.1) 1 (2.8) 
134 2(0.6) 2(1.6) 1 (1.1) 1 (2.8) 
'Values are the number of alleles positive for each genotype, with the percentage given 
in parentheses. 
2n, number of investigated alleles. 
3All patients with vitiligo. 
4Patients with vitiligo and no other autoimmune disease. 
5Patients with vitiligo and one or more autoimmune disease. 
*P= 0.01; **P= 0.31; ***P= 0.0002 (compared to controls). 
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Table 3.4: CTLA-4 106 base pair allele frequency and clinical subclass of 
vitiligo. 
Controls 
(n = 173)1 
Segmental 
(n = 5) 
Focal 
(n = 5) 
Symmetrical 
(n = 39) 
Number of 346 10 10 78 
alleles 
investigated 
Number of 47 2 1 17 
106 base pair 
alleles 
Frequency of 13.6% 20.0% 10.0% 22.0% 
the 106 base 
pair allele 
P value2 - 0.63 1.0 0.08 
1n, number of patients. 
2Compared to controls. 
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3.4.2.2 Age of onset 
No association was found between the age of onset of vitiligo and the 106 base 
pair genotype (Table 3.5). Fisher's exact test was applied due to small sample 
values. 
3.4.2.3 Gender 
When the data was analysed with respect to gender (Table 3.6), a significant (x2 
= 12.5; P=0.0004) increase in the frequency of the 106 base pair genotype was 
found only in the female patients. However, this significance is probably 
conveyed by the higher proportion of patients in this subgroup with an 
associated immune disorder, rather than by gender alone, thus demonstrating 
the problem of multiple comparisons. 
3.4.2.4 Antibody status 
Some of the patients in this study had previously been tested for autoantibodies 
against the melanocyte antigens tyrosinase, TRP-1, TRP-2 and PmeI17 (Kemp 
et al. 1997a; Kemp et al. 1997b; Kemp et al. 1998b; Kemp et aL 1998c) but no 
correlation was apparent between those patients with humoral autoreactivity and 
the 106 base pair allele. 
3.4.3 Odds ratios associated with the CTLA-4 106 base pair allele 
The odds ratio conferred by the 106 genotype was 1.8 for patients with vitiligo, 
4.3 for vitiligo patients with an associated autoimmune disorder and 1.2 for 
vitiligo patients without an associated autoimmune disorder. 
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Table 3.5: CTLA-4 106 base pair allele frequency and age of onset. 
Controls 
(n=173)1 
Vitiligo 
0-10 yr 
(n=11) 
Vitiligo 
11-20 yr 
(n=12) 
Vitiligo 
21-40 yr 
(n=23) 
Vitiligo 
>40 yr 
(n=18) 
Number of 346 22 24 46 36 
alleles 
investigated 
Number of 47 5 6 11 8 
106 base 
pair alleles 
Frequency 13.6% 22.7% 25.0% 23.9% 22.2% 
of the 106 
base pair 
allele 
P value2 - 0.22 0.13 0.08 0.21 
in, number of patients. 
2Compared to controls. 
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Table 3.6: CTLA-4 106 base pair allele frequency in males and females in 
the investigated groups. 
Male Female 
Controls Vitiligo Controls Vitiligo 
(n=84)' (n=19) (n=89) (n=45) 
Number of 168 38 178 90 
alleles 
investigated 
Number of 20 3 27 27 
106 base 
pair alleles 
Frequency of 12.0% 8.0% 15.2% 30.0% 
the106 base 
pair allele 
P value2 - 0.46 - 0.0004 
x-square - 0.54 - 12.5 
1n, number of patients. 
2Compared to controls. 
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3.5 Discussion 
These results indicate that there is no association between the 106 base pair 
allele and vitiligo in patients without an associated autoimmune disorder (P = 
0.31). The odds ratio conferred by the 106 allele in this patient group was 1.2, a 
significantly lower value than those previously published for autoimmune 
diseases: Graves disease, 2.1; autoimmune hypothyroidism, 2.2 (Kotsa et al. 
1997). In vitiligo patients with one or more associated autoimmune disorder, the 
frequency of the 106 base pair allele was significantly increased, (P = 0.0002), 
when compared to healthy controls. However, 15 out of 18 of these patients 
had immune disorders that have been demonstrated to be associated with the 
presence of the 106 base pair allele (e. g., Graves disease, autoimmune 
hypothyroidism, autoimmune Addison's disease, and type 1 diabetes mellitus). 
A disease genotype predisposing to other autoimmune disorders may, therefore, 
have created the apparent association of vitiligo and the 106 base pair allele in 
this patient group. It was found, however, that the odds ratio conferred by the 
106 base pair allele in this group of patients was significantly greater than that 
found for patients with only Graves disease (Kotsa et al. 1997), autoimmune 
hypothyroidism (Kotsa et al. 1997) or autoimmune Addison's disease (Kemp et 
al. 1998a), an odds ratio of 4.3 versus values of 2.1,2.2 and 2.2, respectively. 
This suggests that multiple autoimmunity may be determined in part by the 
CTLA-4 polymorphism, and autoimmune endocrinopathy patients with the 106 
base pair allele may be more likely to develop vitiligo. 
It would appear from this study that vitiligo, at least without an associated 
autoimmune disorder, is not influenced by the CTLA-4 exon 4 microsatellite 
polymorphism. However, this does not rule out an autoimmune basis for the 
disease nor the involvement of T cells in its pathogenesis. The initiation of 
autoimmunity may be caused by the action of diverse cell types. The role of T 
cells in the disease pathogenesis may be to drive antibody formation in aT 
helper 2-type activity, in response to B cell-recognised autoantigen/s. 
Furthermore, active proliferation of a cytotoxic T cell response may be caused by 
an imbalance of signaling through the cytokine network, rather than by faulty 
negative regulation via the CTLA-4 receptor. 
There are difficulties related to attempting to identify a vitiligo 
susceptibility gene through a population-based, case-control association study. 
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It is a very sensitive technique, providing the control population is carefully 
genetically matched, and can detect minor genetic associations which are not 
necessary for disease expression but which represent an increased risk for the 
disease (Barbesino et al. 1998). Despite this sensitivity, genetic heterogeneity 
between and within population groups may prevent significant differences in the 
frequency of a particular allele from being detected. It is possible that such 
variations have accounted for the failure of several studies to detect significant 
associations between CTLA-4 polymorphisms and autoimmune disease 
including, post-partum thyroiditis (Waterman et al. 1998), and bullous and 
cicatrical pemphigoid (Drouet et al. 2000), and chronic inflammatory disorders 
such as asthma and atopy (Heinzmann et al. 2000). Population-based, case- 
control studies lack specificity (Lander & Schork 1994). They cannot distinguish 
between a disease allele at a disease loci and a nearby allele, which does not 
affect disease expression, but is in linkage disequilibrium (transmitted with) the 
disease causing allele. Therefore the association reported here between CTLA- 
4 and vitiligo with associated autoimmunity may in fact represent an association 
with a polymorphism/s in a gene/s located in close proximity to CTLA-4 on the 
chromosomal region 2q33, for example, CD28 or the newly identified Inducible 
T-cell co-stimulator (ICOS) gene (Hutloff et al. 1999). 
Small data sets generate a risk of bias or chance probabilities revealing 
falsely positive associations and to test thoroughly the association of CTLA-4 
with vitiligo, a larger data set and transmission studies of the allele in family 
groups are required. A recent case-control study, in which a larger cohort of 
vitiligo patients was analysed for association with CTLA-4 polymorphisms, also 
suggests genetic association with vitiligo (Kristensen et al. 2000). Furthermore, 
a family study involving 552 vitiligo patients and their families (Section 1.2.3) 
also indentified polymorphic markers for the CD28/CTLA-4 gene region, 
including the CTLA-4 microsatellite marker, that are positively associated with 
vitiligo susceptibility (McCormack et al. 2001 b). In both of these studies, genetic 
association was suggested in all vitiligo patients, not only in those patients with 
other autoimmunity (Dr. W. T. McCormack; University of Florida, personal 
communication). Further experiments, including family-based genome 
screening, are needed to map the genetic susceptibility markers in greater 
detail. 
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The failure to find a significant association with a single gene 
polymorphism in the vitiligo patients, as a whole, most likely reflects the complex 
spectrum of the disease itself. Previous genetic studies have concluded that 
vitiligo is most likely due to the action of genes at multiple loci (Majumder et al. 
1993; Kim et al. 1998; Acros et al. 1999), which therefore makes the effect of an 
individual locus difficult to establish. Other genes whose dysfunction affects 
immune regulation may control the development of autoimmune vitiligo for 
example, those encoding complement components C2 and C4, or the 
autoimmune regulator (AIRE) gene described previously (Section 1.2.3). It is 
also possible that environmental factors, such as stress (Sections 1.3.1 and 
1.3.2) or infections (Section 1.3.3), interact with genes to contribute significantly 
to disease development. 
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4 Molecular mapping of the B cell epitopes of 
melanocyte-specific autoantigens tyrosinase and 
PmeI17 
4.1 Introduction 
4.1.1 Antibody-antigen interactions 
In order for binding to take place between an antibody and its antigen, there 
must be complementarity between surface structures on the antigen and the 
combining site of the antibody. The precise region of the antibody's combining 
site which contacts with the antigen is termed the paratope, and the part of the 
antigen recognised by the paratope is termed the epitope. Antigens are highly 
diverse in size and primary sequence, as well as in their secondary structure 
which can be adapted by post-translational modifications such as glycosylation 
(Westwood & Hay 2001). Consequently, antigenic epitopes are extremely 
varied but can be loosely classified in two categories as: (i) linear or continuous 
epitopes which constitute part of a linear amino acid sequence on a polypeptide 
chain, and (ii) conformational or discontinuous epitopes which are formed by two 
or more stretches of the primary sequence that are distant from each other, but 
are brought together in the folded secondary or tertiary structure of the antigen. 
The size of an epitope is subject to controversy, but it is thought that linear 
epitopes can range in length from 5-6 amino acids (Roitt 1997) to up to 15-22 
amino acids (von Mikecz et aL 1995) and that conformational epitopes can 
consist of approximately discontinuous 16 amino acid side-chains (Roitt 1997). 
The specificity of a particular antibody is not absolute, given that both paratope 
and epitope are deformable, and there is the possibility of an antibody binding to 
multiple cross-reactive epitopes. 
In contrast to the processed linear epitopes presented to T cells, B 
lymphocytes usually recognise antigen in the context of the native molecule. 
The most likely areas of a protein to contain B cell epitope regions are, 
therefore, parts of peptide chains that protrude from the globular surface. These 
external structures are likely to be hydrophilic. Using this information, and the 
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fact that some amino acids are thought to be more antigenic than others 
(Westwood & Hay 2001), it is possible to predict areas of probable antigenicity 
on a particular protein. However, in order to determine the exact location of 
epitopes on an antigen, experimental epitope mapping techniques need to be 
applied. 
4.1.2 Methods of B cell epitope mapping 
The techniques currently available for mapping linear and conformational B cell 
epitopes are summarised in Table 4.1. The most precise available method of 
defining the area of an antigen making contact with an antibody is x-ray 
crystallography of the antigen-antibody complex. This technique has the 
advantage of allowing the study of the three-dimensional structures and, 
therefore, can yield information about conformational epitopes. However, it is 
costly and requires sufficiently large quantities of a pure monoclonal antibody (or 
fragment of) and its antigen to produce crystal. If the primary amino acid 
sequence of the antigen is known, there are two main approaches to B cell 
epitope mapping. The first method relies on molecular manipulation at the 
cDNA level using techniques such as PCR, site-directed mutagenesis, and 
restriction with DNA exonuclease and endonucleases. Substitutions and/or 
deletions are created in the amino acid sequence followed by comparative 
analysis of the immunoreactivity of these recombinant proteins by either 
immunoblotting, immunoprecipitation or enzyme-linked immunosorbent assay 
(ELISA) (Petterson 1992). Examples of studies in which B cell epitopes have 
been identified in autoimmune disease using recombinant proteins are given in 
Table 4.2. The second technique begins at the peptide level and involves the 
analysis of antibody reactivity to either synthetic peptides or enzymatically 
digested protein fragments (Petterson 1992). However, these methods can only 
accurately detect linear epitopes and short sequences that may constitute part 
of a conformational epitope. More recently, the use of phage-display technology 
has allowed the identification of conformational peptide epitopes (Williams et al. 
2001). 
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Table 4.1: A summary of techniques for mapping linear and 
conformational B cell epitopes. 
Technique Suitable for which type/s Reference 
of epitope 
X-RAY CRYSTALLOGRAPHY' Conformational and linear Amit et al. 1986 
PHAGE-DISPLAY2 Conformational and linear Williams et al. 2001 
i) Random-peptide library 
ii) Single chain Fv3 fragment (scFv) 
library 
SYNTHETIC PEPTIDES4 Mostly linear Petterson 1992 
i) Peptide synthesiser 
(Generates peptides >10 amino acid 
residues) 
ii)'PEPSCAN'5 Sumar 2001 
(Peptides s 10 amino acid residues) 
PEPTIDE FRAGMENTS6 Mostly linear Petterson 1992 
Derived enzymatically from the 
whole protein 
RECOMBINANT PROTEIN7 Mostly linear Petterson 1992 
Subcloning and expression8 of 
cDNA encoding peptide fragments 
generated by: 
i) Naturally occurring restriction sites Petterson 1992 
ii) Exonuclease digestion Petterson 1992 
Iii) Polymerase chain reaction (PCR) Petterson 1992 
iv) Site-directed mutagenesis Perdue 2001 
1 Allows direct analysis of the 3-dimensional structure of an antigen-antibody complex. 2 Epitope regions are determined by affinity selection screening with either (i) antibody, or (ii) antigen. 
3 Fv, variable region of the fragment with antigen binding (Fab) of an immunoglobulin. 
° Can be used in a number of different assay systems including enzyme-linked immunosorbent assay 
JELISA) and immunoprecipitation using monoclonal antibody (mAb) or polyclonal sera. 
'PEPSCAN' involves the synthesis of short overlapping peptide sequences on to solid supports 
jpolystyrene pins) which are then used in a modified ELISA. 
Can be used in a number of different assay systems including ELISA and immunoprecipitation using 
mAb or polyclonal sera. 
Can be used in a number of different assay systems including immunoblotting, ELISA, 
Immunoprecipitation and radioimmunoassays (RIA) using mAb or polyclonal sera. 8A variety of expression vectors/systems may be used. Vectors may fuse a tag to the protein for 
purification, or allow the incorporation of a radiolabelled amino acid into the recombinant protein for 
RIA. 
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Table 4.2: Examples of previous studies employing recombinant proteins 
to map B cell epitopes in autoimmune disease. 
Study Antigen Disease Techniques 
Burch et al. 1993 Thyroid stimulating Graves' disease 
Subcloning of cDNA amplif- 
led by PCR. Expressed in 
hormone-receptor bacteria. Immunoprecipit- 
ation (IP) experiments with 
patient sera. 
Peterson & Krohn 1994 Steroid 17a- Autoimmune Subcloning of endonucl- tricted cDNA e re e 
hydroxylase Addison's disease 
as s 
fragments and exonuclea- 
se digestion. Expressed In 
bacteria and immunoblot- 
ted with patient sera. 
Wedlock et al. 1993 Steroid 21ydroxyIaSe -h Autoimmune 
Subcloning of endonucl- 
ease restricted cDNA 
Addison's disease fragments. Expressed in 
bacteria and immunoblot- 
ted with patient sera. 
Song et al. 1994b Steroid 21-hydroxylase Autoimmune 
Subcloning of cDNA amplif- 
led by PCR. Expressed in 
Addison's disease bacteria and Immunoblot- 
ted with patient sera. 
Vol ato et al. 1998 P Steroid 21-h drox lase YY Autoimmune 
e of edonucD 
eaase 
lonise 
res t trictted cDNA 
Addison's disease fragments. Site-directed 
mutagenesis. Expressed 
In bacteria. IP experiments 
with patient sera. 
Nikoshkov et al. 1999 Steroid 21-hydroxylase Autoimmune Ex 
Exppresressed en se In b baccte tead riaa. IP . IP Addison's disease experiments with patient 
sera. Also expressed In 
mammalian cells and 
immunoblotted with patient 
sera. 
von Mikecz et al. 1995 Ribosomal protein L7 Systemic lupus led by 
Subcloning of cDNA amplif- 
PCR. Expressed In 
erythematosus and bacteria and immunoblot 
mixed connective -ted with patient sera. Also 
tissue disease IP experiments with patient 
sera. 
S ren et al. 1996 Y Glutamate Type 1 diabetes ease 
hi 
reofstrictteedonucl- ease restricted cDNA 
decarboxylase mellitus fragments and cDNA ampl- ified by PCR. Expressed In 
bacteria. IP experiments 
with patient monoclonal 
antibodies (mAbs). Also 
expressed in mammalian 
cells and immunoblotted 
with mAbs. 
Daw et al. 1996 Glutamate Type 1 diabetes ease 
hi 
reofstrictteedonucl. ease restricted cDNA 
decarboxylase mellitus fragments and cDNA ampl- 
ified by PCR. Expressed In 
bacteria. IP experim- 
ents with patient sera. 
Lin et al. 1999 'BP 180' Bullous 
Subcloning of cDNA amplif- 
ied by PCR. Expressed in 
(collagen XVII) pemphigoid bacteria and Immunoblot- ted with patient sera. 
Kemp et al. 2001 a Sodium iodide Autoimmune Subcloning of cDNA amplif- 
symporter thyroid disease 
ied by PCR. Expressed In 
bacteria. IP experim- 
ents with patient sera. 
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4.1.3 The role of B cell epitopes in autoimmunity 
Mapping of B cell epitopes on autoantigens can provide an understanding of the 
association of an autoantigen with autoimmune pathogenesis. For example, 
epitopes may reside in functional domains of autoantigenic proteins. Indeed, 
autoantibodies in myasthenia gravis, directed against the acetylcholine receptor, 
are known to bind to an epitope in the acetylcholine-binding site which can 
directly inhibit the receptor function (Hoedemaekers et al. 1997). Similarly, the 
autoantigen epitopes in systemic lupus erythematosus (SLE) have been found 
to reside in highly conserved regions of proteins and can thus inhibit functions of 
both structural proteins and enzymes (Casiano & Tan 1996). For example, anti- 
nuclear antibodies targeting tRNA synthetase and DNA polymerase delta 
auxiliary protein have been shown to functionally inhibit the aminoacylation of 
tRNA and DNA replication and repair, respectively, in in vitro studies (Tan et al. 
1994). Futhermore, epitope mapping may provide insight into the initiation of 
the autoimmune process. Autoimmunity may be triggered by an initial infection 
with a foreign pathological organism (Wucherpfennig 2001). One of the 
mechanisms by which this might induce immune disease is the phenomenon of 
molecular mimicry, in which a microbial peptide has sufficient structural similarity 
with a self-peptide to evoke a cross-reactive autoimmune response. For 
example, an epitope on the bacterium Yersinia entercolitica has homology with 
the extracellular domain of human thyroid-stimulating hormone receptor, which 
could cross-react with autoantibodies in Graves' disease (Tomer & Davies 
1993). In addition, similarities between epitopes on the parasite Trypanosoma 
cruzi and the cardiac muscle protein myosin cause the aberrant immune 
response in Chagas' disease (Roitt 1997). 
As well as providing insights into the mechanisms of autoimmune 
pathogenesis, the molecular characterisation of B cell epitopes also allows for 
new and more specific assays to be established (Lernmark 2001). For example, 
if the epitope of a pathogenic autoantibody can be precisely defined, 
recombinant proteins containing only the significant epitope region could be 
used to measure titres of pathogenic autoantibodies within the heterogeneous 
antibody population of a patient's serum (Ishii et al. 1997). 
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A further application of epitope mapping lies in the development of 
specific-active immunotherapies: the ability to determine a single relevant 
antigenic site within a target protein is the basis for the development of synthetic 
vaccines for the prevention of and protection against disease (Atabani 2001). 
There is a need for vaccines to be epitope specific to eliminate the possibility of 
cross-reactivity with self-protein or related antigens and also to make the 
production of the synthetic peptides economical. Specific, active 
immunotherapy with respect to the present study is discussed in Section 4.5. 
4.2 Aim 
In this study, the previously identified autoantibody reactivity to the melanocyte- 
specific autoantigens tyrosinase (Song et al. 1994a; Baharav et al. 1996; Kemp 
et al. 1997a) and Pmell7 (Kemp et al. 1998b) in vitiligo patient sera was further 
characterised, with respect to the B cell epitopes involved, since this may give 
further clues into the nature of the immune response in vitiligo. This was 
undertaken by the construction of deletion derivatives of tyrosinase cDNA using 
both exonuclease III treatment and PCR amplification. Truncated derivatives of 
Pmel17 cDNA were created by subcloning of specific cDNA fragments 
generated by endonuclease restriction and PCR amplification. Full-length 
tyrosinase and its deletion derivatives, and full-length Pmel17 and its truncated 
derivatives, were then be translated in vitro with [3SS]methinonine to produce 
[35S]-labelled intact and modified proteins, which were employed for testing 
antibody reactivity in vitiligo patient sera in radioimmunoassays. The 
experiments performed on tyrosinase and PmeI17 are presented separately in 
Sections 4.3 and 4.4, followed by an overall discussion in Section 4.5. 
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4.3 Mapping the B cell epitopes of tyrosinase 
4.3.1 Materials and Methods 
4.3.1.1 Patients and controls 
Sera from five vitiligo patients (one male, four females; mean age: 50 years; 
range: 24-64 years (yr); disease duration: 3-22 yr; vitiligo type: one segmental, 
one symmetrical/periorificial, three symmetrical), which were previously shown 
to contain tyrosinase antibodies (Kemp et al. 1997a), were analysed in these 
experiments. With respect to autoimmune disorders, the two patients with the 
lowest levels of tyrosinase antibodies had no personal or family history of 
associated autoimmune diseases. The three patients with the highest levels of 
tyrosinase antibodies also had an associated autoimmune disorder: Graves' 
disease in one and autoimmune hypothyroidism in two. Sera from 20 healthy 
individuals (nine male and 11 female; age range: 23-47 yr; mean age: 31 yr), 
with no history of either vitiligo or autoimmune disorders, were used as controls. 
4.3.1.2 Generation of tyrosinase cDNA deletion derivatives by exonuclease III 
treatment 
This technique involves plasmid containing the cDNA of interest initially being 
linearised by the use of two restriction endonucleases, one to create a 5' 
overhanging end, which is susceptible to exonuclease digestion, and one to 
create a 3' overhanging end, which is resistant to exonuclease digestion. In this 
way, subsequent deletions produced by exonuclease III digestion can only 
proceed in one direction (Putney et al. 1981; Henikoff 1984). The extent of 
exonuclease III deletions is controlled by the removal of timed aliquots during 
the digestion and the rate of the enzyme's activity can be slowed down by 
allowing the reaction to proceed with a sub-optimal NaCl concentration. A 
schematic diagram summarising the procedure of creating nested deletions is 
given in Figure 4.1. 
Deletion derivatives of tyrosinase cDNA were generated using a Nested 
Deletion Kit according to the manufacturer's instructions (Amersham Pharmacia 
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Biotech). Full-length tyrosinase cDNA, cloned as a Sall-Xbal fragment in 
pBluescript SK (Stratagene, La Jolla, CA, U. S. A) (Kemp et al. 1997a), was 
digested with Sacl restriction endonuclease (Promega) at a Sad site residing in 
a 3' direction from the tyrosinase cDNA. The plasmid was then digested with 
enzyme Xbai (Promega), the site for which is located upstream of the Sacl site. 
Exonuclease III (Amersham Pharmacia Biotech) was then used to create 
unidirectional deletions from the 3' end of the cDNA fragment. Exonuclease III 
digestion was carried out in a 40 pl reaction volume comprising 2 pg Xbal/Sacl 
digested pBSTYR DNA, 90-130 U of exonuclease III, in buffer containing 66.67 
pM Tris-HCI (pH 8.0), 0.67 mM MgCl2 and 50 pM NaCl (Amersham Pharmacia 
Biotech), the reaction was allowed to proceed at 37°C for 12 min. Two- 
microlitre samples were removed from the reaction at 3 min intervals after which 
S1 nuclease treatment of the linear DNA was carried out as follows: 1.8-2.7 U of 
S1 nuclease (Amersham Pharmacia Biotech), in buffer containing 150 mM 
potassium acetate (pH 4.6), 1.25 M NaCl, 5 mM ZnSO4 and 25% (v/v) glycerol 
(Amersham Pharmacia Biotech), was added to each of the 2-pi exonuclease III- 
digested samples which were then incubated for 30 min at room temperature. 
The reaction was stopped by the addition of 1 pl S1 stop solution comprising 
303 mM Tris base and 50 mM EDTA (Amersham Pharmacia Biotech) followed 
by 10 min incubation at 65°C. Half of each S1-treated sample was then 
subjected to electrophoretic analysis on 0.8% (w/v) agarose gels (Section 2.12) 
and the other half re-ligated in 20-pl reaction volumes comprising 0.5-0.7 U T4 
DNA Ligase, 1.25% (w/v) polyethylene glycol (PEG) and T4 ligase buffer 
(Amersham Pharmacia Biotech). 
The recircularised plasmids were used to transform Escherichia coli 
JM109 (Promega) as detailed elsewhere (Section 2.12). Plasmid DNA was 
purified from individual transformants using a Wizard Minipreps DNA Purification 
System (Promega) (Section 2.7.1) and analysed by gel electrophoresis using 
0.8% (w/v) agarose gels (Section 2.9) to assess which constructs still contained 
a fragment of tyrosinase cDNA. 
Appropriate plasmids were sequenced by the dideoxy chain termination 
method, as previously described (Section 2.15), with M13 reverse primer 
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Tyrosinase cDNA 
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Xbal 
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Linearise by restriction digestion with 
Xbal and Sacl 
5' overhang created by Xbal 3' overhang created by Sacl 
(susceptible to exonuclease) (exonuclease resistant) 
Digest with exonuclease III 
exonuclease digestion of 
Remove timed aliquots 
cDNA 
S1 nuclease to remove 
single-stranded DNA 
Figure 4.1: A schematic diagram of the procedure for creating nested 
deletions of tyrosinase. 
Tyrosinase deletion derivatives were generated from full-length tyrosinase cDNA in the 
expression plasmid pBluescript SK by the method of Henikoff (1984). 
Adapted from a figure in the 'Promega Protocols & Applications Guide' (Promega). 
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(Promega) and [a_35 S]dATP (NEN Life Science Products), in order to determine 
the exact location of the 3' end of the tyrosinase cDNA fragment. The deletion 
derivatives are summarised in Table 4.4. 
4.3.1.3 Subcloning of fragments of tyrosinase cDNA 
Tyrosinase cDNA fragments of varying lengths were generated from tyrosinase 
cDNA in pcDNA3TYR (Kemp et al. 1997b) by PCR amplification (Table 4.4). 
Restriction sites for EcoRl and Xbal were incorporated into the 5' and 3' 
oligonucleotide primers, respectively, in order to allow subcloning of the PCR 
products into pcDNA3 (Figure 4.2; Invitrogen, Abingdon, U. K. ). The primers 
(Gibco-BRL, Paisley, U. K. ) used to generate the fragments are shown in Table 
4.3. 
Samples of pcDNA3TYR DNA (50 ng) were subjected to 27 cycles of 
PCR amplification in a DNA Thermal Cycler (Perkin-Elmer/Cetus) using the 
following conditions: 94°C, 1 min; 55°C, 1 min; 72°C, 2 min; and 72°C for 10 min 
to terminate the reaction. The composition of each PCR reaction was as 
previously described (Section 2.13). 
The PCR products were purified using a Wizard PCR Preps DNA 
Purification System (Promega) from 0.8% (w/v) agarose gels as detailed 
previously (Section 2.10), restricted with EcoRl (Promega) and Xbal and then 
ligated into pcDNA3 (Section 2.11). The ligation reaction was then used to 
transform E. coli JM109. Plasmid DNA was purified from individual 
transformants using a Wizard Miniprep DNA Purification System, digested with 
EcoRl and Xbal and analysed by agarose gel electrophoresis on 0.8% (w/v) 
agarose. The appropriate recombinant plasmids were sequenced (Section 
2.15) using T7 and SP6 primers (Promega) to verify that no sequence errors 
had been introduced. The plasmid created are summarised in Table 4.4. 
4.3.1.4 Coupled in vitro transcription and translation and electrophoretic 
analysis 
The plasmid constructs (Table 4.4) were used in a TnT® T7 Coupled 
Reticulocyte Lysate System (Promega) to produce and label tyrosinase and its 
deletion derivatives with [35S]methionine in vitro. Each tyrosinase cDNA was 
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Figure 4.2: A map of the pcDNA3 vector detailing restriction sites. 
(Invitrogen). 
Tyrosinase cDNA fragments were cloned into the EcoRI-Xbal sites of this vector. 
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Table 4.3: Oligonucleotide primers used to generate tyrosinase cDNA 
fragments by PCR amplification. 
Base Primers Primer sequences2 
pairs' 
1-831 TYR1 5'TTGA TTTCGCCGCCATGCTCCTGGCTGTT3' 
TYR2 5'AATCTAGACGCCTAGCTACAGACAATCTGCA3' 
1-675 TYR1 
TYR225 5'AATCTAGACGCCTACAGCTTCTGGATTTCTTG3' 
1-717 TYR1 
TYR240 5'AATCTAGACGCCTACCGCCAGTCCCAATATGG3' 
1-765 TYR1 
TYR255 5'AATCTAGACGCCTACTGACCTCCCATGTACTC3' 
1-849 TYR1 
TYR283 5'AATCTAGACGCCTAGTTGTACTCCTCCAATCG3' 
1-867 TYR1 
TYR289 5'AATCTAGACGCCTAGCATAAAGACTGATGGCT3' 
1-885 TYR1 
TYR295 5'AATCTAGACGCCTATCCCTCGGGCGTTCCATT3' 
1-1305 TYR1 
TYR435 5'AATCTAGACGCCTAATTTCTGTACAGTGGTAT3' 
1-1344 TYR1 
TYR448 5'AATCTAGACGCCTAGTCATAGCCCAGATCTTT3' 
1-1383 TYR1 
TYR461 5'AATCTAGACGCCTATTGAAAAGAGTCTGGGTC3' 
1 The numbers correspond to bp of tyrosinase cDNA included in the construct with the A 
residue of the initiating ATG codon assigned as bp number one. 
2 The EcoRl and Xbal restriction sites are underlined. The ATG translation initiation codon 
in forward primer TYR1 and the TAG translation termination codon in all reverse primers are 
shown in bold-type face. 
95 
inserted in the correct orientation to allow expression from the T7 promoter, and 
each template contained appropriate start and stop codons to ensure accurate 
translation. The TnT® T7 Coupled Reticulocyte Lysate System (Promega) is 
'cell-free'; purified reticulocyte lysate contains ribosomes, tRNA, and all the 
initiation, elongation and termination factors necessary for protein synthesis, but 
contains little endogenous mRNA, which would produce unwanted background 
protein. 
A standard reaction mix contained: rabbit reticulocyte lysate, 25 NI; TnT® 
T7 RNA polymerase, 1 NI; TnT® reaction buffer, 2 pl; amino acids minus 
methionine, 1 NI; RNasin (Promega), . 40 U; plasmid template, 2 pg; 
[35S]methionine (1000 Ci/mmol; 10 mCi/ml; Amersham), 4 NI; sterile dH2O to a 
final volume of 50 NI. The reaction was incubated for 120 min at 30°C and then 
stored at -200C until needed. 
SDS-PAGE of in vitro translated products was performed in 12.5% SDS- 
polyacrylamide resolving gels and 4% SDS-polyacrylamide stacking gels 
(Section 2.17) which were stained, dried and autoradiographed as described 
elsewhere (Section 2.17). 
4.3.1.5 Immunoprecipitation assays 
Vitiligo sera were tested for binding to [35S]-tyrosinase and its labelled deletion 
derivatives in immunoprecipiation experiments as follows. For each assay, an 
aliquot of the in vitro translation reaction mixture (equivalent to 12,000- 20,000 
counts per minute (cpm) of trichloroacetic acid (TCA)-precipitable material) was 
suspended in 50 pl of immunoprecipitation buffer containing 20 mM Tris-HCI pH 
8.0,150 mM NaCl, 1% Triton X-100 and 10 lag/ml aprotinin (Bayer, Newbury, 
U. K. ). Serum was then added to a final dilution of 1: 10. After incubation 
overnight with gentle rotation at 4°C, 50 pl of protein G Sepharose 4 Fast Flow 
slurry (Amersham Pharmacia Biotech), prepared according to the 
manufacturer's directions, was added and incubated for 1h at 4°C. The protein 
G Sepharose-antibody complexes were then collected by centrifugation and 
washed six times with immunoprecipitation buffer at 4°C. Immunoprecipitated 
radioactivity was then evaluated in a Wallac 1217 Rackbeta liquid scintillation 
analyser (Wallac U. K., Milton Keynes, U. K. ). 
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The binding reactivity of each of the sera to full-length tyrosinase and 
each deletion derivative was expressed as an antibody (Ab) index calculated as: 
cpm immunoprecipitated by tested serum/mean cpm immunoprecipitated by 20 
healthy control sera. Each serum was analysed in at least two experiments and 
the mean Ab index was calculated from these. The upper level of normal for 
each assay with a different ligand was calculated using the mean Ab index +3 
SD of 20 control sera. Patient sera with an Ab index greater than the upper 
level of normal were regarded as positive for binding to the radiolabelled ligand 
used in the assay. 
4.3.1.6 Computer analysis 
Predictions of B cell epitopes were carried out using a computer program based 
on a scale of hydrophilicity (Parker et al. 1986) by Dr. Part Peterson (Institute of 
Biomedical Sciences, University of Tampere, Finland). Genbank homology 
searches were performed using the Sequence Analysis Software package, GCG 
(University of Wisconsin, WN, U. S. A. ). 
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4.3.2 Results 
4.3.2.1 In vitro translation of tyrosinase cDNA and its deletion derivatives 
For identification of autoepitopes on tyrosinase, the cDNA in pBSTYR was 
deleted with exonuclease III treatment. As the deletions were carried out from 
the 3' end of the tyrosinase cDNA, the correct translational reading frame was 
maintained. The exact location of the 3' end of each of the tyrosinase cDNA 
deletion derivatives, as determined by sequencing, is shown in Table 4.4. 
PCR amplification was used to generate tyrosinase cDNA fragments of 
varying lengths which were then cloned into pcDNA3 (Table 4.4). DNA 
sequencing of the fragments was carried out to verify that no sequence errors 
had been introduced. 
Products generated from in vitro translation of tyrosinase cDNA and its 
deletion derivatives were evaluated by SDS-PAGE and autoradiography (Figure 
4.3a and 4.3b). Major bands representing the intact and modified [35S]-labelled 
tyrosinase proteins were found in each case (Table 4.4). 
4.3.2.2 Immunoprecipitation of tyrosinase deletion derivatives with sera from 
vitiligo patients 
Sera from five vitiligo patients were tested for their ability to immunoprecipitate 
[35S]-labelled tyrosinase and its modified derivatives. The results of the reactivity 
of the vitiligo sera with the tyrosinase deletion derivatives are summarised in 
Table 4.5. 
One patient serum did not react when tyrosinase containing a C-terminal 
deletion of amino acids 462-529 was used. Another serum studied failed to 
react with any derivative containing amino acid deletions beyond residue 447. 
The remaining three vitiligo sera reacted with derivatives deleted up to amino 
acid residues 254,294, and 300, respectively. 
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Table 4.4: Deletion derivatives used in determining the B cell epitopes on 
tyrosinase which are recognised by vitiligo sera. 
Tyrosinase 
construct 
Amino acids 
encoded' (bp2) 
Predicted molecular 
weight of expressed 
protein3 (kDa) 
Estimated molecular 
weight of expressed 
protein4 (kDa) 
pcDNA3TYR5 1-529 (1-1587) 58 58 
pTYR9.8 1-500 (1-1502) 55 56 
pTYR9.10 1-480 (1-1441) 53 52 
pTYR9.2 1-426 (1-1279) 47 47 
pTYR10.7 1-398 (1-1194) 44 44 
pTYR9.6 1-362 (1-1088) 40 42 
pTYR9.1 1-354 (1-1063) 39 38 
pTYR10.4 1-313 (1-940) 34 30 
pTYR10.6 1-301 (1-903) 33 27 
pTYR1.2 1-277 (1-831) 30 24 
pTYR10.10 1-209 (1-632) 23 17 
pTYR225 1-225 (1-675) 25 20 
pTYR240 1-240 (1-717) 26 21 
pTYR255 1-255 (1-765) 28 23 
pTYR283 1-283 (1-849) 31 25 
pTYR289 1-289 (1-867) 32 26 
pTYR295 1-295 (1-885) 32 27 
pTYR435 1-435 (1-1305) 48 45 
pTYR448 1-448 (1-1344) 49 48 
pTYR461 1-461 (1-1383) 51 50 
1 Numbers correspond to the amino acid residues of tyrosinase with the intiating methionine 
as residue one. 
2 Numbers correspond to bp of tyrosinase cDNA with the A residue of the intiating ATG 
codon assigned as bp number one. 
3 Predicted from the amino acid sequence of the protein. 
4 Estimated from the mobility of the protein in SDS-polyacrylamide gels. 
5 Encodes full-length tyrosinase. 
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Figure 4.3: SDS-polyacrylamide gel electrophoresis and autoradiography 
of products arising from in vitro translation of tyrosinase cDNA and its 
deletion derivatives. 
Tyrosinase cDNA and its deletion derivatives were translated in vitro in a TnT® T7 Coupled 
Reticulocyte Lysate System as described in Section 4.3.1.4. Subsequently, 5 µl of the 
reaction mixture were added to 20 µl of SDS sample buffer, boiled for 5 min and, 10 µl of 
this mixture were then analysed by SDS-PAGE on a 12.5% gel. (a) Full-length tyrosinase in 
vitro translated from pcDNA3TYR (lane 1); deletion derivatives of tyrosinase in vitro 
translated from: pTYR9.8 (lane 2); pTYR9.10 (lane 3); pTYR9.2 (lane 4); pTYR10.7 (lane 5); 
pTYR9.6 (lane 6); pTYR9.1 (lane 7); pTYR10.4 (lane 8); pTYR10.6 (lane 9); pTYR1.2 (lane 
10); pTYR10.10 (lane 11). (b) pTYR461 (lane 1); pTYR448 (lane 2); pTYR435 (lane 3); 
pTYR295 (lane 4); pTYR289 (lane 5); pTYR283 (lane 6); pTYR225 (lane 7); pTYR240 (lane 
8); pTYR255 (lane 9). 
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Table 4.5: Reactivity of vitiligo sera to tyrosinase deletion derivatives. 
Reactivity of sera' Upper 
level of 
normal for 
the 
Tyrosinase 1 2 3 4 5 assay' 
construct 
pcDNA3TYR 3.00 (+) 2.95 (+) 2.68 (+) 1.65 
(+) 1.80 (+) 1.36 
pTYR9.8 3.95(+) 2.91 (+) 2.79(+) 1.83 (+) 1.94 
(+) 1.41 
pTYR9.10 3.94 (+) 2.88 (+) 2.86 (+) 1.41 (+) 2.04 
(+) 1.19 
pTYR461 nd3 nd nd 1.80(+) 1.09 
(-) 1.13 
pTYR448 nd nd nd 1.72 
(+) 0.99 (-) 1.30 
pTYR435 nd nd nd 1.22 (-) 1.23 
(-) 1.26 
pTYR9.2 3.58 (+) 2.82 (+) 2.77 (+) 1.14 (-) 0.91 
(-) 1.23 
pTYR10.7 4.40 (+) 3.54 (+) 3.06 (+) 1.12 
(-) 1.10 (-) 1.24 
pTYR9.6 3.61 (+) 2.49 (+) 2.81 (+) 0.90 (-) 
0.92 (-) 1.35 
pTYR9.1 3.74 (+) 3.02 (+) 2.74 (+) 1.02 (-) 1.00 (-) 
1.21 
pTYR10.4 4.00 (+) 3.10(+) 2.77(+) 0.95 (-) 0.88 (-) 1.13 
pTYR10.6 4.14(+) 3.19(+) 2.94(+) 1.04(-) 0.99 (-) 
1.47 
pTYR295 nd 2.7 (+) 0.92 (-) nd nd 1.33 
pTYR289 nd 1.06(+) 0.98 (-) nd nd 1.08 
pTYR283 nd 1.14 (-) 1.00 (-) nd nd 
1.25 
pTYR1.2 3.76 (+) 1.18 (-) 1.06 (-) 1.04 (-) 0.98 (-) 1.22 
pTYR255 3.23 (+) nd nd nd nd 1.26 
pTYR240 1.24 (-) nd nd nd nd 1.25 
pTYR225 1.16 (-) nd nd nd nd 1.16 
pTYR10.10 1.24 (-) 1.04 (-) 1.00 (-) 1.02 (-) 0.89 (-) 1.25 
1 The binding reactivity of each of the sera to the full-length tyrosinase and each deletion 
derivative was expressed as an antibody index calculated as: cpm immunoprecipitated by 
tested serum/mean cpm immunoprecipitated by 20 healthy control sera. Each serum was 
analysed in at least two experiments and the mean antibody index was calculated from 
these. 
2The upper level of normal for each assay with a different ligand was calculated using the 
mean antibody index +3 SD of 20 control sera. Patient sera with an antibody index greater 
than the upper level of normal were regarded as positive for binding to the radiolabelled 
ligand used in the assay W. (-) denotes negative for binding to the radiolabelled ligand 
used in the assay. 3 nd, not determined. 
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The results of the immunoprecipitation experiments indicate that multiple 
epitope domains exist on tyrosinase: between amino acids 240-254 
(DEAKCDICTDEYMGG), 289-294 (CNGTPE) and 295-300 (GPLRRN) located 
centrally in the tyrosinase molecule, and between 435-447 
(NGDFFISSKDLGYD) and 461-479 (QDYIKSYLEQASRIWSWLL) found 
towards the C-terminal of the protein. The reactivity of each serum to each 
epitope is shown in Table 4.6. 
The 3' end deletion procedure predominantly reveals those antigenic 
regions which are closer to the N-terminus of the polypeptide. The reactivity of 
three of the sera with the C-terminal antigenic regions was therefore unable to 
be confirmed because of the presence of reactivity with epitope regions located 
nearer to the N-terminal domain of tyrosinase. 
4.3.2.3 Computer prediction of putative antigenic regions within tyrosinase 
The computer prediction analysis identified several putative antigenic regions 
within tyrosinase (Figure 4.4). All the epitope regions defined by the vitiligo 
sera were found in these putative antigenic areas: antigenic domains 289-294 
and 295-300 were within the predicted epitope region 275-315, antigenic 
domains 435-447 and 461-479 were located in the predicted epitope region 
430-470 and antigenic domain 240-254 was located in the predicted epitope 
region 230-260. 
4.3.2.4 Comparison of identified epitope regions with the amino acid sequences 
of TRP-1 and TRP-2 
The amino acid sequence of two of the identified epitope regions (amino acids 
289-294 and 295-300) had homology to an amino acid sequence present in both 
TRP-1 (Kwon 1993) and TRP-2 (Yokoyama et al. 1994): a tyrosinase peptide of 
12 residues (amino acids 291-302) included eight identical and two 
conservatively changed amino acids when compared to an amino acid 
sequence present in TRP-1 (amino acids 305-318), and eight identical residues 
when compared to an amino acid sequence in TRP-2 (amino acids 301-315). 
This is illustrated in Figure 4.5. Additionally, no homology was found between 
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Table 4.6: Epitope regions on tyrosinase recognised by vitiligo sera'. 
Patient 
Amino acids 1 2 3 4 5 
240-254 + - --- 
289-294 NA + --- 
295-300 NA NA +-- 
435-447 NA NA NA +- 
461-479 NA NA NA NA + 
1 Reactivities with epitope regions are indicated: + denote reactivity with the specified 
epitope region; - denotes unreactive with specific epitope region; NA denotes reactivity with 
the specified epitope region unknown. 
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Figure 4.4: Antigenicity plot of the deduced amino acid sequence of 
tyrosinase. 
Local antigenicity values, calculated as detailed previously (Parker et al. 1986), are plotted 
against the amino acid residues of tyrosinase. The y-axis scale from 0 to 100 reflects 
increasing antigenicity. 
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Tyrosinase 291 GTPEGPLRRNP -- G 302 
TRP-1 305 STEDGPIRRNP-AG 317 
Tyrosinase 291 GTPEGPLRRN P-- G 302 
TRP-2 301 GTYEGLLRRNQMGR 314 
Figure 4.5: Amino acid sequence homology between an autoantigenic 
region of tyrosinase and a peptide sequence of TRP-1 and of TRP-2. 
Numbers represent the amino acid residues of the protein with the intiation methionine being 
assigned as number one. Identical amino acids are indicated by bold type-face and 
conservative amino acid changes are underlined. 
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the epitope regions described here and any other proteins including those of 
viral and bacterial origin. 
4.3.3 Results summary 
The construction and expression of several deletion mutants of tyrosinase 
enabled the characterisation of multiple B cell epitope domains between amino 
acids 240-254 (DEAKCDICTDEYMGG), 289-294 (CNGTPE) and 295-300 
(GPLRRN) located centrally in the tyrosinase molecule, and between 435-447 
(NGDFFISSKDLGYD) and 461-479 (QDYIKSYLEQASRIWSWLL) found 
towards the C-terminal of the protein. Since the 3' deletion method 
predominantly reveals those antigenic regions which are closer to the N- 
terminus of the polypeptide, the reactivity of three of the sera with the C-terminal 
antigenic regions was unable to be confirmed because of the presence of 
reactivity with epitope regions located nearer to the N-terminus of tyrosinase. In 
order to examine the reactivity of these sera with the C-terminus of tyrosinase, 
further deletion derivatives would need to be constructed which exclude the 
central regions of the protein. 
Since tyrosinase shows amino acid sequence homology with TRP-1 
(Kwon 1993) and TRP-2 (Yokoyama et al. 1994), the identified tyrosinase 
autoantigenic regions were compared for amino acid homology with both the 
tyroinase-related enzymes to locate possible cross-reactive domains. The 
amino acid sequence of two of the identified epitope regions (amino acids 289- 
294 and 295-300) had homology to an amino acid sequence in both TRP-1 
(Kwon 1993) and TRP-2 (Yokoyama et al. 1994): a tyrosinase peptide of 12 
residues (amino acids 291-302) included eight identical and two conservatively 
changed amino acids when compared to an amino acid sequence present in 
TRP-1 (amino acids 305-318), and eight identical residues when compared to 
an amino acid sequence in TRP-2 (amino acids 301-315). This finding is 
consistent with previous studies in which three vitiligo patients were identified 
whose sera contained tyrosinase antibodies which cross-reacted with both TRP- 
1 and TRP-2 (Kemp et al. 1997a; Kemp et al. 1997b; Kemp et aL 1998c). In this 
present work, two of these patients had tyrosinase antibodies which reacted 
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with the epitope region 289-294 and 295-300, respectively. The third patient had 
tyrosinase antibodies which recognised the 240-254 antigenic domain. 
However, reactivity of this patient sera with the 289-294 and 295-300 epitope 
regions may have been masked by antibody binding to the site closer to the N- 
terminus of tyrosinase. The sera from the remaining two patients, which were 
found to contain tyrosinase antibodies but not antibodies to TRP-2 or TRP-1 
(Kemp et al. 1997a; Kemp et al. 1997b; Kemp et al. 1998c), reacted with 
epitopes 435-447 and 461-479, respectively, which did not appear to be 
homologous to amino acid sequences in either TRP-1 or TRP-2. 
The present results indicate that multiple regions of tyrosinase are 
epitopes for autoantibodies from the vitiligo patients studied and regions 289- 
294 and 295-300 are likely to contain epitopes which are cross-reactive with 
both TRP-1 and TRP-2. 
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4.4 Mapping the B cell epitopes of PmeI17 
4.4.1 Materials and Methods 
4.4.1.1 Patients and controls 
Sera from three vitiligo patients (three females; mean age: 50 yr; age range: 43- 
59 yr), which were previously shown to contain Pmell7 antibodies (Kemp et al. 
1998b), were analysed in these experiments. In addition to symmetrical type 
vitiligo, the three patients had an associated autoimmune disorder: Graves' 
disease in one and autoimmune hypothyroidism in two. A further set of 20 sera 
from vitiligo patients (12 male and eight female; age range; 30-77 yr; mean age; 
55 yr), previously untested for Pmel17 antibodies, were also examined. 
Nineteen patients had symmetrical type vitiligo and one presented with 
segmental vitiligo. An associated autoimmune disease was also diagnosed in 
three of the 20 patients: alopecia areata in one and autoimmune hypothyroidism 
in two. 
Sera from 20 healthy individuals, with no history of either vitiligo or 
autoimmune disorders, were used as controls (Section 4.3.1.1). As a further two 
sets of controls, sera from 10 patients (eight female and two male; age range: 
21-84 yr; mean age: 43 yr) with Graves' disease and nine patients (nine female; 
age range: 24-65 yr; mean age: 45 yr) with Hashimoto's thyroiditis, all without 
clinical signs of vitiligo, were analysed. 
4.4.1.2 Specific antiserum 
Anti-Pmel17 rabbit polyclonal antiserum AZN-LAM (Schreurs et al. 1997) was a 
gift from Dr. Marco Schreurs (Department of Tumour Immunology, University 
Hospital Nijmegen, Nijmegen, The Netherlands). This antiserum was generated 
against a synthetic peptide corresponding to the C-terminal sixteen amino acids 
of Pmel17. 
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4.4.1.3 Generation of Pmel17 deletion constructs by PCR amplification 
Full-length human Pmel17 cDNA, cloned as an EcoRl-Xhol fragment in 
pcDNA3, was a gift from Dr. Paul Robbins (National Institutes of Health, 
Bethesda, MD, U. S. A. ) and was used to generate Pmel17 cDNA fragments of 
varying lengths by PCR amplification. Restriction sites for EcoRl and Xbal were 
incorporated into the 5' and 3' oligonucleotide primers, respectively, in order to 
allow subcloning of the PCR products into pcDNA3. The primers (Gibco-BRL) 
used to generate the Pmel17 cDNA fragments are listed in Table 4.7. 
Samples of plasmid DNA containing Pmel17 cDNA (50 ng) were 
subjected to 27 cycles of PCR amplification in a DNA Thermal Cycler as 
described in Section 4.3.1.3 above. The PCR amplification products were 
purified and subcloned into pcDNA3 using materials and methods outlined 
previously (Section 4.3.1.3). Appropriate recombinant plasmids were 
sequenced by the dideoxy chain termination method with T7 and SP6 primers, 
as before (Section 4.3.1.3), in order to verify that no sequence errors had been 
introduced. The deletion derivatives are summarised in Table 4.8. 
4.4.1.4 Generation of Pmel17 deletion constructs by subcloning of Pmel17 
cDNA fragments 
Endonuclease restriction was used to generate fragments of PmeI17 cDNA 
which were subsequently subcloned into vector pcDNA3 (Figure 4.6). Briefly, 
plasmid pcDNA3 containing full-length Pmel17 cDNA was restricted initially with 
the appropriate enzymes. The required cDNA fragments were then purifed from 
0.8% (w/v) agarose gels using a Wizard PCR Preps DNA purification kit 
(Promega; Section 2.10) and ligated into pcDNA3 which had been restricted with 
the necessary endonuclease(s) (Promega). Plasmid pPMEL17-582 was 
constructed by the initial subcloning of a 1139 base pair (bp) Hindill-BgAl 
fragment into the Hindlll-BamHl site of pcDNA3 followed by insertion of a 512 bp 
Hindill fragment into the Hindill site of the recombinant plasmid. The required 
recombinant plasmids were identified from transformants of E. coli JM109 by 
endonuclease digestion and agarose gel electrophoresis. DNA sequencing with 
T7 primer was used to determine the orientation of the Pmel17 cDNA fragment 
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Table 4.7: Oligonucleotide primers used to generate Pmel17 cDNA 
fragments by PCR amplification. 
Base Primers Primer sequences2 
pairs' 
1-1983 PmeI17-1 5'TTGAATTCGCCGCCATGGATCTGGTGCTA3' 
PmeI17-661 5'AATCTAGACGCCTAGGGGCTATTCTCACC3' 
1-1962 PmeI17-1 
PmeI17-654 5'AATCTAGACGCCTAACAAGAGCAGAAGAT3' 
1-1932 PmeI17-1 
PmeI17-644 5'AATCTAGACGCCTACCAGTGACTGCTGCT3' 
1-1902 PmeI17-1 
Pmel17-1900 5'AATCTAGACGCCTATACGGAGAAGTCTTGCTT3' 
1-1728 PmeI17-1 
PmeI17-1750 5'AATCTAGACGCCTAGCTGTTGGTATCAGC3' 
1-1381 PmeI17-1 
PmeI17-1400 5'AATCTAGACGCCTAACCATCCAGCAGGGGGCC3' 
1-1230 PmeI17-1 
PmeI17-1250 5'AATCTAGACGCCTAAAGCACCACAATTGATAC3' 
1-1113 PmeI17-1 
PmeI17-371 5'AATCTAGACGCCTAGCTCTCTGCAGTTGG3' 
1-1068 PmeI17-1 
PmeI17-356 5'AATCTAGACGCCTAAGTGGTTGGCACCTG3' 
1-1023 PmeI17-1 
Pm eI17-341 5'AATCTAGACGCCTATGGCGCCTGACCAGG3' 
1-978 PmeI17-1 
PmeI17-1000 5'AATCTAGACGCCTATTGGCCAGCTGTGGTGTT3' 
1-829 PmeI17-1 
PmeI17-850 5'AATCTAGACGCCTACACCACAAGTGCCCG3' 
The numbers correspond to base pairs of Pmel17 cDNA included in the construct with the 
A residue of the initiating ATG codon assigned as base pair number one. 
2The EcoRl and Xbal restriction sites are underlined. The ATG translation initiation codon in 
forward primer PmeI17-1 and the TAG translation termination codon in all reverse primers 
are shown in bold-type face. 
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multiple cloning site of pcDNA3 
Hindlil 
Kpnl 
BamH I Hind Ill Bg1ll 
EcoRl BamHI Kpnl Xhol 
pcDNA3PMEL17 ý 
Hind III HindlII 
pPMEL17-148 512 bp Hindill fragment 
cloned into the Hindill 
site of pcDNA3 
BamHI BamHI 
pPMEL17-194 
630 bp BamHI fragment 
cloned into the BamH1 site 
of pcDNA3 
Kpnl Kpnl 1221 bp Kpnl fragment 
pPMEL17-387 cloned into the Kpnl 
site of pcDNA3 
Hind III Hind III B1 11 
pPMEL17-582 
1651 bp Hind I ll-Bg/I I 
fragment cloned into 
the Hindill-BamHl 
site of pcDNA3 
Figure 4.6: Schematic diagram of full-length Pmel17 cDNA in pcDNA3 and 
its truncated derivatives constructed by subcloning of restriction 
fragments. 
The blue lines represent Pmel17 cDNA and the red lines pcDNA3. This representation is 
not to scale. 
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with respect to the T7 promoter in pcDNA3. The deletion derivatives are 
summarised in Table 4.8. 
4.4.1.5 Coupled in vitro transcription and translation and electrophoretic 
analysis 
The plasmid constructs (Table 4.8) were used in a TnT® T7 Coupled 
Reticulocyte Lysate System, with [35S]methionine, to synthesise and radiolabel 
Pmel17 and its deletion derivatives in vitro, as previously described (Section 
4.3.1.4). SDS-PAGE of in vitro translated products was performed in either 10% 
or 15% SDS-polyacrylamide resolving gels and 4% SDS-polyacrylamide 
stacking gels as detailed previously (Sections 2.17 and 4.3.1.4) which were 
stained, dried and autoradiographed as described elsewhere (Section 2.17). 
4.4.1.6 Radiobinding assays 
Vitiligo (n = 23), Hashimoto's thyroiditis (n = 9), Graves' disease (n = 10) and 
healthy control (n = 20) sera, as well as anti-Pmel17 rabbit antiserum AZN-LAM, 
were tested for binding to [35S]Pmel17 and its labelled deletion derivatives in 
radiobinding assays as detailed elsewhere (Section 4.3.1.5). 
The binding reactivity of each of the sera to full-length Pmel17 and each 
deletion derivative was expressed as an antibody (Ab) index calculated as 
previously described (Section 4.3.1.5). Each serum was analysed in at least two 
experiments and the mean Ab index was calculated from these. The upper level 
of normal for each assay with a different ligand was calculated, as previously 
described (Section 4.3.1.5), and those patient sera with an Ab index greater 
than the upper level of normal were regarded as positive for binding to the 
radiolabelled ligand used in the assay. 
4.4.1.7 Computer analyses 
Predictions of B cell epitopes were carried out as previously described for 
tyrosinase epitope mapping experiments (Section 4.3.1.6) by Dr. Part Peterson 
(Institute of Biomedical Sciences, University of Tampere, Finland. Genbank 
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homology searches were performed using the Sequence Analysis Software 
package as before (Section 4.3.1.6). 
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4.4.2 Results 
4.4.2.1 In vitro translation of Pmel17 cDNA and its deletion derivatives 
For identification of autoepitopes on PmeI17, PCR amplification was used to 
generate PmeI17 cDNA fragments of varying lengths which were then cloned 
into pcDNA3. DNA sequencing of the fragments was carried out to verify that no 
sequence errors had been introduced. In addition, subcloning of various 
Pmel17 cDNA fragments was undertaken (Figure 4.6). All the constructs used 
in this study are listed in Table 4.8. 
Products generated from in vitro translation of Pmel17 cDNA and its 
deletion derivatives were evaluated by SDS-PAGE and autoradiography (Figure 
4.7 a, b, c). In each case, major bands representing the intact and modified 
[35S]-labelled PmeI17 proteins were found (Table 4.8). 
4.4.2.2 Radiobinding assay of PmeI17 deletion derivatives with sera from 
patients and controls 
Of the sera analysed, none from patients with either Graves' disease (n = 10) or 
Hashimoto's thyroiditis (n = 9) was positive in the radiobinding assays when 
either full-length PmeI17 or any of its deletion derivatives were used as the 
radiolabelled antigen. Five out of twenty vitiligo patient sera were reactive 
against full-length Pmel17 (Table 4.9). Of these, four reacted with all derivatives 
deleted up to amino acid residue 341. One vitiligo patient serum failed to react 
with any derivative containing amino acid deletions beyond residue 644. The 
remaining 18 vitiligo patient sera analysed did not bind to full-length Pmel17 or 
any of its deleted derivatives. The positive control serum AZN-LAM only reacted 
with full-length Pmel17, indicating that the last seven amino acids at the C- 
terminal of the protein are required for antibody binding. 
4.4.2.3 Identification of the antibody binding sites on PmeIl7 
The results of the radiobinding assays indicate that at least two epitope domains 
on Pmel17 are recognised by sera from patients with vitiligo: one between 
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Table 4.8: Deletion derivatives used in determining the B cell epitopes on 
Pmel17 which are recognised by vitiligo sera. 
Amino acids 
PmeI17 construct 
encoded' (bP) 
Predicted molecular 
weight of expressed 
protein3 (kDa) 
Estimated molecular 
weight of expressed 
protein4 (kDa) 
pcDNA3PMEL175 1-668 (1-2004) 73 71 
pPMEL17-661 1-661 (1-1983) 73 69 
pPMEL17-654 1-654 (1-1962) 72 69 
pPMEL17-644 1-644 (1-1932) 71 68 
pPMEL17-634 1-634 (1-1902) 70 68 
pPMEL17-576 1-576 (1-1728) 63 64 
pPMEL17-528 1-528 (1-1584) 58 61 
pPMEL17-460 1-460 (1-1381) 51 52 
pPMEL17-410 1-410 (1-1230) 45 48 
pPMEL17-387 1-387 (1-1161) 43 47 
pPMEL17-371 1-371 (1-1113) 41 42 
pPMEL17-356 1-356 (1-1068) 39 39 
pPMEL17-341 1-341 (1-1023) 38 36 
pPMEL17-326 1-326 (1-978) 36 39 
pPMEL17-276 1-276 (1-829) 30 32 
pPMEL17-194 1-194 (1-582) 21 28 
pPMEL17-148 1-148 (1-446) 16 22 
1 Numbers correspond to the amino acid residues of Pmel17 included in the construct with 
the initiating methionine as residue number one. 
2 Numbers correspond to base pairs of Pmel17 cDNA included in the construct with the A 
residue of the intiating ATG codon assigned as base pair number one. 
3 Predicted from the amino acid sequence of the protein. 
° Estimated from the mobility of the protein in SDS-acrylamide gels. 
5 Encodes full-length Pmel17. 
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Figure 4.7: SDS-PAGE and autoradiography of products arising from in 
vitro translation of Pmel17 cDNA and its deletion derivatives. 
Pmel17 cDNA and its deletion derivatives were translated in vitro in a TnT® T7 Coupled 
Reticulocyte Lysate System as described in Section 4.3.1.4. Subsequently, an aliquot of 
each reaction mixture was added to SDS-sample buffer, boiled for 5 min and then analysed 
by SDS-PAGE. (a) A 10% gel with [35S]-labelled products from in vitro translation of: Full- 
length Pmel17 (lane 1); pPMEL17-634 (lane 2); pPMEL17-576 (lane 3); pPMEL17-528 (lane 
4); pPMEL17-460 (lane 5); pPMEL17-410 (lane 6); pPMEL17-387 (lane 7). (b) A 10% gel 
with [35S]-labelled products from in vitro translation of: Full-length Pmel17 (lane 1); 
pPMEL17-661 (lane 2); pPMEL17-654 (lane 3); pPMEL17-644 (lane 4); pPMEL17-371 (lane 
5); pPMEL17-356 (lane 6); pPMEL17-341 (lane 7). (c) A 15% gel with [35S]-labelled products 
from in vitro translation of: pPMEL17-326 (lane 1); pPMEL17-276 (lane 2); pPMEL17-194 
(lane 3); pPMEL17-148 (lane 4). 
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Table 4.9: Reactivity of vitiligo sera to Pmel17 deletion derivatives. 
Reactivity of se ra' Upper 
level of 
normal for 
the 
Pmel17 1 2 3 4 5 assay' 
construct 
pcDNA3Pmel17 2.98 (+) 3.14 (+) 3.62 (+) 4.10 (+) 3.86 (+) 1.26 
pPmell7-661 nd3 nd 3.37 (+) nd nd 1.17 
pPmeI17-654 nd nd 3.33 (+) nd nd 1.19 
pPmeI17-644 nd nd 3.54 (+) nd nd 1.32 
pPmeI17-634 2.62 (+) 3.10 (+) 1.31 (-) 4.11 (+) 3.80 (+) 1.42 
pPmeI17-576 2.38 (+) 2.89 (+) 1.12 (-) 4.24 (+) 3.76 (+) 1.17 
pPmeI17-528 2.23 (+) 2.76 (+) 1.27 (-) 3.98 (+) 3.85 (+) 1.36 
pPmeil7-460 2.26 (+) 2.86 (+) 1.05 (-) 4.00 (+) 3.90 (+) 1.21 
pPmell7-410 2.35 (+) 2.67 (+) 1.05 (-) 3.64 (+) 3.70 (+) 1.30 
pPmell7-387 2.50 (+) 2.86 (+) 1.04 (-) 3.26 (+) 3.64 (+) 1.23 
pPmell7-371 2.77 (+) 2.89 (+) nd 3.44 (+) 3.71 (+) 1.26 
pPmeI17-356 2.56 (+) 3.13 (+) nd 3.25(+) 3.25 (+) 1.16 
pPmeil7-341 2.59 (+) 2.95 (+) nd 2.98(+) 3.05 (+) 1.24 
pPmell7-326 0.89 (-) 1.16 (-) 1.01 (-) 1.12 (-) 1.09 (-) 1.31 
pPmell7-276 0.80 (-) 0.97 (-) 1.27 (-) 0.98 (-) 1.07 (-) 1.33 
pPmell7-194 0.72 (-) 0.72 (-) 0.98 (-) 0.99 (-) 1.10 (-) 1.18 
pPmell7-148 0.75 (-) 0.66 (-) 1.16 (-) 1.00 (-) 1.14 (-) 1.20 
' The binding reactivity of each of the sera to the full-length Pmel17 and each deletion 
derivative was expressed as an antibody index calculated as: cpm immunoprecipitated by 
tested serum/mean cpm immunoprecipitated by 20 healthy control sera. Each serum was 
analysed in at least two experiments and the mean antibody index was calculated from 
these. 
2The upper level of normal for each assay with a different ligand was calculated using the 
mean antibody index +3 SD of 20 control sera. Patient sera with an antibody index greater 
than the upper level of normal were regarded as positive for binding to the radiolabelled 
ligand used in the assay W. (-) denotes negative for binding to the radiolabelled ligand 
used in the assay. 
3 nd, not determined. 
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amino acids 634 and 644 (VPQLPHSSSHW) located at the C-terminal of the 
protein and a second between amino acids 326 and 341 
(QVPTTEVVGTTPGQAP) found towards the centre of the Pmel17 molecule 
(Table 4.10). Of the vitiligo sera examined, four reacted with the same epitope 
at amino acids 326-341 and one reacted with the epitope at the C-terminal 
domain (amino acids 634-644). As deletion from the 3' end of a molecule 
reveals predominantly antigenic regions which are nearer to the N-terminus of 
the protein, the reactivity of four of the sera with the C-terminal epitope domain 
was not confirmed because of the presence of reactivity with the antigenic 
region found closer to the N-terminal end of Pmel17. 
4.4.2.4 Antigenicty predictions for PmeI17 
Computer prediction analysis identified several putative antigenic regions within 
Pmel17 (Figure 4.8). One extensive putative antigenic domain (amino acids 
290-340) encompassed the identified epitope amino acids 326-341. The 
epitope located at the C-terminal of Pmel17 (amino acids 634-644), however, 
was within a region of the protein predicted to have low antigenicity. 
4.4.2.5 Protein homology searches 
The amino acid sequences of the identified PmeI17 epitopes were compared to 
the amino acid sequences of the related melanogenic enzymes tyrosinase 
(Takeda et al. 1989), tyrosinase-related protein-1 (TRP-1) (Cohen et al. 1990) 
and tyrosinase-related protein-2 (TRP-2) (Yokoyama et al. 1994). No sequence 
homology was found between either of the Pmel17 epitopes and the 
aforementioned proteins. 
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Table 4.10: Epitope regions on PmeI17 recognised by vitiligo seral. 
Patient 
Amino acids 1 2 3 4 5 
326-341 
634-644 
++-++ 
NA NA + NA NA 
1 Reactivities with epitope regions are indicated: + denote reactivity with the specified 
epitope region; - denotes unreactive with specific epitope region; NA denotes reactivity with 
the specified epitope region unknown. 
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Figure 4.8: Antigenicity profile of the deduced amino acid sequence of 
Pmel17. 
Local antigenicity values, calculated as previously detailed (Parker et al. 1986), are plotted 
against the amino acid residues of Pmel17. The y-axis scale from 0-100 reflects increasing 
antigenicity. 
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4.4.3 Results summary 
These results indicate that at least two epitope domains are present in PmeI17: 
one between amino acids 326 and 341 (QVPTTEVVGTTPGQAP) and a second 
between amino acids 634 and 644 (VPQLPHSSSHW). These were located 
centrally and towards the C-terminal, respectively, of the Pmel17 protein. Four 
vitiligo patient sera reacted with the same epitope at amino acids 326-341 and 
one reacted with the epitope at the C-terminal domain (amino acids 634-644). 
The reactivity of four of the sera with the C-terminal antigenic domain could not 
be confirmed because of the presence of reactivity with the epitope region 
located nearer to the N-terminus of the Pmel17 molecule. In order to examine 
the reactivity of these sera with the C-terminus of Pmel17, further deletion 
derivatives would need to be constructed which exclude the central regions of 
the protein. 
Computer analysis of the potential B cell epitopes on Pmel17 revealed 
that the epitope domain encompassing amino acids 326-341 was located in an 
area of the protein which was predicted to be highly antigenic. In contrast, the 
epitope identified at the C-terminal of Pmel17 (amino acids 634-644) was 
located in a region of the protein predicted to have low antigenicity. Computer 
predictions of putative antigenic regions may not always correlate, therefore, 
with epitopes found experimentally. 
There is considerable amino acid sequence homology between Pmel17 
(Kwon et al. 1991) and other melanogenic enzymes, for example, tyrosinase 
(Takeda et aL 1989), TRP-1 (Cohen et al. 1990) and TRP-2 (Yokoyama et al. 
1994). We therefore compared the Pmel17 autoantigenic regions for amino acid 
homology with these proteins to locate possible cross-reactive domains. 
However, no sequence homology was found between either of the Pmel17 
epitopes and the melanogenic proteins analysed. This finding is consistent with 
a previous study from this laboratory in which no Pmel17 antibodies were 
identified that were cross-reactive with either tyrosinase, TRP-1 or TRP-2 (Kemp 
et al. 1998b). It also suggests that the IgG response to Pmel17 is distinct from 
the antibody response to the other melanocyte-specific antigens. 
Although only two regions of Pmel17 were recognised as epitopes for the 
autoantibodies in the vitiligo patients studied, it is possible that if a larger cohort 
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of vitiligo patient sera contaning PmeI17 antibodies was tested, more 
autoreactive epitopes may be identified. 
4.5 Discussion 
The in vitro translation system is a useful procedure for producing both intact 
and modified [35S]methionine-labelled proteins, which can then be used for 
testing antibody reactivity and for epitope mapping (Wedlock et al. 1993; Daw et 
al. 1996; Volpato et al. 1998; Kemp et al. 2001 a). In this chapter the technique 
was used to radiolabel full-length and deletion derivatives of both tyrosinase and 
Pmel17, which were then used in radiobinding assays to identify antigenic 
regions on both proteins. A disadvantage of the use of deletion derivatives is in 
the inevitable loss of native conformation and, therefore, of epitope regions 
which are brought together by the secondary structure of the protein (Petterson 
1992). In Graves' disease, for example, it has been reported that the 
autoantibodies to the thyrotropin receptor, which are responsible for disease 
activity, recognise a number of different conformational epitopes (Morgenthaler 
et al. 1999). In so far as short linear sequences may contribute to 
conformational epitopes it may be possible to identify at least part of some 
conformational epitopes using the methodology applied in this study. In 
addition, a previous study employing site-directed mutagenesis to dissect 
reactivity to a conformational autoepitope of steroid 21-hydroxylase in 
autoimmune endocrinological diseases, suggested that testing of radiolabelled 
antigens in liquid-phase immunoprecipitation assay can be conformation- 
sensitive (Nikoshkov et al. 1999). Nevertheless, it would be of interest to apply 
phage-display technology (Table 4.1; Scott 1992; Williams et al. 2001) to future 
epitope mapping studies of tyrosinase and Pmel17. Phage-display is more 
suited to the study of conformational epitopes since expressed proteins are able 
to fold into their correct three-dimensional structures in the periplasmic space of 
the bacterial host, and can maintain a native arrangement once displayed on the 
surface of a phage particle (Wilson & Finlay 1998). 
Tyrosinase and Pmel17 may be considered cytoplasmic autoantigens, 
since they are associated with the melanosomal membrane within melanocytes, 
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and are not thought to be expressed on the melanocyte cell surface. However, 
since the amino acid sequence of two of the identified epitope regions in 
tyrosinase had homology to an amino acid sequence present in TRP-1, and 
TRP-1 can be expressed on the melanocyte surface (Takechi et al. 1996), 
cross-reactivity with surface epitopes may be responsible for anti-tyrosinase 
antibody reactivity. In addition a transport protein, the melansome transport 
signal (MTS), has been implicated in directing melanosomal glycoproteins to the 
endocytic pathway leading to MHC class II-mediated antigen presentation on 
the melanocyte surface (Wang et al. 1999). It is possible that damage to 
melanocytes, by mechanisms which could include cytotxic T cell lysis, might 
cause release and degradation of intracellular proteins thereby exposing 
epitopes to autoreactive antibodies. Alternatively, autoantibodies might 
encounter these protein epitopes by directly penetrating the cytoplasm. Cellular 
uptake of anti-nuclear antibodies has previously been demonstrated in non- 
hemopoietic cells (Isenberg et aL 1997). 
The use of human sera in the mapping of B cell epitopes can be 
problematic because sera contain multiple antibody species against a particular 
autoantigen and the immune response tends to diversify with duration. It is 
difficult therefore to examine the reactivity of a specific autoantibody in isolation 
and it is not possible to discriminate between a single autoantibody targeted at 
an epitope and a set of closely-related autoantibodies directed at the same 
epitope. In order to characterise the array of autoantibodies present in a 
particular serum and the epitope specificity of a particular autoantibody, the 
production of human monoclonal antibodies from the patient is usually required. 
Indeed, monoclonal antibodies isolated from individuals with insulin-dependent 
diabetes mellitus have been successfully employed to identify the antibody 
binding sites on glutamic acid decarboxylase, an autoantigen in this disease 
(Syren et al. 1996; Table 4.2). Although the monoclonal antibody approach can 
allow the precise characterisation of epitopes recognised by a specific antibody, 
it is difficult to know the relative frequencies of the different monoclonal 
antibodies in the patient under investigation. Despite this, the isolation of 
monoclonal antibodies from vitiligo patients will allow a more complete and 
detailed analysis of the epitopes recognised by tyrosinase and Pmel17 
autoantibodies. 
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The potential applications of the molecular characterisation of B cell 
epitopes in disease include: (i) a greater understanding of the association of an 
autoantigen with autoimmune pathogenesis, (ii) possible insights into the 
initiation of the autoimmune process, (iii) the establishment of novel and more 
specific assays for measuring autoantibodies in patient sera and (iv) the 
development of specific-active immunotherapies. The ways in which these 
criteria were met by the study undertaken will be discussed below. 
Firstly, an association of the autoantigens tyrosinase and Pmel17 with 
vitiligo pathogenesis may be revealed by examining the location of the identified 
epitopes with respect to the functional domains of each protein. For example, if 
the epitopes reside in, or contribute to, the structure of the active sites of 
tyrosinase/Pmell7, autoantibodies targeting these epitopes might inhibit 
melanogenic activity. However, none of the identified tyrosinase B cell epitopes 
maps to the two copper-binding regions (amino acid residues 154-220 and 343- 
385) which are located in the catalytic site of the enzyme (Tomita et al. 1989). 
The role of Pmel17 in melanogenesis, and therefore its functionally significant 
domains, has yet to be fully elucidated (Section 1.1.4). However, the centrally 
positioned epitope identified in Pmel17 (amino acids 326-341) lies within a 
region of the protein containing an amino acid repeat motif (amino acid residues 
315-392) thought to be functionally important (Kwon 1993). 
Secondly, no apparent homology was identified between the specified 
epitope regions and any microbial proteins, this would suggest that molecular 
mimicry does not initiate the production of tyrosinase and Pmel17 
autoantibodies in vitiligo patients. However, as yet uncharacterised B cell 
epitopes on tyrosinase and Pmel17, which may be revealed by a study 
employing a larger cohort of vitiligo patients or conformational epitope mapping 
techniques, may demonstrate cross-reactivity. Moreover, the current computer 
databases are unlikely to represent all microbial proteins. 
Thirdly, since the both tyrosinase and Pmel17 had multiple epitope 
regions and the antibody response provoked in vitiligo patients was 
heterogenous, it is unlikely that a more specific assay for measuring reactivity to 
either protein, limited to the epitope regions identified here, would be suitable for 
screening vitiligo patients. 
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Finally, since the specific destruction of melanocytes is the goal of 
melanoma therapy and is a consequence of vitiligo, the identification of epitopes 
on both tyrosinase and Pmel17 could be used in the development of specific 
immunotherapies for treatment of this disease. In a recent study, it has been 
shown that antibody reactivity to Pmel17 and to tyrosinase is present in 48% 
and 57% of melanoma patients, respectively (Huang et al. 1998). It would, 
therefore, be of interest to determine the epitopes on PmeI17 and tyrosinase 
which elicit the IgG responses in these melanoma patients and to ascertain if 
they are the same epitopes as those reported here for vitiligo. As expected 
since B and T lymphocytes often recognise different autoepitopes, no precise 
homology was apparent between reported cytotoxic T cell epitopes on Pmel17 
(Kawakami et al. 1995; Tsomides et al. 1997) and tyrosinase (Brichard et al. 
1993; Wolfel et al. 1994; Kang et al. 1995; Tsomides et al. 1997) in melanoma 
patients and the B cell epitopes reported here for vitiligo. Cytotoxic T cell 
epitopes have recently been identified in vitiligo for tyrosinase and Pmel17 
(Lang et al. 2001; Palermo et al. 2001) and these also showed no homology 
with the B cell epitopes characterised in this study. 
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5 An investigation of autoantibody responses to the 
melanocyte-specific antigen MelanA in vitiligo 
patients 
5.1 Introduction 
5.1.1 Structure and function of MelanA 
The MelanA gene was first isolated from a human melanoma cell line cDNA 
library by its reactivity with autologous cytotoxic T cells (Coulie et al. 1994). The 
same gene was independently cloned by analysis of the antigenic targets of 
melanoma tumour-infiltrating lymphocytes and named MART-1 (Melanoma 
Antigen Recognised by T cells-1) (Kawakami et al. 1994a). Analysis of normal 
human cells and tissues for expression of MelanA mRNA demonstrate that it is 
melanocyte-specific and can, therefore, be termed a melanocyte differentiation 
antigen (Coulie et al. 1994; Kawakami et al. 1994a). The MelanA protein is a 
relatively short polypeptide of 118 amino acids in length with a single highly 
hydrophobic transmembrane domain. Subcellular fractionation analysis has 
suggested that MelanA is concentrated in melanosomes and in the endoplasmic 
reticulum (ER) (Kawakami et al. 1997). It does not, however, share any 
homology with other melanosomal proteins and, unlike tyrosinase and Pmel17, 
does not contain a leader sequence. Rather, it is a type III membrane protein 
with a signal-anchor region that functions as both an ER targeting sequence and 
as a transmembrane domain, and is orientated in the membrane with the C- 
terminal exposed to the cytosol (Rimoldi et aL 2001). The role of MelanA in the 
melanosome and in melanogenesis has yet to be elucidated. 
5.1.2 The immune response to MelanA in vitiligo 
Several recent studies have demonstrated specific cytotoxic T cell responses 
against MelanA in patients with vitiligo (Ogg et al. 1998; Lang et al. 2001; 
Palermo et al. 2001). In the first of these studies, a MelanA peptide bound to an 
appropriate MHC class I antigen, HLA-A2, in tetrameric complexes, was 
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incubated with peripheral blood lymphocytes from both vitiligo patients and 
normal subjects, and the frequency of MelanA-specific cytotoxic T lymphocytes 
quantified by flow cytometric analysis (Ogg et al. 1998). MelanA-specific CD8+ 
cytotoxic T lymphocytes were observed at a significantly high frequency in 7 out 
of 9 (78%) HLA-A2 positive vitiligo patients and only 1 out of 6 (17%) HLA-A2 
positive normal control subjects. Furthermore, a high proportion of the MelanA- 
specific T cells from the vitiligo patients were shown to be expressing the skin- 
homing receptor cutaneous lymphocyte-associated antigen (CLA), in contrast to 
those of the one positive control subject, and their frequency correlated with the 
extent of depigmentation. The same technique was applied by a second study 
to detect MelanA-specific cytotoxic T lymphocytes in the circulation of vitiligo 
patients and healthy controls with similar findings: 9 out of 9 (100%) vitiligo 
patients and 2 out of 6 (33%) healthy controls (Palermo et al. 2001) had such T 
cells. A third study used an enzyme-linked immunospot (ELISPOT) assay for 
detection of HLA-A2 restricted, MelanA-specific cytotoxic T cells using IFN-y- 
specific antibody, and reported that the presence of these cells correlated with 
vitiligo disease activity (Lang et al. 2001). Among the 10 patients in this study 
with actively progressing disease, 7 (70%) had cytotoxic T cell reactivity to 
MelanA, compared with 4 out of 22 (18%) with only moderately progressing 
disease, and 1 out of 17 (6%) control subjects. The results of these studies are 
consistent with a role for skin-homing melanocyte-specific T lymphocytes in the 
pathogenesis of vitiligo. 
Since MelanA is targeted by cytotoxic T cells (Ogg et al. 1998; Lang et al. 
2001; Palermo et al. 2001) in vitiligo, it is possible that autoantibodies that target 
MelanA are also present in vitiligo patient sera. Moreover, the detection of 
MelanA-specific autoantibodies may prove valuable for the development of 
diagnostic and therapeutic tools for vitiligo. 
5.2 Aim 
The aim of the present study was to examine vitiligo patient sera for the 
presence of autoantibodies to MelanA. For this analysis, both Western blotting 
with a glutathione S-transferase (GST)-MelanA fusion protein and a radiobinding 
assay with [35S]-labelled MelanA were used. 
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5.3 Material and Methods 
5.3.1 Sera 
Serum samples from 51 patients with vitiligo (28 female, 23 male; mean age: 45 
yr; age range, 14-77 yr) were analysed in this study. Of these patients, 13 had 
an associated autoimmune disease: alopecia areata, 2; autoimmune thyroid 
disease, 7; systemic lupus erythematosus, 2; autoimmune thyroid disease and 
pernicious anaemia, 1; scleroderma, 1. The vitiligo patients were diagnosed 
with the following subtypes: peri-orificial, 1; symmetrical, 37; symmetrical and 
peri-orificial, 6; symmetrical and segmental, 1; segmental, 2; focal, 2; universal, 
1; occupational, 1. Sera from 26 normal individuals (9 male, 17 female; mean 
age: 36 yr; age range: 22-59 yr), all without clinical signs of vitiligo or 
autoimmunity, were used as controls. 
5.3.2 Specific antibodies 
Monoclonal anti-MelanA antibody A103 was purchased from Novocastra 
Laboratories (Newcastle-upon-Tyne, U. K. ). Anti-GST antibody was from 
Amersham Pharmacia Biotech. Anti-goat, anti-mouse and anti-human IgGs 
conjugated to horse-radish peroxidase were from Sigma. 
5.3.3 Cloning of MelanA cDNA into pcDNA3 
MelanA cDNA cloned between the BgIIl-Ncol sites of pSC11 was a gift from 
Professor Vincenzo Cerundolo (Institute of Molecular Medicine, Nuffield 
Department of Clinical Medicine, University of Oxford, Oxford, U. K. ). The cDNA 
was subcloned into plasmid pcDNA3 in order to allow expression of MelanA 
from the T7 promoter in the vector. Briefly, 5 pg of pSCI 1/MelanA plasmid was 
restricted with enzymes Bglll (Promega) and Ncol (Promega) (Section 2.8) and 
the resulting DNA fragments resolved in a 0.8% (w/v) agarose gel (Section 2.9). 
The 400 bp full-length MelanA cDNA fragment was excised from the gel and 
purified according to a Wizard PCR Prep DNA Purification System (Promega). 
The 5'-protuding termini of the MelanA cDNA fragment, created by Bglll and 
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Ncol digestion, were end-filled using a DNA Polymerase I Large (Klenow) 
Fragment Mini Kit (Promega). The end-filling reaction consisted of 1 pg of the 
purified BgIII-Ncol restricted MelanA cDNA fragment, 1x Klenow buffer (50 mM 
Tris-HCI, pH 7.2; 10 mM MgSO4; 1 mM DTT), 10 mM of each dNTP, 0.1 mg/ml 
bovine serum albumin (BSA), 1U Klenow polymerase and dH2O to a final 
volume of 10 pl. The reaction was allowed to proceed for 20 min at 37°C, after 
which time the Klenow polymerase was inactivated by heating to 65°C for 15 
min. The end-filled MelanA cDNA fragment was ligated into EcoRV-restricted 
pcDNA3 (Section 2.11), which was then used to transform E. coli JM109 
(Section 2.12). Plasmid DNA was purified from individual transformants using a 
Wizard Minipreps DNA Purification System (Section 2.7.1), digested with Hindlll 
and Xbal and analysed by agarose gel electrophoresis. One appropriate 
recombinant plasmid was sequenced by the dideoxy chain termination method 
as previously described (Section 2.15), using T7 primer with [a_35 S]dATP to 
verify the clone. The recombinant plasmid, pcMelanA, was then purified with a 
Qiagen Plasmid Maxi Kit (Qiagen Ltd. ) (Section 2.7.2). 
5.3.4 Cloning of MelanA cDNA into pGEX-4T-1 
MelanA cDNA was cloned into pGEX-4-T-1 (Amersham Pharmacia Biotech) 
(Figure 5.1) in order to create a glutathione S-transferase (GST)-MelanA fusion 
protein which could be purified using a glutathione-linked affinity resin (Smith & 
Johnson 1988). A full-length fragment of MelanA cDNA was generated from 
pcMelanA by PCR amplification. Restriction sites for EcoRI and Xhol were 
incorporated into the 5' and 3' oligonucleotide primers (Life Technologies), 
respectively, in order to allow subcloning of the PCR product into pGEX-4T-1. 
The primers used are listed in Table 5.1. 
A 50 ng sample of pcMelanA was subjected to 36 cycles of PCR 
amplification (Section 2.13) using an ExpandTM High Fidelity PCR System 
(Roche Diagnostics Ltd. ) and the following conditions: 94°C, 1 min; 55°C, 1 min; 
72°C, 2 min; and 72°C for 10 min for termination. The PCR product was 
restricted with EcoRl and Xhol and purified according to a Wizard PCR Prep 
DNA Purification System (Section 2.10). Two-micrograms of pGEX-4T-1 vector 
was restricted with EcoRl and Xhol and purified, following agarose gel 
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Figure 5.1: A map of the pGEX-4T-1 vector detailing restriction sites. 
(Amersham Pharmacia Biotech) 
Full-length MelanA cDNA was cloned into the EcoRI-Xhol sites of this vector to create an in- 
frame fusion with glutathione S-transferase (GST). 
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Table 5.1: Oligonucleotide primers used to generate MelanA cDNA by PCR 
amplification. 
Base Primer Primer sequence 
pairs' 
1-354 MelanA/EcoRl 5'GGGAATTCATGCCAAGAGAAGATGCT3' 
MelanA/Xhol 5'CCCTCGAGTCATTAAGGTGAATAAGGTGGTGG3' 
'The numbers correspond to base pair of MelanA cDNA included in the construct with the A 
residue of the initiating ATG codon assigned as base pair number one. 
2EcoRI and Xhol restriction sites are underlined. The first and last codons of MelanA cDNA 
in the forward and reverse primers, respectively, are shown in bold-type face. 
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electrophoresis, as previously described (Section 2.9). The MelanA cDNA 
fragment was then ligated into the EcoRl and Xhol sites of pGEX-4T-1 (Section 
2.11) and used to transform E. coli DH5a (Clontech Laboratories U. K. Ltd., 
Basingstoke, U. K. ) (Section 2.12). Plasmid DNA was purified from individual 
transformants using a Wizard Minipreps DNA Purification System, digested with 
EcoRl and Xhol and analysed by agarose gel electrophoresis. One appropriate 
recombinant plasmid was sequenced using a 5' pGEX sequencing primer 
(Amersham Pharmacia Biotech), as previously detailed (Section 2.15), to verify 
that no sequence errors had been introduced. The recombinant plasmid, pGST- 
MelanA, was then purified with a Qiagen Plasmid Maxi Kit (Qiagen Ltd. ) (Section 
2.7.2) 
5.3.5 Coupled in vitro transcription and translation of MelanA cDNA 
Plasmid pcMelanA was used in a TnT* T7 Coupled Reticulocyte Lysate System 
(Promega) to produce MelanA in vitro and concomitantly label the protein with 
[35S]methionine (Amersham Pharmacia Biotech) as detailed elsewhere (Section 
4.3.2.1). 
5.3.6 Radiobinding assays 
For each assay, an aliquot of the in vitro translation reaction mixture (equivalent 
to 50,000-100,000 counts per minute of trichloroacetic acid-precipitable material) 
was suspended in 50 pl of immunoprecipitation buffer. Serum was then added 
to a final dilution of 1: 50. Radiobinding assays were carried out as previously 
described (Section 4.3.1.5). 
5.3.7 Expression and affinity purification of GST-MelanA 
Escherichia coli DH5a containing either pGST-MelanA or pGEX-4T-1 was 
cultured overnight in 20 ml of LB with 100 pg/ml ampicillin (Sigma). Each culture 
was then inoculated into 1L of fresh LB containing 100 pg/ml ampicillin and 
incubated at 37°C until an OD600 of 0.6 was reached. Isopropyl-ß- 
thiogalactopyranoside (IPTG; Promega) was subsequently added to a final 
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concentration of 1 mM and the cultures incubated for a further 3h to allow 
expression of either GST or GST-MelanA protein. The cultures were harvested 
by centrifugation and resuspended in 10 ml of ice cold phosphate-buffered 
saline (PBS) containing 0.1% (v/v) Tween 20,1 pM PepstatinA (CN 
Biosciences, Nottingham, U. K. ), 1 pM Na-tosyl-phenylalanyl chloromethyl 
ketone (CN Biosciences) and 10 pg/mi aprotinin. Cells were lysed using 
sonication followed by the addition of Triton X-100 to a final concentration of 1% 
(w/v). The bacterial lysates were centrifuged at 5000 g for 10 min to remove 
unlysed cells and the supernatants retained on ice. 
For affinity purification of GST and GST-MelanA, 2 ml of 50% (w/v) 
glutathione-agarose beads (Sigma), prepared as detailed bellow, were added to 
the bacterial supernatants. Briefly, lyophilised glutathione-agarose beads were 
swelled in dH2O at 200 pl/g for 2 h. A 50% (w/v) bead-slurry was prepared by 
collecting the glutathione-agarose beads by centrifugation at 1000 g and gently 
resuspending in an equal volume of PBS/0.1% (v/v) Tween 20 with protease 
inhibitors as detailed above. Following overnight incubation of the bacterial 
supernatants and glutathione-agarose beads with gentle agitation at 4°C, the 
beads were washed four times with 10 ml of ice cold PBS/0.1 % (v/v) Tween 20 
with protease inhibitors and collected by centrifugation at 1000 g. After the final 
wash, the beads were resuspended in 2 ml of SDS sample buffer and bound 
proteins were eluted by boiling for 5 min before storing at -20°C. Thirty- 
microlitre aliquots were subjected to subsequent electrophoretic and western 
blot analysis. 
5.3.8 Electrophoretic analysis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of 
GST and GST-MelanA was performed in 12% (w/v) polyacrylamide resolving 
gels and 4% (w/v) polyacrylamide stacking gels as described elsewhere 
(Section 2.17). After electrophoresis, gels were stained with 0.05% (w/v) 
Coomassie blue in 10% (v/v) glacial acetic acid/25% (v/v) isopropanol and 
destained with 10% (v/v) glacial acetic acid/25% (v/v) isopropanol, 1h each at 
room temperature, in order to visualise protein bands. 
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SDS-PAGE of in vitro translated and radiolabelled MelanA was also 
performed in a 12% (w/v) polyacrylamide gel and a 4% (w/v) stacking 
polyacylamide gel. Five-microlitres of in vitro translated and radiolabelled 
MelanA, mixed with 10 pl of SDS sample buffer, was loaded on to the gel. 
Following staining and destaining as above, the gel was soaked in Amplify 
fluorographic reagent (Amersham Pharmacia Biotech) for 30 min at room 
temperature before drying under vacuum at 60°C for 2h onto 3MM 
chromatography paper. The gel was autoradiographed at -70°C. 
5.3.9 Western blot analysis 
Following SDS-PAGE, proteins were transferred electrophoretically to 
nitrocellulose (Bio-Rad Laboratiries Ltd. ) overnight at 40 volts in 20% (v/v) 
methanol, 25 mM Tris-HCI, 192 mM glycine (pH 8.3) using a Trans-Blot SD 
semi-dry transfer cell (Bio-Rad laboratories Ltd. ). Membranes were then soaked 
overnight at 4°C in PBS containing 5% (w/v) skimmed milk. Nitrocellulose strips 
were subsequently incubated for 2h at room temperature with either patient 
sera, anti-GST antibody or MelanA monoclonal A103 at a final dilution of 1: 100 
in PBS with 5% (w/v) skimmed milk. Washing of the strips, 4 times each for 15 
min, was carried out in PBS containing 0.05% (w/v) Tween 20. Subsequently, 
the strips were probed with the appropriate horse-radish peroxidase conjugated 
IgG used at a final dilution of 1: 1000 in PBS/5% (w/v) skimmed milk. After 
washing 4 times for 15 min in PBS/0.05% (v/v) Tween 20, the blots were 
processed using ECLTM Western blotting detecting reagent (Amersham 
Pharmacia Biotech) as described below. Equal volumes of ECLTM detection 
solutions 1 and 2 were mixed to give ECLTM Western blotting detecting reagent 
in a sufficient quantity to cover the nitrocellulose strips. The washed strips were 
drained of excess PBS/0.05% (v/v) Tween 20 and arranged protein side up on 
an acetate sheet. The detection reagent was added to the surface of the strips 
and held, by surface tension, for 1 min at room temperature without agitation. 
Excess detection reagent was then drained and the acetate sheet and strips 
wrapped in Saran Wrap (Scientific Laboratory Supplies Ltd., Hessle, U. K. ) and 
exposed to Fuji RX x-ray film. 
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5.4 Results 
5.4.1 In vitro transcription-translation of MelanA 
In vitro transcription-translation of MelanA was evaluated by SDS-PAGE and 
autoradiography which revealed a protein product with an estimated molecular 
weight of 22 kDa (Figure 5.2). This agrees well with the molecular weight of 20- 
22 kDa previously reported (Chen et al. 1996) but is larger than the mass of 13 
kDa predicted from the amino acid sequence of the protein (Kawakami et al. 
1994a). The difference in size has been attributed to post-translation 
modification of the protein, not applicable here, or to aberrant protein mobility in 
the SDS-PAGE system (Chen et al. 1996). 
5.4.2 Radiobinding assays 
Sera from 51 vitiligo patients and 20 healthy controls were tested for their ability 
to immunoprecipitate [35S]MelanA in the radiobinding assay. For each serum a 
MelanA antibody index was assigned, this being the mean MelanA antibody 
index of at least two experiments. The upper level of normal for the radiobinding 
assay (mean MelanA antibody index +3 SD of 20 healthy controls) was 
estimated as a MelanA antibody index of 1.59 (Figure 5.3). 
None of the healthy individuals was positive for MelanA autoantibodies 
(mean MelanA antibody index ± SD = 1.02 ± 0.19). Of the 51 vitiligo patients 
tested, none had a MelanA antibody index above 1.59 (Figure 5.3) and all were 
considered negative for MelanA autoantibodies. The mean ± SD of the vitiligo 
patient group was 0.84 ± 0.26. 
5.4.3 Expression and purification of GST-MelanA 
Following expression of GST-MelanA in E. coli DH5a and affinity purification 
using glutathione agarose, the fusion protein was resolved by electrophoresis in 
a 12% SDS-polyacrylamide gel and visualised by Coomassie blue staining 
(Figure 5.4). This demonstrated a protein band with an apparent molecular 
weight of 45 kDa consistent with the size of the MelanA polypeptide, previously 
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Figure 5.2: SDS-PAGE and autoradiography of in vitro translated 
[35S]MelanA. 
Lane 1, in vitro translated MelanA radiolabelled with [35S] methionine. 
136 
3 
x 
a) 
0 
cc 
d 
2 
0 
O 
00080 
0 
8g8 
00000000 
0 
00000000 
0 0000 0000 0000 
OöROO g0 
Vitiligo Control 
Figure 5.3: MelanA antibody indices of patient sera in the radiobinding 
assay. 
The sera used were: vitiligo (n = 51), and healthy controls (n = 20). The MelanA antibody 
index shown for each serum is the mean MelanA antibody index of at least two experiments. 
The dotted line shows the upper level of normal (mean MelanA antibody index +3 SD of 20 
healthy control sera) for the radiobinding assay. 
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Figure 5.4:. SDS-polyacylamide gel of purified of GST and GST-MelanA 
fusion protein. 
GST and GST-MelanA were affinity purified with glutathione agarose beads from E. coli 
DH5a bacterial cell sonicates and resolved by SDS-PAGE in a 12% gel. Protein bands were 
visualised using Coomassie blue staining. Lane 1, GST-MelanA purified from bacterial 
sonicate prepared following treatment of a culture with IPTG; lane 2, GST purified from 
bacterial sonicate prepared following treatment of a culture with IPTG; lane 3, GST-MelanA 
purified from bacterial sonicate prepared from a culture previously untreated with IPTG; lane 
4, GST purified from bacterial sonicate prepared from a culture previously untreated with 
IPTG. 
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reported as 20-22 kDa, plus the 26 kD contributed by the GST leader sequence. 
The results in Figure 5.4 also imply a limited recovery of GST-MelanA. This is 
probably, in part, due to a decrease in the solubility of the fusion protein relative 
to the GST leader polypeptide alone. The gel also shows that a basal level of 
expression of GST and GST-MelanA occurs in cells not treated with IPTG. 
To identify the fusion protein specifically, a Western blot of purified GST 
and GST-MelanA was made and probed using the anti-MelanA monoclonal 
antibody A103. The antibody reacted with the fusion protein at 45 kDa but not 
with the GST polypeptide at 26 kDa (Figure 5.5). Both GST and GST-MelanA 
were found to react with anti-GST antibody in immunoblotting experiments (data 
not shown). 
5.4.4 Western blotting analysis 
To examine the reactivity of vitiligo sera with GST-MelanA, a Western blot of 
GST-MelanA was made onto nitrocellulose. Strips of membrane were probed 
with vitiligo patient (n = 51) and control sera (n = 20) and the anti-MelanA 
monoclonal antibody A103 followed by either anti-human or anti-mouse horse- 
radish peroxidase conjugated IgG, as appropriate. None of the vitiligo patient 
sera were found to react with GST-MelanA and a sample of the results is shown 
in Figure 5.6. 
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Figure 5.5: Western blot of purified of GST and GST-MelanA fusion protein 
probed with anti-MelanA monoclonal antibody A103. 
GST and GST-MelanA were affinity purified with glutathione agarose beads from E. coli 
DH5a bacterial cell sonicates, resolved by SDS-PAGE in a 12% gel and transferred to 
nitrocellulose. The membrane was probed with anti-MelanA monoclonal antibody A103 at a 
1: 100 dilution followed by anti-mouse IgG horse-radish peroxidase conjugate at a 1: 1000 
dilution. After treatment with ECLTM Western blotting detecting reagents, the blot was 
exposed to x-ray film. Lane 1, GST-MelanA purified from bacterial sonicate prepared 
following treatment of a culture with IPTG; lane 2, GST purified from bacterial sonicate 
prepared following treatment of a culture with IPTG; lane 3, GST-MelanA purified from 
bacterial sonicate prepared from a culture previously untreated with IPTG; lane 4, GST 
purified from bacterial sonicate prepared from a culture previously untreated with IPTG. 
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Figure 5.6: Western blot of purified GST-MelanA fusion protein probed 
with anti-MelanA monoclonal antibody A103, vitiligo patient sera and 
healthy control sera. 
GST-MelanA was affinity purified with glutathione agarose beads from an E. coli DH5 a 
bacterial cell sonicate, resolved by SDS-PAGE in a 12% gel and transferred to 
nitrocellulose. Strips of membrane were probed with either vitiligo sera or healthy control 
sera at a dilution of 1: 100 followed by anti-human IgG horse-radish peroxidase conjugate at 
a dilution of 1: 1000. One strip was probed with anti-MelanA monoclonal antibody A103 at 
1: 100 dilution followed by anti-mouse IgG horse-radish peroxidase conjugate at 1: 1000 
dilution. After treatment with ECLTM Western blotting detecting reagents, the blot was 
exposed to x-ray film. Lane 1, anti-MelanA monoclonal antibody A103; lanes 2-7, vitiligo 
patient sera; lanes 8-13, healthy control sera. 
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5.5 Discussion 
Autoantibodies to the melanocyte-specific protein MelanA could not be detected 
in the sera of vitiligo patients by either of the assay methods applied in this 
study, although previous studies have detected a specific cytotoxic T 
lymphocyte response against MelanA in vitiligo patients (Ogg et al. 1998; Lang 
et al. 2001; Palermo et al. 2001). B cells and cytotoxic T lymphocytes 
encounter antigen differently, both in the appropriate presentation of the antigen 
in the context of separate classes of MHC molecules and in the structure of 
epitope/s recognised, and therefore it is possible that MelanA only contains 
epitopes that induce cellular rather than humoral autoreactivity. Alternatively, 
MelanA may contain B cell epitopes that are inadequately exposed to immune 
recognition to stimulate a response, at least in the setting of vitiligo. Although a 
recent study suggested that melanosome transmembrane proteins can be 
transported to the surface of melanocytes and processed as MHC class II 
antigens via the endocytic pathway (Wang et al. 1999), the subsequent 
induction of an antibody response, via stimulated CD4+ cells, may depend on a 
sufficient level of surface expression and the expression of appropriate MHC 
class li molecules by the melanocyte. Additionally, temporal aspects may be 
relevant when looking for antibodies against MelanA in vitiligo, since they may 
be produced after chronic disease progression. The observed immunogenicity 
of MelanA to cytotoxic T cells may arise through cross-reactivity with viral 
antigens; a cytotoxic T cell epitope on MelanA is homologous to glycoprotein C 
from the herpes simplex virus (Loftus et al. 1996). It would be of interest to 
study a cohort of vitiligo patients with sustained T cell reactivity against MelanA 
as antibody production may be observed by determinant spreading in these 
patients. 
An immune response to MelanA was first characterised in melanoma 
patients, and indeed the protein was identified by its reactivity with melanoma 
patient T lymphocytes (Coulie et al. 1994; Kawakami et al. 1994a). MelanA 
contains several immunodominant epitopes for both cytotoxic (Kawakami et al. 
1994c; Castelli et al. 1995; Romero et al. 1997; Pittet et al. 1999) and helper T 
cells (Zarour et al. 2000) in melanoma patients and has, therefore, been used in 
specific immunotherapy strategies (Nestle et al. 1998; Rosenberg et aL 1998). 
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In a recent immunotherapy study, a patient developed melanoma-associated 
hypopigmentation (Section 1.5) as a result of adoptive transfer of MelanA- 
specific autologous cytotoxic T cells and the depigmentation was attributed 
directly to the destruction of melanocytes by these cells (Yee et al. 2000). The 
humoral immune response to MelanA has been investigated in melanoma 
patients using recombinant MelanA protein in enzyme-linked immunosorbent 
assay (ELISA), and no MelanA-specific antibodies were detected in the sera of 
127 melanoma patients or 70 control subjects (Stockert et al. 1998), which fits 
with data found in the present series of vitiligo patients. 
The results of this study indicate that either MelanA is not a target of the 
humoral response in vitiligo patients or that any antibody reactivity to the protein 
is not detectable even when using a sensitive radiobinding assay. It is possible 
that MelanA-specific antibodies would be identified if a mammalian expression 
system was used to produce MelanA protein with native conformation. The 
bacterial expression systems used in this study are only appropriate for the 
discovery of antibodies recognising linear epitopes. Additionally, the amount of 
free, measurable antibody in patient sera might be too low for detection due to 
sequestering of antibody at sites of vitiligo lesions (Merimsky et al. 1996). 
Alternatively, the immune response to MelanA in vitiligo may be analogous to 
that of melanoma, in that cellular reactivity is predominant, and a humoral 
response apparently absent. 
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6 Identification of putative vitiligo autoantigens 
using cDNA phage-display technology 
6.1 Introduction 
6.1.1 Phage-display technology 
Filamentous phage, so called because of their narrow rod-shaped appearance 
(Figure 6.1), comprise three families of bacterial viruses that depend on the F- 
pilus for infection of their E. coli host (Wilson & Finlay 1998). Each phage 
particle consists of a single-stranded DNA genome packaged in a tube made up 
of 2700 copies of a major coat protein, pVlll, closed at the ends by four or five 
copies of each of four species of minor coat proteins, including pill (Figure 6.1) 
(Wilson & Finlay 1998). The discovery that insertion of foreign DNA fragments 
into the filamentous phage gene gill results in the display of the encoded foreign 
polypeptide as a fusion protein with the minor coat protein pill on the phage 
surface (Smith 1985), led to the development of phage-display technology. 
Phage-display allows the construction of diverse libraries of fusion proteins that 
can be selected on the basis of their binding properties, and which are physically 
linked to the genetic material that encodes them. The technique has become a 
powerful tool for studying protein-ligand interactions and has been applied to the 
study of receptor-ligand (Bass et al. 1990; Jacobsson & Frykberg 1996), 
enzyme-substrate (Matthews & Wells 1993; Redl et al. 1999), transcription 
factor-ligand (Butteroni et al. 2000), and antibody-antigen (Barbas 1993; Winter 
et al. 1994; Bartoli et al. 1998; Burgoon et al. 2001) interactions. 
6.1.2 Identification of antigens using cDNA phage-display 
Previous immunological applications of phage-display include immunoscreening 
of phage libraries displaying antibody fragments with a known, immobilised 
antigen (Barbas 1993), and epitope mapping by using specific antibodies to 
screen a library displaying random peptide sequences generated 
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7 nm 
-º1-- 
single-stranded 
genome 
890 nm t 
Figure 6.1: The filamentous phage. 
pVII, pIX 
4 or 5 copies each 
pvIII 
2700 copies each 
pVI 
5 copies 
pIII 
5 copies 
A schematic representation of the structure of a filamentous phage particle reproduced from 
(Wilson & Finlay 1998). A single-stranded circular genome is surrounded by -2700 copies 
of the major coat protein pVlll, and 4 or 5 copies of each of four types of minor coat proteins, 
including pill. Part of the coat sheath, formed by copies of the major coat protein, is not 
shown in order to reveal the phage genome. 
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from a selected antigen (Scott 1992). More recently, immunoscreening of 
proteins translated from a cDNA expression library on phage has been utilised 
to identify novel antigens (Burgoon et al. 2001). Used in this way, phage-display 
technology provides several advantages over conventional immunoscreening of 
plasmid or lambda-phage cDNA libraries performed after transfer of phage 
plaques or bacterial colonies to nitrocellulose membrane. Firstly, by screening 
the cDNA library in a fluid-phase, denaturation of proteins displayed on the 
surface of the phage is avoided. In addition, immobilisation of the IgG instead of 
the cDNA library allows the specific enrichment of phage particles that interact 
with the antibody immobilised onto a solid-phase by repeated rounds of 
selection. Moreover, as many as 1010-10" individual clones can be screened in 
a single experiment since this number of phage particles occupies only a small 
volume. 
6.1.3 The pJuFo vector 
The phage-display expression vector pJuFo (Crameri & Suter 1993; Crameri et 
al. 1994) was designed to circumvent problems associated with the translation of 
cDNA libraries on phage. In particular, the presence of translational stop codons 
or non-coding regions at the 3' end of cDNAs which can prevent the expression 
of N-terminal pill fusion proteins. This cannot be avoided by expression of C- 
terminal pill fusions, since the attachment of a protein to the C-terminus of pill 
would impair its incorporation into the phage coat. The vector pJuFo overcomes 
the limitations of direct fusions to the pill protein, by expressing the cDNA insert 
fused to the C-terminus of a Fos protein and a Jun protein as an N-terminal 
fusion to pill (Crameri & Suter 1993; Crameri et al. 1994) (Figure 6.2). The Jun 
and Fos proteins have a high protein-protein affinity leading to formation of a 
Jun/pIII-Fos/cDNA heterodimer, which is then incorporated into the phage 
surface during phage morphogenesis. The strategy therefore permits both the 
expression of complex cDNA library repertoires and the covalent attachment of 
the expressed products as Fos-fusion proteins on the surface of filamentous 
phage particles. The pJuFo system is outlined in greater detail in Figure 6.2. 
Phage displaying IgG-binding peptides can be isolated by interaction with 
immobilised patient antibody, a procedure referred to as biopanning (Figure 6.3). 
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ISOLATION OF 1 IDENTIFICATION OF 
RECOMBINANT pJuFo cDNA 
PHAGEMID 
ISOLATION 
of phage 
INFECTION of E. co//and 
GROWTH of enriched 
phage library OOH 
Phage 
library 
(1010 cfu) 
REPEAT ROUNDS 
I OF ENRICHMENT 
SEVERAL TIMES 
ELUTION 
of specific phage 
phage 
displaying IgG- 
binding proteins 
Biotinylated IgG 
Fos 
bound to displayed gene 
streptavidin Jun , product 
coated magnetic If- , COOH beads 
WASH 
AFFINITY to remove non- 
SELECTION of phage specific, 
displaying 1g G- unbound phage 
binding protein on 
their surface 
Figure 6.3: Enrichment of phage displaying cDNA on products on their 
surface. 
A ligand (e. g. an antibody molecule) coated to a solid-phase surface (e. g. a magnetic bead) 
is used to capture phage expressing cDNA-encoded products by ligand-product interaction. 
Phage that bind specifically to the ligand can be isolated after consecutive rounds of phage 
growth and adsorption. Adapted from (Crameri & Suter 1993). 
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The cDNAs encoding immunoreactive peptides can be recovered from phage 
particles by infection of bacterial cultures and then identified by DNA sequencing 
and database searches. 
Phage-display based on the pJuFo cloning system (Crameri & Suter 1993; 
Crameri et al. 1994) has been used to demonstrate that the large subunit of 
human immunodeficiency virus-1 reverse transcriptase interacts with ß-actin 
(Hottiger et al. 1995), and to identify allergens that bind to human IgE antibodies 
using yeast and fungal cDNA phage-display libraries (Crameri & Blaser 1996; 
Crameri et aL 1996; Lindborg et al. 1999). 
6.2 Aim 
The aim of the present study was to identify novel melanocyte autoantigens in 
vitiligo exploiting the benefits of phage-display based on the pJuFo cloning 
system (Crameri & Suter 1993; Crameri et al. 1994). 
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6.3 Materials and methods 
6.3.1 Library construction 
The construction and cloning of a human melanoma cDNA expression library, 
employing a SMART TM cDNA Library Construction Kit (Clontech Laboratories 
U. K. Ltd. ), is schematically represented in Figure 6.4 and outlined in detail 
below. The cloning of the cDNA library in a A-phage expression vector, 
ATriplEx2, and filamentous phage-display vector, pJuFo, was used to allow 
future conventional immunoscreening of library inserts as well as the selective 
enrichment by phage-display techniques. 
6.3.1.1 RNA extraction 
Cultured human Skmel23 melanoma cells were a gift from Professor Sheila 
MacNeil (Division of Clinical Sciences (North), University of Sheffield). RNA was 
prepared from 2x 106 cells using TRIZOL®LS Reagent (Life Technologies Ltd. ). 
Briefly, cells were pelleted by centrifugation and lysed directly in I ml 
TRIZOL®LS Reagent by repetitive pipetting. The homogenised sample was 
incubated for 5 min at room temperature to allow complete dissociation of 
nucleoprotein complexes. The organic and aqueous phases were then 
separated by the addition of 250 pl of chloroform (BDH) followed by 
centrifugation of the mixture for 15 min at 12,000 rpm in a Microcentaur 
centrifuge (Sanyo Gallenkamp plc, Loughborough, U. K. ). The upper aqueous 
layer was carefully removed to a fresh 1.5 ml eppendorf tube and total RNA 
recovered by precipitation with an equal volume of isopropyl alcohol (BDH). The 
RNA precipitate was pelleted by centrifugation for 10 min at 12,000 rpm, washed 
with 1 ml 70% (v/v) ethanol and air-dried for 10-15 min. The RNA pellet was 
then dissolved in 400 pl sterile RNase-free water and allowed to rehydrate for 30 
min at 4°C. RNase-free water was prepared by the addition of 
diethylpyrocarbonate (DEPC) (Sigma) to 0.01% (v/v). The quality of the RNA 
was assessed by agarose gel electrophoresis of a 5-pl aliquot of the preparation 
and the quantity measured by photometry at 260 nm. 
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Total RNA extraction from cultured human melanoma cells. 
Synthesis of cDNA library fragments by 
long distance PCR with oligo(dT) priming. 
Cloning of cDNA library fragments into a 
A-phage expression vector, ATriplEx2, and 
amplification of A-phage library in a bacterial host 
Conversion of ATriplEx2 library into a 
phagemid pTripIEX2 library. 
Mass excision of cDNA library fragments from pTripIEX2 and 
subcloning into the filamentous phage-display vector pJuFo. 
SMARTTM 
cDNA library 
Construction 
Kit 
Preparation of the cDNA phage-display library by electroporation into 
a bacterial host and superinfection with helper phage. 
Figure 6.4: A brief overview of the melanoma cDNA library construction. 
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6.3.1.2 Synthesis of cDNA library fragments 
Total RNA was then processed in a SMARTTM cDNA Library Construction Kit 
(Clontech Laboratories U. K. Ltd. ), as detailed below, to prepare melanoma 
cDNA fragments restricted with endonuclease Sfil ready for cloning into a A- 
phage library expression vector, ATriplEx2. All reagents were supplied by the 
SMARTTM cDNA Library Construction Kit, unless otherwise stated. Firstly, 
single-stranded (ss) cDNA was reverse transcribed from 3 pg of prepared total 
RNA in a 10-pi reaction containing 1 pM SMART IIITM oligonucleotide, 1 pM 
CDS III oligo(dT) primer, 2 pi 5x First-Strand buffer (250 mM Tris, pH8.3; 30 mM 
MgCI2; 375 mM KCI), 2 mM DTT, 1 mM dNTPs and 600 U Moloney Murine 
Leukemia Virus (M-MLV) Reverse Transcriptase (RT; Promega) by incubation 
for 1h at 42°C. The first-strand ss cDNA was placed on ice until needed. 
Secondly, double-stranded (ds) cDNA was synthesised by long-distance 
(LD) PCR using primers designed to both selectively amplify full-length ss 
templates and introduce Sfil restriction sites to the resulting ds cDNA products. 
The 50-pl LD PCR reaction comprised 2 pl of the previously prepared ss cDNA, 
10 pi 1 Ox Advantage® 2 PCR buffer, 2 pi 50x dNTP mix, 0.2 pM of each of the 5' 
and 3' PCR primers, 2 pl of 50x Advantage® 2 Polymerase mix and 80 pl sterile 
dH2O. After initial denaturation by heating to 95°C for 1 min, the reaction mixture 
was subjected to 20 cycles of LD PCR amplification in a DNA Thermal Cycler 
(Perkin-Elmer/Cetus) using the following conditions: 95°C, 15 sec; 68°C, 6 min. 
When cycling was complete, the LD PCR reaction, containing amplified ds 
cDNA, was placed on ice. A 5-pl aliquot was analysed by electrophoresis on a 
1.1% (w/v) agarose gel and the approximate yield and size range of cDNA 
products was compared with a figure illustrating the expected result provided in 
the maufacturer's protocol. 
The Advantage® 2 Polymerase was subsequently removed from the LD 
PCR reaction by Proteinase K digestion. Briefly, 2 pi of Proteinase K (20 pg/pI) 
was added to 50 pl of the amplified ds cDNA, mixed and heated to 42°C for 20 
min. The ds cDNA was then extracted from the mixture using phenol: 
chloroform (1: 1 v/v) as follows; an equal volume of phenol: chloroform (1: 1 v/v) 
(BDH) was mixed with the reaction by continuous gentle inversion for 1-2 min 
and then centrifuged at 13,000 rpm in a Microcentaur centrifuge (Sanyo) for 5 
min to separate the organic and aqueous phases. The aqueous phase was 
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carefully removed, transferred to a fresh tube and an equal volume of chloroform 
added. The mixture was centrifuged at 13,000 rpm after which the aqueous 
phase removed to a fresh tube and the organic phase and interface discarded. 
The cDNA was recovered from the aqueous phase by precipitation with 2.5 
volumes of 95% (v/v) ethanol, 1.3 pl glycogen (20 mg/ml) and 0.1 volumes of 3 
M sodium acetate. The cDNA precipitate was washed with 100 pl of 80% (v/v) 
ethanol, air-dried and resuspended in 79 pl sterile dH2O. 
Finally, the cDNA was subjected to digestion with Sfil endonuclease. 
The digestion was performed in a 100-pl reaction comprising 79 PI of cDNA, 10 
pI (1 Ox) Sfil buffer, 1 pi BSA, and 200 U Sfil, at 50°C for 2 h. The SM-restricted 
cDNA fragments were then size fractionated according to the kit, using a 
CHROMA SPINTM-400 Column, to select fragments of 500-2000 bp for ligation 
into a A-phage library vector, ATriplEx2 (Figure 6.5a). 
6.3.1.3 Construction of a melanoma cDNA library in ATripIEx2 phage vector 
The cDNA fragments were ligated into ATriplEx2 vector in a reaction comprised 
of 1x ligation buffer (50 mM Tris-HCI, pH 7.8; 10 mM MgCl2i 10 mM DTT; 0.5 
mg/ml BSA), 1 mM ATP, 200 U T4 DNA ligase, 1 pl ATriplEx2 vector (500 ng) 
with 1 volume of melanoma cDNA (approximately 50 ng) and dH2O to a final 
volume of 5 NI. The ligation reaction was incubated overnight at 16°C. 
The ligation was subsequently packaged into A-phage using Gigapack Ill® 
Gold packaging extract (Stratagene) as per the manufacturer's instructions. 
Briefly, 1 pl of the ligation reaction was added to a 25-pl aliquot of the packaging 
extract, which had been rapidly thawed from storage at -80°C immediately prior 
to use. The tube was gently mixed and then incubated at room temperature for 
2 h. Five hundred mircolitres of 1x lambda dilution buffer (100 mM NaCl; 10 mM 
MgSO4i 35 mM Tris-HCI; 0.01% (w/v) gelatin) and 20 pl of chloroform were 
subsequently added to the tube, which was spun briefly to collect debris before 
transfer of the supernatant to a clean tube for storage at 4°C. 
The titre of the resulting library was determined by infection of E. coli 
XL1-Blue cells as detailed below. Fifteen millilitres of LB medium (Section 2.3), 
supplemented with 10 mM MgSO4 and 0.2 % (w/v) maltose, was inoculated with 
a single colony of E. coli XU-Blue grown on LB agar containing 10 pg/ml 
tetracycline and 10 mM MgSO4. The culture was shaken at 200 rpm overnight, 
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at 37°C, until a culture OD600 of 2.0 was reached. The cells were then pelleted 
by centrifugation and resuspended in 7.5 ml of 10 mM MgSO4. A range of 
dilutions (I: 5-1: 20) of the packaging extract was prepared in 1x lambda 
dilution buffer and used to infect E. coli XL1-Blue. One-microlitre aliquots of 
each phage dilution were added to 200-pl aliquots of E. coli XL1-Blue and 
allowed to adsorb at 37°C for 15 min. Four millilitres of molten (45°C) LB 
overlay, containing 0.8% (w/v) agar and 10 mM MgSO4i was added to each 
infection, mixed and poured over 90-mm LB agar plates (Section 2.3.1) 
containing 10 mM MgSO4. Once the overlay had hardened the plates were 
inverted and incubated at 37°C overnight until lysis plaques were visible. The 
number of plaques on each plate was counted and the titre (plaque forming units 
(pfu)/ml) calculated for the packaged ligation. An approximate total of 1x 106 
independent library clones was estimated from the titre (pfu/ml) of the packaged 
ligation. 
Since the multiple cloning site of ATriplEx2 is embedded within the coding 
sequence of the a-polypeptide of beta-galactosidase (IacZ) (Figure 6.5), it was 
possible to determine the percentage of recombinant clones by blue-white 
screening on medium containing X-gal (5-bromo-4-chloro-3-indolyl-ß-D- 
galactoside; Promega) and IPTG (Sambrook et al. 1989). Screening was 
performed on plates containing 500-1000 plaques prepared as previously 
described for the titration except that 2.5 mM of each X-gal and IPTG was 
additionally added to the LB overlay. No blue (i. e., non-recombinant) plaques 
were apparent indicating that the library was 100% recombinant. 
The library was amplified by scaling-up the infection of bacterial host cells 
previously described for the titration experiment. An aliquot of log-phase E. coli 
XL1-Blue was infected with a sufficient quantity of the ATriplEx2 library to yield 
approximately 145,000 plaques on a large (22 cm x 22 cm) petri dish, containing 
LB agar supplemented with 10 mM MgSO4. This was repeated on a further six 
large dishes to yield an approximate total of 1x 106 plaques, each representing 
an independent library clone. The plates were incubated overnight at 37°C until 
the lysis plaques were confluent, 30 ml of 1x lambda dilution buffer was then 
added to the surface of each plate and they were stored for a further 3h at 4°C. 
The surface overlay from each plate was then scraped and poured into a 
separate 50 ml polypropylene screw-top tube and allowed to stand for an h at 
room temperature to produce a 1-phage lysate. The amplified library lysate was 
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then cleared of agar and cell debris, and any remaining intact bacterial cells 
lysed, by the addition of 0.1 volumes of chloroform followed by vortexing for 2 
min and centrifugation at 5000 g for 10 min. The supernatant from each 50 ml 
tube was pooled in a single fresh sterile 50-ml tube and stored at 4°C. One- 
millilitre aliquots for long-term storage at -70°C were transfered to sterile 1.5-ml 
eppendorf tubes and dimethyl sulphoxide (DMSO; Sigma) was added to each 
tube to a final concentration of 7% (v/v). 
The titre of the final amplified library was measured as previously 
described for the unamplified library and estimated at 1x 1010 pfu/ml. 
6.3.1.4 Conversion of the ATriplEx2 library to a phagemid pTriplEx2 library 
The conversion of the )TriplEx2 library to a phagemid pTriplEx2 library was 
carried out by transduction of the recombinant A-phage into a bacterial host in 
which Cre recombinase is being expressed. The pTriplEx2 phagemid (Figure 
6.5 b) is embedded within IoxP sites in ATriplEx2, Cre recombinase activity 
promotes in vivo excision and circularisation of pTriplEx2 phagemid from the 
recombinant phage at the IoxP sites. A large-scale preparation of the pTriplEx2 
phagemid was prepared so that the melanoma cDNA inserts could be excised 
for cloning into pJuFo. 
Escherichia coli strain BM25.8, grown at 31 °C, provided the necessary 
Cre recombinase activity and a stock was maintained on LB agar containing 50 
pg/ml kanamycin and 34 pg/ml ampicillin. For large-scale culture, a single 
colony of E. coli BM25.8 was picked from the stock plate and used to inoculate 
10 ml of LB medium, supplemented with 50 pg/ml kanamycin, 0.2% maltose and 
10 mM MgCI2, which was shaken at 150 rpm at 31°C overnight. The following 
day, a further 10 mM MgCI2 was added to the culture prior to infection with a 1-pl 
aliquot of the ATriplEx2 library at 31°C for 15 min without shaking. The infected 
culture was then supplemented with 100 pg/ml ampicillin and shaken at 150 rpm 
at 31 °C for 21/2 h, before sub-culture into 100 ml of fresh LB medium containing 
100 pg/ml ampicillin and growth at 31°C, as before, for a further 4 h. Finally, the 
library culture was subbed into 500 ml of fresh LB medium containing 100 pg/ml 
ampicillin and maintained, shaking at 150 rpm, at 31°C for 24 h. The presence 
of the excised phagemid pTriplEx2 was detected in a 10-ml aliquot of the culture 
by use of a Wizard Minipreps DNA Purification System (Promega) 
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ATriplEx2 (42.3 Kb) 
Multiple cloning site (MCS) 
Melanoma cDNA was cloned in the SM sites of the kTriplEx2 MCS. 
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Ampr IoxP 
Figure 6.5: A schematic diagram of the ATripIEx2 vector (a) and pTriplEx2 
phagemid (b). 
Adapted from a figure in the SMARTTM cDNA Library Construction Kit User Manual 
(Clontech). 
Melanoma cDNA was cloned into the Sfil sites of ATriplEx2 to create a ATriplEx2 library. 
Subsequent transduction of the ATriplEx2 library into E. coli strain BM25.8 promoted in vivo 
excision and circularisation of pTriplEx2 phagemid at the IoxP sites. The phagemid 
pTriplEx2 library was then purified ready for mass excision of the library inserts to allow 
subcloning into the phage-display vector pJuFo-Sfi. 
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pTriplEx2 
The pTriplEx2 phagemid is embedded within 
ATriplEx2 flanked by loxP sites at the A junctions. 
(Section 2.7.1). A large bacterial pellet was harvested by centrifugation of the 
culture at 5000 g for 30 min, and stored at -20°C. A large-scale phagemid 
preparation was subsequently made from the pellet using a Qiagen Plasmid 
Maxi Kit (Qiagen) as previously described (Section 2.7.2). 
The cDNA library inserts were excised from 20 pg of pTriplEx2 using Sfil 
digestion. The restricted vector was subjected to agarose electrophoresis in a 
0.8% (w/v) agarose gel, and the Sfi1 cDNA library fragments recovered using a 
Wizard PCR Preps DNA Purification System (Section 2.10). Recovered library 
fragments were dried down in a vacuum drier and resuspended in 10 pl TE 
buffer. 
6.3.1.5 Subcloning of cDNA library fragments into the phage-display vector 
pJuFo-Sfi 
Initially, the pJuFo vector (Crameri & Suter 1993) (Figure 6.6), a gift from 
Professor R. Crameri (Swiss Institute of Allergy and Asthma Research, Davos, 
Switzerland), was modified by Mr. Lee Shunburne (Division of Clinical Sciences 
(North), University of Sheffield) to allow cloning of Sfi1-restricted cDNA 
fragments. Briefly, primers 5'CTAGAGGCCATTATGGCCTGCAGGATCCG 
GCCGCCTCGGCCGGTAC3' and 5'CGGCCGAGGCGGCCGGATCCTGCA 
GGCCATAATGGCCT3' (Life Technologies Ltd.; the Sfil restriction site coding 
sequence is underlined in the text) were treated with T4 polynucleotide kinase 
(Promega), annealed and then ligated into pJuFo restricted with enzymes Xbal 
and Kpnl. 
To construct the melanoma phage-display cDNA library, approximately 
0.5 pg of SM-restricted cDNA inserts were ligated to 3 pg of SM-digested pJuFo- 
Sfi phagemid in a 50-µl reaction at 16°C overnight (Section 2.11). A 2-pl aliquot 
of the ligation reaction was electroporated into electrocompetent E. coli XL1- 
Blue cells (Stratagene) (Table 2.1a) as described by the manufacturer. Briefly, a 
50-pl aliquot of E. coli XL1-Blue cells was thawed, on ice, and added to a pre- 
chilled 0.1 cm electroporation cuvette (Invitrogen). The 2-pl aliquot of the 
ligation reaction was added to the cells and mixed by gentle pipetting. The 
cuvette was then placed into the electroporator ('E. coli pulser', Bio-Rad 
Laboratories Ltd. ) and a charge of 1800 V applied. After electroporation, 2 ml of 
SOC medium (Life Technologies Ltd. ) were added to the cells and the culture 
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Figure 6.6: A schematic diagram of the pJuFo-Sfi vector. 
(Adapted from Crameri & Suter 1993; Crameri et al. 1994). 
The melanoma cDNA library inserts were cloned into the Sfil sites of this vector to create a 
fusion with Fos. The annealing positions for the cycle sequencing primer and flanking PCR 
primers used for the analysis of recombinant phagemid cDNA inserts are indicated. 
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shaken at 200 rpm for 1h at 37°C. Ligation efficiency was determined by 
plating aliquots of the culture onto LB agar containing 50 pg/ml ampicillin and 
10pg/ml tetracycline. Five separate electroporations were performed and an 
approximate total of 1x 106 ampicillin/tetracycline resistant independent clones 
was obtained. 
6.3.1.6 Preparation of the cDNA phage-display library 
In order to prepare the melanoma cDNA phage-display library, 100 ml of fresh 
LB medium supplemented with 50 pg/ml ampicillin and 10 pg/ml tetracycline 
were added to the pooled electroporated cells. The culture was then shaken at 
200 rpm for 1h at 37°C before superinfection with 1x 1012 pfu of VCMS13 
helper phage (Stratagene) at room temperature for 30 min. The culture was 
subsequently transferred to 400 ml of LB medium supplemented with 50 pg/ml 
ampicillin, 10 pg/ml tetracycline and 10 pg/ml kanamycin. After overnight 
incubation at 200 rpm and 37°C, the culture was centrifuged at 5000 rpm in an 
MSE Centaur 1 centrifuge (Sanyo Gallenkamp plc) for 20 min and phage 
particles precipitated from the supernatant by the addition of 0.2 volumes of 2.5 
M NaCI/20% (w/v) polyethylene glycol 4000 at 4°C for 1 h. Phage were 
harvested by centrifugation at 5000 rpm for 20 min and resuspended in 2-3 ml of 
PBS containing 137 mM NaCl, 2.7 mM KCI, 10.1 mM Na2HPO4,1.8 mM 
KH2PO4, (pH 7.4). The phage titre was determined by infecting 2 ml of log- 
phase E. coli XL1 -Blue (Stratagene) with an aliquot of the phage-display library, 
incubating at room temperature for 30 min and then plating out samples of the 
culture onto LB agar containing 50 pg/ml ampicillin and 10 pg/mi tetracycline. A 
titre of 1x 10" colony-forming units (cfu) was estimated. 
6.3.2 Qualification of the cDNA library 
6.3.2.1 Colony transfer of library-infected E. coli host to nylon membrane 
In order to assess the quality of the melanoma cDNA library, transfer of library 
DNA from infected E. coli host to nylon membrane was performed. Briefly, 2 ml 
of log-phase E. coli XL1-Blue was infected with an aliquot of the phage-display 
library and incubated at room temperature for 30 min. A sample of the culture, 
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equivalent to 25,000 cfu, was then plated out onto LB agar containing 50 pg/ml 
ampicillin and 10 pg/ml tetracycline in a 20 cm2 petri dish. Infected bacterial 
colonies were visualised after overnight incubation at 37°C. After pre-cooling 
the dish to 4°C, to ease subsequent removal of the nylon membrane without 
smearing of the colonies, a 20-cm2 piece of Hybond N+ nylon membrane 
(Amersham Pharmacia Biotech) was positioned above the dish and gently 
lowered onto the agar, allowing the middle of the membrane to touch the surface 
before the outer edges. The membrane was carefully removed after 1 min and 
placed, colony side up, on to a stack of 3MM chromatography paper soaked in 
denaturing solution (1.5 M NaCl; 0.5 M NaOH) for 7 min. The membrane was 
then placed on to a stack of 3MM chromatography paper soaked in neutralising 
solution (1.5 M NaCI; 0.5 M Tris HCI, pH 7.2; 0.1 mM EDTA), colony side up, for 
3 min. The neutralisation step was repeated with fresh neutralisation solution for 
a further 3 min. The membrane was then washed vigorously in 2x saline sodium 
citrate (SSC; 30 mM NaCl; 33 mM Na-citrate) to remove bacterial debris, and 
air-dried on a piece of 3MM paper. 
6.3.2.2 DNA hybridisation 
Two nylon colony-lift filters were hybridised with a [32P]-labelled cDNA probe for 
either a ubiquitous gene, ß-actin, or for the melanocyte-specific gene tyrosinase, 
in order to assess the frequency of cDNAs encoding these proteins in the library. 
The ß-actin (full-length cDNA available in the laboratory) and tyrosinase 
(full-length cDNA fragment excised from pcDNA3TYR (Kemp et al. 1997b) with 
Kpnl and Xbal), cDNAs were 5'-end labelled with [y-32P]ATP (ICN 
Pharmaceuticals Ltd. ) using T4 polynucleotide kinase. The 20-pl labelling 
reaction was comprised of 1 pg of the relevant oligonucleotide, 10 pCi [y- 
32P]ATP (10 mCi/ml; 3000 Ci/mmol), 0.1 volumes of 10x T4 Polynucleotide 
kinase buffer and 10 U of T4 Polynucleotide kinase, was incubated at 37°C for 
10 min followed by heating to 70°C for 10 min to inactivate the kinase enzyme. 
Each filter was prehybridised at 55°C in ExpressHyb hybridisation 
solution (Clontech) for 1-2 h. Filters were then hybridised by the addition of 1pI 
of either the [32P]ß-actin or [32P]tyrosinase cDNA probe for 4-5 h. The filters 
were subesquently washed twice at 65°C with 2x SSC, 1% (w/v) SDS for 30 
min, and at least twice with 1x SSC, 1% (w/v) SDS for 15 min. Further washes 
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were performed, if necessary, until there was an appreciable reduction in the 
radioactivity detected with a Geiger counter in the discarded washes, which 
represents the unbound probe. 
Subsequently, filters were subjected to autoradiography for 1-12 h at 
-70°C and the number of positive colonies counted and expressed as a 
percentage of the total number of colonies originally transferred to the filter. 
The frequency of E. coli colonies infected with phage containing ß-actin 
cDNA was found to be 0.03%. The frequency of E. coli colonies infected with 
phage containing tyrosinase cDNA was found to be 0.2%. 
6.3.3 Patients 
Sera from 10 vitiligo patients (3 male, 7 female; mean age: 52 yr; age range: 23- 
77 yr) were used in this study (Table 6.1). None of these patients had a related 
autoimmune disorder or family history of autoimmune disease. All of these 
vitiligo sera contained antibodies shown to have reactivity with protein bands 
from Skmel23 melanoma cell line extracts at either 100,70 or 50 kDa in 
immunoblotting experiments performed by Dr. E. Helen Kemp (Division of 
Clinical Sciences (North), University of Sheffield, unpublished data). 
6.3.4 Isolation and biotinylation of IgG 
IgG was isolated from the sera of patients by protein G Sepharose 4 Fast Flow 
affinity column chromatography (Amersham Pharmacia Biotech). Eluted IgG 
fractions were concentrated using an Amicon Concentrator (Amicon Inc., 
Beverley, MA, U. S. A. ). The concentrated IgG was filter-sterilised with a Millex" 
Filter Unit (Millipore Corp. ) and the final concentration measured by photometry 
at 280 nm. Biotinylation of the IgG was performed using EZ-LinkTM Sulfo-NHS- 
LC-LC-Biotin (Pierce, Rockford, IL, U. S. A. ), according to the manufacturer's 
protocol. Briefly, a1 mg/ml solution of Sulfo-NHS-LC-LC-Biotin was made up 
immediately prior to setting up the reaction, which comprised 2 mg of IgG 
sample in 1 ml PBS and 75 pl of the Sulfo-NHS-LC-LC-Biotin solution. The 
reaction was mixed gently and allowed to proceed for 2h on ice, after which 
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Table 6.1: Details of the vitiligo patients used in this study. 
Size of immuno- 
Patient Gender Age at Age at Disease reactive protein/s Vitiligo sub- 
sample onset duration in Skmel23 cell type 
date extract blots' 
1 Male 68 yr 58 yr 10 yr 100 kDa2 Symmetrical 
and 
peri-orificial 
2 Female 43 yr 31 yr 12 yr 70 kDa Symmetrical 
3 Male 77 yr 70 yr 7 yr 50 + 70 kDa Symmetrical 
and 
peri-orificial 
4 Female 54 yr 21 yr 33 yr 50 + 100 kDa Symmetrical 
and 
peri-orificial 
5 Female 52 yr 46 yr 6 yr 50 + 70 kDa Symmetrical 
6 Female 40 yr 31 yr 9 yr 
7 Female 70 yr 70 yr <1 yr 
8 Female 58 yr 54 yr 4 yr 
9 Male 23 yr 22 yr 1 yr 
10 Female 37 yr 1 Oyr 27yr 
50 + 70 kDa Symmetrical 
and 
peri-orificial 
70 kDa Symmetrical 
50 kDa Segmental 
70 kDa Peri-orificial 
70 kDa Symmetrical 
and 
segmental 
'Unpublished data from western blotting experiments performed by Dr E. Helen Kemp 
(Division of Clinical Sciences (North), University of Sheffield). 
2kDa, kilodalton. 
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time unreacted biotin was removed by dialysis against fresh PBS. All IgG 
samples were stored at 4°C until required. 
6.3.5 Paramagnetic bead preparation 
Dynabeads® M-280 Streptavidin (Dynal Biotech, Oslo, Norway) were used to 
immobilise biotinylated IgG during the isolation of phage displaying antibody- 
binding peptides. For each experiment, a 20-pl (10 mg/ml) sample of beads 
was washed extensively with 500-pl aliquots of PBS containing Tween 20 at 
0.05% (v/v). A Dynal Magnetic Particle Concentrator (Dynal Biotech) was used 
to separate the beads after each wash and the beads were finally resuspended 
in 235 pl of sterile water. 
6.3.6 Isolation of phage displaying IgG-binding peptides (biopanning) 
A 15-pl aliquot of biotinylated IgG was incubated with 235 pi of prepared 
Dynabeads® and incubated at 4°C for 30 min on a rotating platform to permit 
antibody-bead binding. The antibody sample used was a pool from ten vitiligo 
patients with each biotinylated IgG at a concentration of 2 mg/ml. To block any 
non-specific phage binding to the beads later in the procedure, 300 pl of 2% 
(w/v) dried milk in PBS containing 10% (v/v) sterile glycerol was added to the 
bead-IgG suspension and incubation at 4°C continued for 1 h. The bead-IgG 
complexes were separated from the blocking buffer using a Dynal Magnetic 
Particle Concentrator, washed twice and finally resuspended in 150 µl of 
PBS/0.05% (v/v) Tween 20 before the addition of a 100-pl sample of phage- 
display library containing 1x 1010 cfu. The suspension was then incubated 
overnight at 4°C to allow interaction of the antibody-bead complexes with 
peptides displayed on the surface of the phage particles. 
The bead-IgG complexes were washed extensively with PBS/0.05°/a (v/v) 
Tween 20 to remove any unbound phage. Bound phage were eluted from the 
bead-IgG complexes with 150 pI of 100 mM HCI (adjusted to pH 2.2 with solid 
glycine), and the beads then magnetically separated from the supernatant that 
contained the phage particles. Neutralisation of the supernatant was 
accomplished by the addition of 9 pi of 2M Tris-HCI (pH 7.6). The phage 
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suspension was subsequently used to infect 2 ml of exponentially growing E. 
co/iXL1 -Blue for 15 min at room temperature. Aliquots of the infected cells were 
then plated onto LB agar containing 50 pg/ml ampicillin and 10 pg/ml 
tetracycline to allow the recovery of pJuFo phagemids with cDNA inserts. 
To generate phage for a further round of selection, the infected E. coli 
XL1 -Blue culture was made up to 10 ml with fresh LB medium and incubated at 
37°C with shaking for 1h before superinfection with 1x 1012 pfu of helper phage 
VCSM13. Following incubation at room temperature for 30 min, the cells were 
transferred to 100 ml of LB containing 50 pg/ml ampicillin, 10 pg/mI tetracycline 
and 10 pg/mI kanamycin. The culture was then incubated with shaking 
overnight at 37°C. Phage were prepared from the infected culture and titred as 
described above and stored at -20°C. This first round library enriched in phage 
displaying IgG-binding peptides was used in a second round of selective 
enrichment as detailed above. In all, three rounds of biopanning were 
undertaken. 
6.3.7 Analysis of recombinant pJuFo phagemid by PCR amplification 
Individual colonies, isolated from the third round of biopanning by plating out the 
infected E. coli XL1-Blue, were grown and pJuFo phagemid prepared using a 
Wizard Minipreps DNA Purification System (Section 2.7.1). Phagemid DNA (50 
ng samples) was subjected to 36 cycles of PCR amplification as described 
previously (Section 2.13) with primers 1192 5'CCGCTGGATTGTTATTACTCGC 
TG3' and 1500 5'TGCAAGGCGATTAAGTTGGGTAAC3' (Life Technologies 
Ltd. ), which flank the Xbal-Kpnl cloning sites in pJuFo, using the following 
conditions: 94°C, 1 min; 55°C, 1 min; 72°C, 2 min; and 72°C for 10 min for 
termination. An aliquot of the PCR amplification products were analysed by 
electrophoresis in 0.8% (w/v) agarose gels (Section 2.9) to confirm the presence 
of a cDNA insert and the remaining reaction directly purified according to a 
Wizard PCR Preps DNA Purification System (Section 2.14) prior to DNA 
sequencing. 
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6.3.8 Sequencing and sequence analysis 
Sequencing of PCR amplification products was performed according to a 
Thermo Sequenase Cycle Sequencing Kit (USB Corp. ) with [y-32P]ATP (ICN 
Pharmaceuticals Ltd. ) and primer 5'-CCGAAATCGCGAA CCTGCTG-3' (Life 
Technologies Ltd. ) which lies upstream of the Xbal cloning site in pJuFo. 
Briefly, 20 pmol of the primer was 5'-end labelled using 30 pCi [y-32P]ATP (10 
mCi/ml; 3000 Ci/mmol) as previously described (Section 6.3.2.2). One microlitre 
of the radiolabelled primer was then used in a cycle sequencing reaction, which 
consisted of 4 pl PCR amplified template, 2 pi reaction buffer (30 mM Tris HCI, 
pH 9.5; 7 mM MgCl2), 8U of Thermo Sequenase polymerase and dH2O to 17.5 
pl. The reaction was divided between four tubes containing 4 pI of either ddGTP 
(150 pM each dATP, dCTP, 7-deaza-dGTP, dTTP, 1.5 pM ddGTP), ddATP (as 
ddGTP, except 1.5 pM ddGTP replaced with ddATP), ddTTP or ddCTP 
termination mix, mixed and overlaid with 10 pl mineral oil. The reaction tubes 
were then placed in a thermal cycler and subjected to 40 cycles using the 
following conditions: 95°C, 30 sec; 55°C, 30 sec; 72°C, 1 min 30 sec. When 
cycling was complete, 4 pl of stop solution (95% (v/v) formamide, 20 mM EDTA, 
0.05% (w/v) bromophenol blue, 0.05% (w/v) xylene cyanol FF) to each of the 
termination reactions. Samples were stored frozen until use. 
Sequenced DNA was subjected to electrophoresis in 6% (w/v) 
acrylamide/7M urea gels with glycerol tolerant gel buffer (USB Corp. ). Samples 
were heated to 75°C immediately prior to loading on to gel, and 2-3 pl of the 
sample termination reaction was loaded on each gel lane. Gels were run for 3-4 
h at 2000 V, dried on 3MM chromatography paper and were subjected to 
autoradiography for 12 h at -70°C. The cDNA sequences were compared with 
international databases (Genbank) using the BLAST network service of the 
National Centre for Biotechnology Information (NCBI, National Institutes of 
Health; Bethesda, MD, U. S. A. ). 
165 
6.4 Results 
6.4.1 Construction of the melanoma cDNA phage-display library 
A melanoma cDNA library was initially constructed in a A-phage expression 
vector, ATripIEX2. The primary size of independent clones in the original A- 
phage library was estimated to be 1x 106 and displayed >99% recombinance 
assessed by blue/white screening. Following library amplification, a titre of 1x 
1010 pfu/ml was achieved. The A-phage library was then converted into a 
phagemid pTriplEX2 library, prior to mass excision and subcloning of cDNA 
inserts into the phage-display vector pJuFo. 
The primary size of the pJuFo melanoma cDNA library was 1x 106 
independent clones. The titre was assessed by infecting E. coli XL1 -Blue with 
the pJuFo library and then plating out the bacteria onto LB agar containing 
ampicillin and tetracycline. In order to determine the frequency of recombinant 
phagemid in the pJuFo library, ten individual cfus were picked and grown and 
the pJuFo phagemid isolated from each culture. Analysis of the phagemids by 
PCR amplification with primers 1192 and 1500, indicated that 9/10 (90%) of 
phagemids in the pJuFo library contained a cDNA insert (Figure 6.7). Following 
amplification with helper phage, a stock phage-display library with a titre of 1x 
1011 cfu/mI was produced. The frequency of recombinant phagemid in the 
phage-display library was determined by picking and growing forty individual cfu 
and isolating the pJuFo phagemid from each culture. Analysis of the phagemids 
by PCR amplification with primers 1192 and 1500, indicated that 36/40 (90%) of 
pJuFo phagemids in the phage-display library contained an inserted cDNA 
fragment. Figure 6.8 demonstrates that the cloned fragments ranged in size 
from 800 to -2,500 bp in length, with the majority of phagemids containing an 
insert of 1500 bp. Hybridisation experiments revealed that the frequency of ß- 
actin and tyrosinase inserts in the library was 0.03% and 0.2%, respectively, 
indicating that the library was relatively complex. Although tyrosinase cDNA had 
a comparatively high abundance, this was as expected in a library derived from 
deeply pigmented cells. This phage-display library was used for the selective 
enrichment of IgG-binding proteins from vitiligo patients. 
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Figure 6.7: PCR amplification of the inserts of 10 clones randomly chosen 
from the primary pJuFo melanoma library. 
PCR amplification of pJuFo phagemid clones was carried out using primers 1192 and 1500, 
and 10-pl aliquots of the resulting products were subjected to agarose gel electrophoresis in 
a 0.8% agarose gel. Lanes are included containing the amplification product of the empty 
vector pJuFo (V; 308 base pairs), a negative control reaction with no DNA template (N), and 
both Lambda Hindill DNA molecular weight markers (Ml) and 100 base pair molecular 
weight markers (M2) (Promega). The sizes (base pairs) of the relevant molecular weight 
markers are shown to the left of the figure. 
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6.4.2 Enrichment of phage displaying IgG-binding peptides 
The melanoma cDNA phage-display library was subjected to three rounds of 
biopanning against a pool of biotinylated IgG from ten vitiligo patients who had 
no other autoimmune disease. Three rounds of enrichments were performed 
and twenty-four individual cfus were picked and grown from each round, and the 
pJuFo phagemid isolated from each culture. Analysis of the phagemids by PCR 
amplification with primers 1192 and 1500 is shown in Figure 6.9 and Table 6.2. 
A divergence on a particular cDNA insert size was not observed and the range 
of inserts sizes remained similar during biopanning. The percentage of 
recombinant phage decreased between the unselected and enriched libraries, 
which might have been due to a selective growth advantage of phage particles 
bearing empty phagemid and therefore not required to secrete a fusion protein. 
Forty individual ampicillin/tetracycline resistant bacterial colonies from the 
third round of enrichment were picked and grown for sequence analysis. 
Phagemid DNA was isolated from each culture and analysed by PCR 
amplification with 1192 and 1500 primers. The PCR amplification products from 
thirty recombinant phagemid were purified and sequenced in order to aid 
identification of the cDNAs by BLAST searches of international databases 
(Genbank). Of the 30 clones sequenced, 28/30 (93%) showed homology with 
DNA sequences present in the databases. Of these homologies, 24/28 (86%) 
corresponded to known genes and the remaining 4/28 (14%) to unidentified 
human cDNA. Approximately one quarter of the clones with correspondence to 
known genes encoded proteins that had not yet been assigned an identity or 
function. The results of the sequence analysis are summarised in Table 6.3. 
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Figure 6.9: PCR amplification of phagemid cDNA inserts from three 
libraries selected by biopanning using vitiligo patient IgG: Round I (a), 
Round 2 (b) and Round 3 (c). 
Phagemid DNA was prepared from twenty-four individual ampicillin and tetracycline resistant 
library colonies from each round of selection and subjected to PCR amplification using 
primers 1192 and 1500. Ten-microlitre aliquots of the resulting products were subjected to 
agarose gel electrophoresis in a 0.8% agarose gel. Lanes are included which contain the 
amplification product of the empty vector pJuFo (V), a negative control amplification with no 
DNA template (N), and Lambda Hindill DNA and 100 base pair molecular weight markers 
(M) (Promega). The sizes (base pairs) of the relevant molecular weight markers are shown 
to the left of the figure. 
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Table 6.3: cDNAs isolated from selective enrichment of the melanoma 
cDNA phage-display library with vitiligo IgG. 
Protein encoded by No. of Genbank Size of insert Previously Reference 
cDNA library accession carrying identified as an 
clones number cDNA (bp)1 autoantigen 
Ubiquitin-conjugating 2/30 B0000468 900 
enzyme 
Integrin beta-4 binding 2/30 XM009691 1000-1500 
protein 
Osteopontin 2/30 XM011125 1000-1500 
Translation elongation 1/30 B0006102 1500-2000 
factor 1 alpha 
Heat shock protein 90 1/30 D87666 800 
Alpha-enolase 1/30 B0004458 
Gamma-enolase 1/30 B0002745 
GTP-binding protein 1/30 B0003658 
SARI 
Melanin-concentrating 1/30 U71092 
hormone receptor 1 
Ribosomal protein L9 1/30 NM000661 
Ribosomal protein L24 1/30 AF212226 
Translation initiation 1/30 B0002513 
factor- 2 
Signal sequence receptor 1/30 XM044177 
PTD 017 2/30 AAH05373 
PTD 010 1/30 XM043589 
CGI-34 1/30 AF132968 
CGI-107 1/30 NMO16045 
CGI-115 1/30 BC020641 
My 028 1/30 AF061731 
Un-named protein 1/30 XM041928 
Unidentified 1/30 XM031540 
Unidentified 1/30 AL136941 
Unidentified 1/30 A0002044 
Unidentified 1/30 A0006992 
No significant matches 1/30 - 
No significant matches 1/30 - 
1500-2000 
1000-1500 
1500-2000 
1500-2000 
800 
1500 
1500-2000 
1500 
1000 
1000-1500 
1500 
1500 
1500-1000 
1000 
1500 
1500 
800 
800 
1000 
1500-2000 
1000-1500 
No 
No 
Type 1 diabetes Flerabraccl et 
mellitus. al. 1999. 
Rheumatoid Sakata et at 
arthritis. 2001. 
Systemic lupus Frampton et at 
erythematosus. 2000. 
Systemic lupus Conroy et al. 
erythematosus. 1994. 
Melanoma with Kiniwa et at 
MAH2. 2001. 
Systemic lupus Pratesi eta!. 
erythematosus 2000. 
No 
No 
No 
No 
No 
Melanoma with Kiniwa et at 
MAH 2001. 
No 
No 
No 
No 
No 
No 
No 
' bp, base pairs. 2 MAH, melanoma-associated hypopigmentation. 
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6.5 Discussion 
The combination of affinity selection and biological amplification employed in 
phage-display technology makes it a particularly useful technique for the 
isolation of novel antigens. Large cDNA libraries, containing up to 1011 
independent clones, can be screened in a single experiment and IgG-binding 
peptides identified, even if their expression in the original library was rare, 
through repeated rounds of enrichment. Furthermore, displayed proteins are 
thought to assume native structure (Skerra & Pluckthun 1988) and are screened 
in liquid-phase in contrast to conventional immunoscreening, which requires 
adsorption of the proteins to nitrocellulose membranes. Indeed, a phage-display 
strategy has been recently applied to the discovery of antigen in chronic human 
inflammatory CNS disease (Burgoon et al. 2001). Additionally, phage-display 
based on the pJuFo system has been successfully employed in this laboratory 
for the isolation of autoantigens in SLE (Kemp et al., unpublished data, Division 
of Clinical Sciences (North), University of Sheffield) and polymyositis (Herd et 
al., unpublished data, Division of Clinical Sciences (North), University of 
Sheffield). 
Several putative antigens were enriched from the melanoma library by 
their ability to bind IgG from vitiligo patients (Table 6.3). A number of these 
proteins had been characterised, or were structurally related to proteins that had 
been characterised, as autoantigens in other disorders. Two distinct isoforms of 
the glycolytic enzyme enolase were enriched in the third round of selection. 
Alpha-enolase is ubiquitously expressed in both cytoplasm and cell membrane 
(Moscato et al. 2000; Gitlits et al. 2001) and has been described as an 
autoantigen in SLE (Pratesi et al. 2000). Gamma-enolase has not previously 
been reported as an autoantigen and its expression is thought to be limited 
primarily to neurons (Gitlits et al. 2001). However, since melanocytes are 
originally derived from the neural crest and are capable of neuronal behaviour, 
such as the synthesis of neurochemicals (lyengar 1989), its presence in the 
library is perhaps not unsurprising. Heat-shock protein 90 was also enriched by 
vitiligo IgG and has been identified as an antigen in SLE (Conroy et al. 1994). 
Furthermore, the heat shock proteins have been implicated in the initiation of 
autoimmune disorders (Elson & Thompson 1994) and the presence of 
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antibodies to this highly conserved protein in patients with vitiligo may represent 
a marker of autoimmunity. Additionally, vitiligo IgG enriched osteopontin, a 
calcium-binding glycoprotein recently described as an autoantigen in type 1 
diabetes mellitus (Fierabracci et al. 1999) and rheumatoid arthritis (Sakata et al. 
2001). A further candidate antigen was the GTP-binding protein SARI and 
antibodies to a melanocyte-expressed GTP-binding protein rab38 have been 
previously demonstrated in melanoma patients (Jager et aL 2000). Interestingly, 
a recent study detected antibodies to two of the vitiligo putative antigens 
reported here, heat shock protein 90 and translation initiation factor 2, by 
screening of a A-phage cDNA library also derived from Skmel23 cells with sera 
from a melanoma patient with melanoma-associated hypopigmentation (Kiniwa 
et aL 2001). 
In addition, three putative antigens with an association to epidermal and 
melanocyte function were isolated. Firstly, the ubiquitin-conjugating enzyme 
huBC9 which has been demonstrated to mediate degradation of the 
microphthalmia-associated transcription factor (MITF), a protein which is known 
to regulate transcription of genes involved in melanogenesis (Xu et al. 2000). 
Secondly, a binding protein was enriched that is specific to integrin beta-4, an 
adhesion molecule shown to be vital for attachment of the epithelial cells to the 
basal layer of the epidermis (van der Neut et al. 1996). Finally, the G protein- 
coupled receptor for melanin-concentrating hormone, which may play a role in 
the regulation of melanocyte behaviour and, indeed, was recently shown to have 
an inhibitory affect on alpha melanocyte-stimulating hormone (a-MSH)-induced 
melanogenesis (Hoogdijn et al. 2001). The melanin-concentrating hormone 
receptor was selected for further study of its immunoreactivity with vitiligo 
antibodies because of its possible regulatory function in skin pigmentation. 
The diversity of clones still apparent in the cDNA library after three 
rounds of biopanning suggests that further rounds of selection might be 
necessary to demonstrate dominant enrichment of a specific IgG-binding 
protein. Additionally, the numbers of phage displaying IgG-binding proteins 
eluted from each subsequent round of biopanning decreased (Table 6.2). The 
poor elution could be attributed to a rare abundance of antigens in the original 
library and to the use of a relatively dilute pool of patient IgG, in which individual 
titres of autoantibodies may be low. Nevertheless, a profile of sequences was 
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revealed which includes proteins with previously demonstrated IgG-binding 
properties and association with autoimmune disease, and a candidate 
autoantigen with a proposed specific function in melanocytes. 
Although these results are encouraging, phage-display does have 
limitations in its application to antigen discovery. Surface-protein expression 
may be prevented by a number of factors, therefore reducing the proportion of 
the cDNA library inserts represented by the phage particles. The displayed 
proteins must be efficiently secreted through the inner membrane of E. coli, fold 
into their correct three-dimensional structures in the periplasmic space and 
maintain their correct configuration on the surface of the phage particle after 
exposure to an oxidising environment (Sambrook & Russell 2001). 
Furthermore, proteins that naturally associate with membranes may not be able 
to pass into periplasm, and proteins containing charged residues might not be 
secreted (Wilson & Finlay 1998). An additional problem is that the computer 
analysis of the enriched proteins can only be as comprehensive as the available 
sequence databases. The complexity of the library is also limited by the quality 
of the cDNA inserts, which may not possess an open reading frame, and by its 
source messenger RNA. It would have been preferable here to use a 
melanocyte, rather than melanoma, cell line in order to better represent the 
proteins expressed by melanocytes in vitiligo. 
In summary, the use of phage-display appears to be applicable to the 
isolation of peptides which are bound by antibodies from vitiligo patients. 
However, further experiments are needed to confirm the reactivity of the putative 
autoantigens to individual vitiligo sera. This can be achieved by testing antibody 
binding to [35S]-labelled antigen produced in the TnT® system (Section 4.3.1.4 ) 
in radioimmunoassay. Due to its reported effects on melanocyte behaviour, the 
melanin-concentrating hormone receptor was singled out for further analysis in 
the subsequent chapter. 
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7 An investigation of autoantibody responses to the 
melanin-concentrating 
vitiligo patients 
hormone receptor 1 in 
7.1 Introduction 
7.1.1 The melanin-concentrating hormone 
Melanin-concentrating hormone (MCH) is a cyclic peptide originally identified in 
the pituitary gland of teleost fish by its ability to induce aggregation of pigment 
granules thereby lightening the appearance of the scales (Kawauchi et al. 1983). 
The physiological roles of MCH in mammals have yet to be fully elucidated but 
since it is highly expressed in regulatory centres of the brain, particularly the 
hypothalamus, and throughout the central and peripheral nervous systems, it is 
thought to act as a neuromodulator or neurotransmitter mediating a broad range 
of behavioural responses (Skofitsch et al. 1985; Bittencourt et al. 1992; Mouri et 
al. 1993; Knigge et al. 1996). Most functional studies of MCH have 
concentrated on its influence on feeding (Qu et al. 1996), a role which is 
highlighted by the lean phenotype created by knocking-out the function of the 
receptor in transgenic mice (Shimada et al. 1998) and by the obese phenotype 
of mice engineered to over-express MCH (Ludwig et al. 2001). The action of 
MCH on the regulation of pigmentation in higher vertebrates, including humans, 
is currently unknown. A recent study demonstrated expression of MCH 
throughout human epidermis and showed a partial inhibition of a-melanocyte- 
stimulating hormone (a-MSH)-induced melanogenesis by MCH in human 
melanocytes (Hoogdijn et al. 2001). Some of the characterised physiological 
functions of MCH, with reference to the antagonistic effects of MCH on a-MSH, 
are shown in Table 7.1. Recently, several studies have identified a 
somatostatin-like receptor SLC-1 (Kolakowski et al. 1996) as the MCH-receptor, 
which was consequently renamed MCHR1 (Bachner et aL 1999; Chambers et 
a/. 1999; Saito et al. 1999; Shimomura et aL 1999). 
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Table 7.1: Physiological functions influenced by MCH1 and a-MSH2. 
Location Ligand Receptor Function 
Fish Salmon a-MSH Not Pigment 
melanophore characterised dispersion. 
Salmon MCH Not Pigment 
characterised aggregation. 
Human Human a-MSH MC1 R3 
melanocyte 
Human MCH MCHR14 
Mouse Rat a-MSH MC1 R 
melanoma cells 
Rat MCH ? 
Mammalian Rat a-MSH 
brain 
Rat MCH 
Reference 
Kawauchi et 
aL 1983. 
Increases [Ca 2116. Hoogdijn et 
Melanogenesis. A 2001. 
Decreases a-MSH 
stimulated [Ca211. 
Partially inhibits a- 
MSH induced 
melanogenesis. 
Melanogenesis. Ludwig et al. 
1998. 
No apparent effect 
on melanogenesis. 
MC4R5 Inhibits feeding. 
MCHR1 Increases feeding. 
Ludwig et al. 
1998. 
Adapted from Saito et al. (2000). 
The large brackets indicate a functionally antagonistic relationship between MCH and a- 
MSH. 
1 MCH, melanin-concentrating hormone. 2 a-MSH, a-melanocyte-stimulating hormone. 
3 MC1 R, melanocortin 1 receptor. ° MCHR1, melanin-concentrating hormone receptor 1. 
5 MC4R, melanocortin 4 receptor. 6 [Ca2jj, intracellular calcium. 
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7.1.2 Melanin-concentrating hormone receptor 1 structure and 
expression 
The melanin-concentrating hormone receptor 1 (MCHR1) is aG protein-coupled 
receptor (Bachner et al. 1999; Chambers et al. 1999; Saito et al. 1999; 
Shimomura et al. 1999) that specifically binds MCH. The G protein-coupled 
receptors are classified in a superfamily of membrane proteins, with a 
distinguishing arrangement of seven transmembrane domains, encompassing 
hundreds of receptors for a diverse range of chemical messengers including 
hormones and neurotransmitters (lismaa & Shine 1992; Eckard & Beck- 
Sickinger 2000). Whilst the precise structure of the MCHR1 protein remains to 
be determined, its primary amino acid sequence is most similar to that of the 
somatostatin and opioid receptor subfamilies (An et al. 2001). Characteristically, 
G protein-coupled receptors require a guanine triphosphate (GTP)-binding 
protein, or G protein, in order to signal through a number of intracellular 
pathways (Hawes et al. 2000). The MCHR1 is capable of coupling to multiple 
types of G protein, which can lead variously to the activation of the MAP kinase 
signalling pathway, to an increase in the level of intracellular calcium ([Ca2li) 
and to a decrease in cyclic adenosine monophosphate (cAMP) when bound by 
MCH (Hawes et al. 2000). 
The expression of MCHR1 has been detected in numerous regions of the 
brain (Kolakowski et al. 1996; Bachner et al. 1999; Chambers et al. 1999; Saito 
et al. 1999; Hervieu et al. 2000; Kokkotou et aL 2001) with relatively high 
expression in the hypothalamus. Moderate expression has also been noted in 
the eye, skeletal muscle and tongue of the rat, although the function of the 
receptor at these locations is unknown (Saito et al. 1999; Saito et al. 2000). The 
receptor is expressed by both human melanocytes (Hoogdijn et al. 2001) and 
keratinocytes (Burgaud et al. 1997) and by human (Hoogdijn et al. 2001; Saito et 
aL 2001) and mouse melanoma cell lines (Drozdz et al. 1995; Hoogdijn et al. 
2001). 
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7.2 Aim 
MCHR1 cDNA was recovered following the third round of biopanning against a 
melanoma cDNA phage-display library with a pool of vitiligo IgG from ten 
patients (Chapter 6). The aim of the present study was to contlrm 
immunoreactivity against the receptor and establish its frequency in sera from 
patients with vitiligo using radiobinding assays with [35S]-labelled MCHR1. 
7.3 Materials and methods 
7.3.1 Patients 
Sera from 55 vitiligo patients (22 male, 33 female; mean age: 48 yr; age range: 
14-77 yr) were used in this study. Of these patients, 41 had no other 
autoimmune disorder and no family history of autoimmune disease and 14 had 
at least one other autoimmune disorder: autoimmune thyroid disease 9; alopecia 
areata, 3; systemic lupus erythematosus, 1; scleroderma, 1. Sera from 28 
healthy individuals (10 male, 18 female; age range: 21-59 yr; mean age: 34 yr) 
were used as controls. As a further two sets of controls, 20 sera from patients 
(5 male, 15 female; mean age: 44 yr; age range: 22-84 yr) with Graves' disease 
(GD) and 16 sera from patients (7 male, 9 female; mean age: 48 yr; age range: 
26-77 yr) with Addison's disease (AD) were tested. 
7.3.2 Specific antisera 
Rabbit polyclonal anti-MCHR1 antiserum MCHR11-S was purchased from Alpha 
Diagnostic International (San Antonio, TX, U. S. A). Other rabbit polyclonal 
antisera against melanocyte-specific proteins that were used as controls 
included: anti-tyrosinase (aPEP7; Tsukamoto et aL 1992); anti-tyrosinase- 
related protein-2 (aPEP8; Tsukamoto et al. 1992); anti-Pmel17 (AZN-LAM; 
Schreurs et al. 1997). 
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7.3.3 Cloning of human MCHR1 cDNA by RT-PCR 
Total melanocyte RNA (1 Ng) was used to prepare cDNA in a 30-pl reaction 
containing 10 mM DTT, 1 mM dNTPs (Promega), 250 ng random primers 
(Promega), 600 U M-MLV Reverse Transcriptase (RT; Promega) and 1X M-MLV 
RT buffer (Promega). The cDNA was subjected to 36 cycles of PCR 
amplification (Section 2.13) with MCHR1-specific primers 5'TTGAATTC 
GCCGCCATGTTGTGTCCTTCCAAG3' and 5'AATCTAGACGCCTATCAGGTG 
CCTTTGCTTC3' using the following conditions: 94°C, 1 min; 55°C, 1 min; 72°C, 
2 min; and 72°C for 10 min for termination. The ATG translation initiation codon 
in the forward primer and the TAG translation termination codon in the reverse 
primer are shown in bold-type face. Restriction sites for EcoRI and Xbal were 
incorporated into the forward and reverse primers (underlined in the text), 
respectively, in order to allow subcloning of the PCR amplification product into 
pcDNA3 and subsequent expression of the MCHR1 cDNA from the T7 promoter 
in the vector. 
The 1300 bp PCR amplification product was purified using a Wizard PCR 
Preps DNA Purification System (Section 2.14), restricted with EcoRl and Xbal 
(Section 2.8), ligated into EcoRI-Xbal-restricted pcDNA3 (Section 2.11) and then 
used to transform E. coli JM109 (Section 2.12). Plasmid DNA was purified from 
individual transformants using a Wizard Minipreps DNA Purification System 
(Section 2.7.1), restricted with EcoRl and Xbal and analysed by electrophoresis 
in a 0.8% (w/v) agarose gel (Section 2.9). One recombinant plasmid was 
sequenced according to a T7 Sequenase® Version 2.0 DNA sequencing kit 
(Amersham), as previously described (Section 2.15), using T7 and SP6 primers 
with [a_35 S]dATP, and according to a Thermo Sequenase Cycle sequencing kit 
(USB Corp.; Section 6.3.8) using the primers listed in Table 7.2 with [y-32P]ATP, 
to verify that no sequence errors had been introduced. The recombinant 
plasmid, pcMCHR1, was purified with a Qiagen Plasmid Maxi Kit (Qiagen Ltd. ) 
(Section 2.7.2). 
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Table 7.2: Oligonucleotide primers used to sequence the MCHR1 
Primers' Primer sequences 
501 5'AGGATTCCAGATGAACGG3' 
631 5'AGCATCTCCTACATCCAA3' 
851 5'TGTGGCACTTTGGGGAGA3' 
911 5'TCACCAGCACCTACATCC3' 
1091 5'CAGGAGGTGCAGTGGGCT3' 
1141 5'CTCTACTGGTTCACCCTG3' 
1321 5'TCCTTTGTGTGCTGGGCA3' 
1348 5'GTGCTACAGCTGACCCCA3' 
1441 5'TGCCTCAACCCCTTTGTG3' 
1 The numbers correspond to the first base pair of the target annealing sequence in the 
MCHR1. 
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7.3.4 In vitro-coupled transcription and translation 
In vitro transcription-translation of pcMCHR1 was performed using a TnT® T7 
Coupled Reticulocyte Lysate System with translation-grade [35S]methionine as 
detailed elsewhere (Section 4.3.1.4). The percentage incorporation of 
[35S]methionine was determined by TCA precipitation according to the 
manufacturer's protocol. Glycosylation of MCHR1 was achieved by the 
inclusion of 4 pI of canine pancreatic microsomal membranes (Promega) in the 
standard 50 pl TnT® T7 Coupled Reticulocyte Lysate reaction mixture. SDS- 
PAGE of in vitro translated MCHR1 was carried out in 12% (w/v) polyacrylamide 
gels as described previously (Section 2.17). Gels were fixed in 10% (v/v) glacial 
acetic acid/25% (v/v) isopropanol and then soaked in Amplify scintillant before 
drying at 60°C for 2h onto 3MM chromatography paper. Autoradiography was 
carried out at -70°C using Fuji RX x-ray film. Pre-stained SDS-PAGE standards 
(Low Range) were from Bio-Rad Laboratories Ltd. 
7.3.5 Radiobinding assays 
For each assay, an aliquot of the in vitro translation reaction mixture (equivalent 
to approximately 100,000 cpm of TCA precipitable material) was suspended in 
50 pl of immunoprecipitation buffer. Serum was then added to a final dilution of 
1: 20. Specific rabbit polyclonal antisera (MCHR11-S; aPEP7; aPEP8; AZN- 
LAM) were used at a final dilution of 1: 100. For dilution experiments, three 
vitiligo sera positive for MCHR1 antibodies and a pool of six healthy control sera 
were used in the radiobinding assay at final dilutions of 1: 20,1: 50,1: 100,1: 200, 
1: 500; 1: 1000 and 1: 2000. Radiobinding assays were carried out as previously 
described (Section 4.3.1.5). 
Antibody levels were expressed as a relative index. An Ab index for 
each serum tested in the immunoprecipitation assay was calculated as: cpm 
immunoprecipitated by tested serum/mean cpm immunoprecipitated by 28 
healthy control sera. Each serum was tested in at least two experiments and 
the mean Ab index was calculated from these. The upper level of normal for the 
assay was calculated using the mean Ab index +3 SD of the population of 28 
healthy individuals. Any serum with an Ab index above the upper level of 
182 
normal was designated as positive for antibody reactivity. For dilution 
experiments, Ab indices were calculated for each serum tested as: cpm 
immunoprecipitated by tested serum at each dilution/the cpm 
immunoprecipitated by a pool of six healthy control sera at each dilution. 
For analysis of immunoprecipitated proteins by SDS-PAGE and 
autoradiography, the protein G Sepharose-antibody complexes were 
resuspended in 50 pl of SDS sample buffer, heated at 100°C, centrifuged and 
the supernatant recovered for electrophoresis in a 12% (w/v) polyacrylamide gel 
which was processed as detailed above. 
7.3.6 Statistical analysis 
The frequency of specific antibodies was compared between patient groups and 
controls using Fisher's exact test for 2x2 contingency tables. P values < 0.05 
(two-tailed) were regarded as significant. 
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7.4 Results 
7.4.1 In vitro transcription-translation of MCHR1 
Plasmid pcMCHR1 was transcribed-translated in vitro in a TnT® T7 Coupled 
Reticulocyte Lysate System. The quality of the in vitro translated radiolabelled 
receptor was evaluated by SDS-PAGE and auto radiography. This revealed a 
protein product with an estimated molecular weight of 45 kDa (Figure 7.1), a 
size that is in close agreement with the molecular weight of 39 kDa predicted 
from the amino acid sequence of the protein (Kolakowski et al. 1996). On the 
addition of canine pancreatic microsomal membranes to the in vitro translation 
reaction, a protein band with an increased molecular weight of 50 kDa was 
visible after SDS-PAGE and autoradiography (Figure 7.1). This was assumed to 
be glycosylated MCHR1. 
7.4.2 Immunoreactivity of MCHR1 
The immunoreactivity of the in vitro translated radiolabelled MCHR1 was 
analysed in radiobinding assays using rabbit polyclonal antisera. MCHR1 was 
immunoprecipitated by MCHR1-specific antiserum MCHR11-S but not by 
antisera aPEP7, aPEP8 or AZN-LAM (Figure 7.2), thereby demonstrating the 
immunoreactivity of labelled MCHR1 to the receptor-specific antiserum. 
7.4.3 Detection of antibodies against MCHR1 in sera from patients 
with vitiligo 
Sera from 55 vitiligo patients, 28 healthy controls, 16 AD patients and 20 GD 
patients were tested for immunoreactivity to MCHR1 in radiobinding assays. For 
each serum, an Ab index was assigned, this being the mean antibody index of at 
least two experiments (Figure 7.3). The mean Ab indices t SD of the control, 
GD, AD, vitiligo groups were: 0.95 t 0.16,0.88 t 0.19,0.92 f 0.26,1.07 t 0.62, 
respectively. The upper level of normal for the radiobinding assay (mean Ab 
index +3 SD of 28 healthy controls) was estimated as an Ab index of 1.48 
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Figure 7.1: SDS-PAGE and autoradiography of in vitro translated MCHR1. 
MCHR1 was translated in vitro in a TnT`® T7 Coupled Reticulocyte Lysate System. To allow 
glycosylation MCHR1, canine pancreatic microsomal membranes were added to the 
transcription-translation reaction. Samples of the in vitro translation reaction were mixed 
with SDS sample buffer and electrophoresed in a 12% SDS-polyacrylamide gel followed by 
autoradiography. In vitro translated MCHR1 (lane 1); in vitro translated and glycosylated 
MCHR1 (lane 2). 
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Figure 7.2: SDS-PAGE and autoradiography of in vitro translated and 
immunoprecipitated MCHR1. 
MCHR1 was produced in vitro in a TnT® T7 Coupled Reticulocyte Lysate System and then 
used in radiobinding assays with either antisera MCHR11-S, aPEP7, aPEP8 or AZN-LAM. 
Immunoprecipitated protein was electrophoresed in a 12% polyacrylamide gel followed by 
autoradiography. In vitro translated MCHR1 (lane 1); in vitro translated MCHR1 
immunoprcipitated with MCHR11-S (lane 2); in vitro translated MCHR1 immunoprcipitated 
with aPEP7 (lane 3); in vitro translated MCHR1 immunoprcipitated with aPEP8 (lane 4); in 
vitro translated MCHR1 immunoprcipitated with AZN-LAM (lane 5). 
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(Figure 7.3). Any serum with an Ab index above this level was considered 
positive for MCHR1 antibodies. On this basis, none of the healthy individuals 
was positive for MCHR1 antibodies. Sera from 20 patients with GD and 16 with 
AD were all negative for antibodies to the receptor. Of the vitiligo patient sera 
examined, 9/55 (16.4%) were considered positive for MCHR1 antibodies. The 
frequency of MCHR1 antibodies in the vitiligo patient group was significantly 
greater than normal (P = 0.025). The use of glycosylated MCHR1 in the 
radiobinding assay did not alter the Ab index of any of the vitiligo or healthy 
control sera tested. 
Three MCHR1 antibody-positive sera were analysed at different dilutions 
in the radiobinding assay along with a pool of sera obtained for healthy subjects. 
An Ab index for each serum sample at each dilution was plotted as a function of 
1/serum dilution (Figure 7.4). For all three vitiligo patient sera, saturated binding 
was observed at dilutions up to 1: 50. SDS-PAGE was used to check that the 
radioactivity immunoprecipitated by each of the MCHR1 antibody-positive sera 
in the radiobinding assays was due to [35S]-labelled receptor. Figure 7.5 
indicates that the positive sera immunoprecipitated a protein band of the correct 
size when compared with in vitro translated MCHR1. 
7.4.4 Analysis of MCHR1 antibody-positive vitiligo patients 
The details of the MCHR1 antibody-positive and antibody-negative patients 
vitiligo patients are compared in Table 7.3. No association was evident between 
the presence of MCHR1 antibodies and either the age of the patient at time of 
serum sampling, the age of the patient at onset of disease, the duration of the 
disease or the gender of the patients. In addition, the clinical sub-type of vitiligo 
did not appear to be related to the occurrence of receptor antibodies and three 
patients who had active vitiligo were all negative for antibodies against MCHR1. 
Furthermore, the presence of an autoimmune disorder did not correlate with 
MCHR1 antibody reactivity. Among the MCHR1 antibody-positive vitiligo 
patients, only 1/9 (11%) was positive for antibodies to tyrosinase, TRP-1, TRP-2 
and Pmel17, and none was positive for antibodies to SOX10, although not all 
sera were tested for each antibody (Table 7.4). 
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Figure 7.3: Radiobinding assays with patient and control sera. 
Vitiligo sera (n = 55), Addison's disease (AD) patient sera (n = 16), Graves' disease (GD) 
patient sera (n = 20) and healthy control sera (n = 28) were analysed in radiobinding assays. 
An Ab index was calculated for each serum sample tested as: cpm immunoprecipitated by 
serum sample/mean cpm immunoprecipitated by 28 healthy controls. The Ab index shown 
for each serum is the mean of at least two experiments. The dotted line shows the upper 
level of normal of 1.48 (mean Ab index +3 SD of 28 healthy controls) for the radiobinding 
assay. 
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Figure 7.4: Dilution experiments. 
Three MCHR1 antibody-positive sera and a pool of six healthy control sera were analysed at 
different dilutions in the radiobinding assays. The Ab index for each serum at each different 
dilution was calculated as: cpm immunoprecipitated by serum sample/mean cpm 
immunoprecipitated by healthy control pool. The Ab index of each positive serum and the 
pool of healthy control sera at each dilution is plotted as a function of 1/serum dilution. 
MCHR1 antibody positive serum 1 (0); MCHR1 antibody positive serum 2 (A); MCHR1 
antibody positive serum 3 (I); healthy control sera (i). 
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Figure 7.5: SDS-PAGE and autoradiography of MCHR1 
immunoprecipitated with either MCHR1 antibody-positive vitiligo or 
healthy control sera. 
MCHR1 was produced in vitro in a TnT° T7 Coupled Reticulocyte Lysate System and then 
used in radiobinding assays with either vitiligo or healthy control sera. Immunoprecipitated 
protein was electrophoresed in a 12% polyacrylamide gel followed by autoradiography. In 
vitro translated MCHR1 (lane 1); in vitro translated MCHR1 immunoprecipitated with vitiligo 
MCHR1 antibody-positive sera (lanes 2-4); in vitro translated MCHR1 immunoprecipitated 
with healthy control sera (lanes 5-7). 
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Table 7.3: Comparison of MCHR1 antibody-positive and antibody-negative 
vitiligo patients'. 
Vitiligo patients (n = 55) 
MCHR1 antibody-positive MCHR1 antibody-negative 
(n = 9) (n = 46) 
Mean age at onset of disease 38 yr (<1-73 yr) 35 yr (6-70 yr) 
(age range) 
Mean age at serum sample 47 yr (23-75 yr) 48 yr (14-77 yr) 
(age range) 
Mean disease duration (range) 10 yr (1-37 yr) 13 yr (<1-49 yr) 
Sex: 
Male 5/9 (56%) 17/46 (37%) 
Female 4/9 (44%) 29/46 (63%) 
Other autoimmune disorder 2/9 (22%)2 12/46 (26%) 
Vitiligo sub-type: 
Peri-orificial 1/9 (11%) 1/46 (2%) 
Symmetrical 6/9 (67%) 36/46 (78%) 
Symmetrical & peri-orificial 1/9 (11%) 4/46 (9%) 
Symmetrical & segmental 1/9(11%) 2/46(4%) 
Segmental 0/9 (0%) 1/46 (2%) 
Focal 0/9 (0%) 1/46 (2%) 
Universal 0/9 (0%) 1/46 (2%) 
The characteristics of the MCHR1 antibody-positive and antibody-negative vitiligo patients 
were compared using Fisher's exact test. All P values were > 0.05, indicating no significant 
difference between the two groups. 
2 Autoimmune thyroid disease was diagnosed in both patients. 
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Table 7.4: Incidence of anti-melanocyte antibodies in MCHR1 antibody- 
positive patients'. 
MCHR1 antibody-positive vitiligo patient 
1 2 3 4 5 6 7 8 9 
Incidence of 
antibodies to: 
Tyrosinase - nd -- nd nd - nd + 
TRP-1 - nd --- nd - nd + 
TRP-2 - nd --- nd - nd + 
PmeI17 - nd --- nd - nd + 
SOX10 - nd nd ----- nd 
1 Negative for antibody reactivity, -; positive for antibody reactivity, +; not determined, nd. 
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7.5 Discussion 
Previously, phage-display technology was employed with a melanoma cDNA 
library to identify MCHR1 as a novel target of autoantibody reactivity in vitiligo 
patients (Chapter 6). Radiobinding assays using [35S]-labelled MCHR1 have 
confirmed the immunoreactivity against the receptor in sera from patients with 
vitiligo. Of the 55 vitiligo sera analysed, antibodies to the receptor were 
detected in 16.4% whereas AD, GD and control sera showed no reactivity, 
indicating a high disease-associated specifity. Two out of the pool of ten vitiligo 
patients used for biopanning against the library (Chapter 6) were among those 
patients reactive against the MCHR1, demonstrating that the original enrichment 
of the receptor from the library was specific. It would also appear that during the 
cDNA library biopanning experiments the reactivity of MCHR1 antibodies from 
these patients was not diluted out by the IgGs of the eight unreactive patients, 
demonstrating the feasibility of using a pool of patients with different 
specificities. 
Glycosylation of MCHR1 did not alter the antibody binding index of any of 
the vitiligo patients, suggesting that any receptor epitope recognised by the 
antibody-positive sera was not altered by glycosylating the protein. Additionally, 
this finding suggests that vitiligo patient sera negative for MCHR1 antibodies do 
not recognise either glycosylated epitopes or epitopes that might be altered by 
post-translational processing of the receptor. Similar findings have been 
reported for the thyroid autoantigens thyroglobulin and thyroid peroxidase, as 
deglycosylation of these molecules had no effect on autoantibody binding (Kiso 
et al. 1992). It is likely that receptor autoantibodies targeting conformational 
epitopes were not detected in the radiobinding assay employed here which used 
recombinant MCHR1. Indeed, the most prevalent antibodies to the thyroid- 
stimulating hormone receptor (TSHR) in Graves' disease patients only react with 
native TSHR as they recognise conformation-dependent epitopes (Morgenthaler 
et al. 1999). The frequency of MCHR1 antibodies in vitiligo may, therefore, be 
higher if native receptor was used to analyse vitiligo sera. This could be 
accomplished by the expression of MCHR1 in a mammalian cell line, which 
could then be used in a flow cytometric assay or whole cell immunoprecipitation 
assay. 
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Analysis of the MCHR1 antibody-positive vitiligo patients revealed no 
obvious association between the presence of receptor antibodies and either 
patient age at the time of serum sampling, patient age at the onset of disease, 
sex, disease duration or vitiligo sub-type. Furthermore, the occurrence of 
MCHR1 antibodies did not correlate with the presence of an autoimmune 
disorder. This finding was in contrast to previous studies in which antibodies to 
the melanocyte-specific enymes TRP-1, TRP-2 and Pmel17 were only detected 
in vitiligo patients who had an autoimmune disorder (Kemp et aL 1997b; Kemp 
et al. 1998b; Kemp et al. 1998c), and antibody reactivity to tyrosinase and 
SOX10 was identified predominantly in patients with autoimmune disease 
(Kemp et aL 1997a; Hedstrand et al. 2001). The presence of MCHR1 antibodies 
was not related to the occurrence of humoral responses to other melanocyte 
antigens: in only one individual with tyrosinase, TRP-1, TRP-2 and Pmel17 
antibodies was immunoreactivity to the receptor also identified. Two other 
vitiligo patients tested in this study were positive for antibodies to all the 
melanogenic autoantigens and one was positive for antibodies to tyrosinase. 
However, neither of them had antibodies to MCHR1. 
The role of the MCH/MCHR1 signalling pathway in the regulation of 
human melanocyte behaviour has yet to be established, but a recent study 
suggested that it might function in the regulation of a-MSH induced 
melanogenesis (Hoogdijn et al. 2001). It is possible, therefore, that MCHR1 
autoantibodies might adversely affect the functioning of the receptor leading to 
the disruption of normal pigmentation. Autoimmune disorders that result directly 
from autoantibody production include Graves' disease and myasthenia gravis 
and in the former, the G protein-coupled TSHR, present on thyroid follicular 
cells, is the target of autoantibodies that stimulate TSHR leading to an increase 
in the synthesis of thyroid hormones and the subsequent clinical symptoms of 
hyperthyroidism (Meek et al. 1964). Future studies will address the issue of 
whether or not the MCHR1 antibodies reported here can alter the activity of the 
receptor with respect to pigmentation. 
MCHR1 is expressed on the surface of melanocytes. It is of interest, 
therefore, to note that autoantibodies in vitiligo patients are most commonly 
directed against antigens on the cell surface (Cui et al. 1992; Cui et al. 1995b). 
Previously, only intracellular melanocyte proteins such as tyrosinase have been 
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reported as autoantigens in vitiligo (Song et al. 1994a; Baharav et al. 1996; 
Kemp et al. 1997a; Kemp et al. 1997b; Kemp et al. 1998b; Kemp et al. 1998c; 
Okamoto et al. 1998; Hedstrand et al. 2001) and this is the first time a surface 
receptor has been specifically identified as an antigen in this disease. 
Expression of MCHR1 is not limited to melanocytes and the receptor is found, 
for example, within the central nervous system (Chambers et al. 1999; Saito et 
aL 1999) and in keratinocytes (Burgaud et al. 1997). Interestingly, a previous 
study reported that some of the antibodies in vitiligo patients do target antigens 
present on other cell types (Cui et al. 1992). If indeed MCHR1 antibodies are 
pathogenic, and this has yet to be determined, the selective destruction of 
pigment cells, as observed in vitiligo, might result from the relative sensitivity of 
melanocytes to immune-mediated injury, as compared with, for example, 
fibroblasts and keratinocytes (Norris et aL 1988a). The ability of vitiligo 
autoantibodies to destroy melanocytes has been previously demonstrated in 
vitro with cultured pigment cells (Norris et al. 1988b) and in vivo following 
passive immunisation of mice grafted with human skin (Gilhar et al. 1995). 
Similar studies could be performed on isolated MCHR1-specific antibodies in 
order to determine their potential pathogenicity. 
The G protein-coupled receptor family is thought to consist of one of the 
largest group of proteins in the human genome, and new receptors and receptor 
subtypes are rapidly being identified (Evans et al. 2001). A second form of the 
receptor, designated MCHR2, with an approximate 36% overall homology to the 
MCHR1, was recently characterised (An et aL 2001; Mori et al. 2001; Sailer et 
al. 2001; Wang et al. 2001). In addition, a splice variant of the MCHR2 has 
been identified, which might modulate activity of the MCHR1 or MCHR2 
receptors by heterodimerisation (An et al. 2001). It would be of interest, 
therefore, to determine whether the MCHR1 autoantibodies identified here 
showed any reactivity to the different forms of the receptor. 
In summary, it has been confirmed that the use of phage-display enabled 
the isolation of a novel autoantigen in vitiligo, MCHR1. The exact role the 
MCHR1 autoantibodies play in the pathogenesis of vitiligo is, as yet, unknown. 
The stimulus for their production may stem from a genetic predisposition to 
autoimmunity, or from a cross-reactive antigen expressed on infecting micro- 
organisms. Equally, antibodies against the receptor might represent a 
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secondary phenomenon arising as consequence of injury to the melanocyte via 
other mechanisms, although they may then act to further exacerbate the 
condition. Alternatively, it is possible that the MCHR1 autoantibodies play no 
part in vitiligo aetiology but might, however, indicate the presence of 
autoreactive anti-MCHR1 T lymphocytes. 
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8 General discussion 
Several hypotheses have been proposed to explain the destruction of cutaneous 
melanocytes in vitiligo. Persuasive observational and experimental evidence 
suggests that immune mechanisms play a role in the development of the 
disease (Section 1.3.6). Characterisation of the autoimmune reactivities in 
vitiligo may be beneficial in the advancement of more appropriate therapies and 
diagnostic tools and, perhaps, in determining the aetiology of the disease. 
Furthermore, similarities between the generation of autoantibodies and 
autoreactive T cells against melanocyte antigens observed in vitiligo, and the 
tumour immunity observed in malignant melanoma immunosurveillance, suggest 
that elucidating the immune response in vitiligo may provide new strategies for 
the treatment of both diseases. 
In the present work, the autoimmune aspects of vitiligo were investigated 
with particular reference to the identification of melanocyte antigens recognised 
by autoantibodies in sera from vitiligo patients. In brief, the thesis aimed to 
examine: (i) possible genetic association of an immune regulatory protein with 
vitiligo, (ii) B cell reactivity to two previously identified vitiligo autoantigens, (iii) 
the prevalence of autoantibodies to a melanocyte antigen which forms a 
significant target for cytotoxic T cells in vitiligo and (iv) the application of a novel 
technique to the identification of additional disease autoantigens. 
Genetic studies of vitiligo have demonstrated the existence of several 
susceptibility genes, which contribute to an overall predisposition to vitiligo 
(Majumder et al. 1993; Kim et al. 1998; Acros et al. 1999). Candidate genes 
include not only those with a role in melanogenesis and other aspects of 
melanocyte behaviour, but also those whose altered function affects immune 
regulation. This latter category is the most likely explanation for the fact that 
polymorphic regions of the CTLA-4 gene are associated with several 
autoimmune disorders and may represent a generalised marker of 
autoimmunity. A microsatellite polymorphism of the CTLA-4 gene was, 
therefore, analysed in a series of vitiligo patients and healthy control subjects 
(Chapter 3). The study failed to reveal an association of the gene polymorphism 
with vitiligo, at least in those patients without an associated autoimmune 
disorder, although the data did suggest that autoimmune endocrinopathy 
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patients carrying the CTLA-4 disease-associated allele may have a greater risk 
of developing vitiligo. Consequently, I was unable to identify a subgroup of 
vitiligo patients in which autoimmune responses may be more likely, for further 
study in subsequent experiments, since it is possible that immune responses are 
the primary cause of vitiligo in some patients but are absent or secondary to 
other pathological mechanisms in others. However, relatively small data sets 
were used and future analysis of this gene would benefit from larger populations 
and transmission studies using family groups. Indeed, genetic association was 
suggested between vitiligo and the CTLA-4 gene in recent case-control 
(Kristensen et al. 2000) and family studies (McCormack et al. 2001b) with 
greater subject numbers. 
The greater part of this thesis has concentrated on the identification and 
characterisation of the melanocyte-specific autoantigens recognised by 
autoantibodies in sera from vitiligo patients. By defining the targets of the 
humoral immune response in vitiligo, it was hoped information would be gained 
as to its relationship to the disease initiation, process and pathogenesis. 
Moreover, the autoantibodies may serve as markers of an autoantigen against 
which there may be a pathologically more important cellular immune response. 
Molecular analysis of the B cell epitopes on two previously identified 
vitiligo autoantigens, the melanosomal enzymes tyrosinase and Pmel17, was 
performed (Chapter 4). Multiple regions of tyrosinase were found to be epitopes 
for autoantibodies from the vitiligo patients studied, two of which are likely to 
contain epitopes that are cross-reactive with both TRP-1 and TRP-2. 
Additionally, at least two epitope domains are present in Pmel17. The finding 
that neither Pmel17 epitope shares sequence homology with other melanogenic 
proteins suggests that the IgG response to Pmel17 is distinct from that to the 
other melanocyte-specific antigens. It has been speculated that the immune 
response in vitiligo may arise from cross-reactivity between self-proteins and 
those of infecting micro-organisms (Le Poole et al. 1993a; Grimes et al. 1996). 
However, no similarity was apparent between the sequence of the identified 
epitope regions and that of microbial peptides to lend support to this theory with 
these particular antigens, with respect to sequenced pathogens. Also, none of 
the epitopes resided in areas of the proteins with recognised functional activity. 
However, the methodology employed here is only suitable for the study of linear 
determinants and further work is needed to fully assess the epitopes recognised 
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by tyrosinase and PmeI17 autoantibodies exploiting techniques which use native 
protein and purified monoclonal antibodies. In particular, the application of 
phage-display (Scott 1992; Williams et al. 2001) to future epitope mapping 
studies would allow expression of antigen in a native arrangement and, 
therefore, enable detection of conformational epitopes. Moreover, the isolation 
of monoclonal antibodies from vitiligo patients would allow a more complete 
analysis of the precise B cell epitope regions, than that obtained from 
heterogeneous sera. 
In addition to the characterisation of known autoantigens, I attempted to 
identify novel targets of vitiligo patient autoantibodies. The presence of 
autoantibodies to MelanA in vitiligo sera was examined (Chapter 5) since 
autoimmune cellular responses to this melanocyte protein have been reported in 
vitiligo and melanoma patients. No MelanA-antibodies were isolated, 
suggesting that either MelanA is not a target of the humoral response in vitiligo 
patients or that any antibody reactivity to the protein is not detectable using the 
techniques applied. This does not rule out the presence of antibodies that target 
conformational epitopes on the native protein and future studies could employ 
mammalian expression systems to produce MelanA protein with native 
conformation to address this. 
A further strategy for identifying vitiligo melanocyte autoantigens was the 
construction and screening of a melanoma cDNA expression library (Chapter 6). 
The recently developed pJuFo phage-display system was used to make the 
cDNA library and to express the proteins encoded therein on the surface of 
filamentous phage. Phage-display based on the pJuFo cloning system (Crameri 
& Suter 1993; Crameri et al. 1994) has previously been used to identify proteins 
that bind to human IgE (Crameri & Blaser 1996; Crameri et al. 1996; Lindborg et 
al. 1999) and IgG antibodies (Kemp et al., unpublished data; Herd et al., 
unpublished data). Several possible autoantigens were enriched from the 
melanoma library by their ability to bind IgG from vitiligo patients, which include 
proteins formerly characterised as autoantigens in other disorders. In addition, 
vitiligo-specific putative antigens with an association to epidermal and 
melanocyte function were isolated. 
Most significantly, the library screening led to the discovery of the 
melanin-concentrating hormone receptor (MCHR1) as a novel target of vitiligo 
autoantibodies. Immunoreactivity against the receptor in sera from patients with 
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vitiligo was subsequently confirmed using radiobinding assays with [35S]-labelled 
MCHR1 (Chapter 7). Antibodies against MCHR1 were found to be highly 
disease-specific and were detected more frequently than vitiligo-specific 
autoantibodies, tyrosinase, TRP-1, TRP-2 and Pmel17 described in prior 
radiobinding assay experiments (Kemp et al. 1997a; Kemp et al. 1997b; Kemp 
et al. 1998b; Kemp et al. 1998c). The specific identification of a surface receptor 
as an antigen in this disease is in agreement with previous reports that the 
autoantibodies in vitiligo patients are most commonly directed against cell- 
surface antigens (Cui et aL 1992; Cui et al. 1995b). It is of note that the MCHR1 
autoantibodies might have additional functional significance to vitiligo if they 
could disrupt normal pigmentation by adversely affecting the role of the receptor 
in metabolically active melanocytes. 
Work is currently in progress, in collaboration with Dr. Brian Hawes 
(Schering-Plough Research Institute, New Jersey, U. S. A. ) to examine the 
effects of vitiligo patient IgG containing anti-MCHR1 antibodies on receptor 
activity. The level of receptor activity will be measured indirectly by calcium flux 
in a MCHR1-transfected mammalian cell line. Additionally, the ability of these 
antibodies to fix complement and, therefore, their potential to inflict cellular injury 
through complement-mediated lysis will be determined by flow cytometric 
analysis. Complement-fixing ability can be measured by the incubation of anti- 
MCHR1 IgG with MCHR1-transfected cells, and untransfected control cells, 
followed by the addition of serum containing all complement factors except C7, 
thereby preventing cell lysis by the exclusion of a terminal complement 
component. The level of deposition of C3 on the cells is subsequently 
measured by flow cytometric analysis and compared between control cells and 
those expressing the receptor. Attempts to characterise the B cell epitopes on 
MCHR1 by construction of a MCHR1 random cDNA fragment phage-display 
library, and by antibody binding to deletions of MCHR1, are also presently being 
undertaken. It would be useful to establish a mammalian cell line stably 
transfected with the receptor in our laboratory for future studies of antibody 
reactivity using immunoblotting, flow cytometric assay or whole cell 
immunoprecipitation assay. In addition, the incorporation of a histidine tag to the 
receptor terminal, prior to expression in mammalian cells, would provide a 
means of preparing sufficient quantities of the pure protein to develop ELISA. 
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The relationship between the MCHR1-antibodies, and indeed all vitiligo 
autoantibodies, and the pathology of the vitiligo lesions is yet to be established. 
The possibility that the MCHR1 autoantibodies play no part in vitiligo aetiology 
but rather indicate the presence of autoreactive anti-MCHR1 T lymphocytes 
should be addressed by an investigation into the T cell reactivities to MCHR1. 
MCHR1 antibodies may nevertheless serve as potentially useful markers of 
cellular disruption in the epidermis of vitiligo patients, even if they prove to be 
neither directly pathogenic nor functionally significant in the immune response. 
Additionally, melanoma patient sera reactivity to MCHR1 could be examined 
since it may represent a novel target for immunotherapy for this disease. 
In conclusion, the work in this thesis has led to the identification of a 
novel autoantigen in vitiligo in addition to several potential targets. The 
preliminary characterisation of humoral reactivity to these antigens, especially 
MCHR1 described in Chapter 7, will be expanded upon in ongoing studies. 
Although this work may contribute to a greater understanding of the autoimmune 
aspects of vitiligo, the ways in which these responses fit into the aetiological and 
pathological disease mechanisms remain uncertain. Whilst vitiligo satisfies most 
of the defining criteria for autoimmune disease, as shown in Table 8.1, it is 
unclear to what extent it can be classified as a truly autoimmune disorder. 
Characterising the specificities of vitiligo autoantibodies will help to resolve the 
relation of the disease to the first, fourth, and possibly the eighth, criteria (Table 
8.1). Additionally, the present work suggests that the detection of expression of 
MCHR1 antigen in vitiligo lesions may increase the likelihood of providing 
evidence to fulfil the fourth criterion. However, it is possible that vitiligo 
represents a spectrum of diseases, which result in the same endpoint, in which 
autoimmune reactivities are involved to a greater or lesser degree. 
Future work is needed to establish whether the immune reactivities in 
vitiligo are driven by several principal antigens, or whether they are elicited to 
diverse immunogenic peptides released from melanocytes perhaps injured by 
other mechanisms. Further characterisation of the putative antigens isolated by 
the library screening may help to address this question. The construction of a 
melanocyte cDNA phage-display library, in addition to the existing melanoma 
library, and refinement of the current screening protocols might allow for 
identification of further autoantigens. The technique could be expanded to 
include the use of smaller pools of patient IgG and an initial round of 'negative' 
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biopanning using healthy control IgG to pre-adsorb non-specific IgG-binding 
proteins. It would also be useful to establish the limits of the technique by 
performing control experiments with a defined antibody or antisera. 
In summary, the work in this thesis has demonstrated the usefulness of 
applying molecular techniques to the study of vitiligo. In particular, the 
application of filamentous phage-display has resulted in the discovery of a novel 
vitiligo autoantigen and is a potentially powerful tool for characterising the 
immune response in this disease. 
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